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Abstract of Thesis 
 
Sarcopenic obesity is common among kidney transplant recipients.  Fluid volume status 
has not been well-investigated following kidney transplantation.  This thesis aimed to 
explore the effects of body composition, including fat mass, muscle mass and fluid volume 
status, on post-transplantation morbidity and fatigue.  These are potential contributing 
factors to long-term patient- and graft- survival, as well as quality of life.   
 
Firstly, the associations between adiposity with inflammation, hepcidin and haemoglobin 
levels were investigated.  Secondly, the effects of hypervolemia on blood pressure and 
levels of N-terminal fragment of pro-hormone B-type natriuretic peptide (NT-proBNP) 
were explored.  Thirdly, the role of muscle mass and fat mass on all domains of fatigue 
were studied.  Finally, the mechanistic aetiology of physical fatigue was examined by 
evaluation of muscle mass, muscular and cardiovascular functions, and fatigue perception. 
 
This thesis concluded that while adiposity displays significant independent association 
with inflammation, its role in determining hepcidin and haemoglobin levels remains 
uncertain.  Reduced muscle mass may be correlated with physical fatigue, but independent 
contribution of fat mass in fatigue remains undefined.  Hypervolemia is associated with 
raised blood pressure and elevated levels of NT-proBNP.  The findings from this thesis set 
the scene for future interventional research and therapeutic strategies.   
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CHAPTER 1:  GENERAL INTRODUCTION 
 
1.1 Body Composition 
 
Body composition describes the quantities of adipose, skeletal and muscle tissues, as well 
as the amount of fluid in human body1,2.  Different body composition parameters, 
specifically the amount of muscle mass, the quantity and distribution of fat mass, and fluid 
volume status are now increasingly considered valuable in clinical practice to advance our 
understanding of their effects on health and quality of life (QoL) outcomes1,3-10. 
 
Body composition can be assessed using several different methods.  The most common 
assessment techniques in clinical practice are anthropometry, including weight, height, 
body mass index (BMI), waist circumference, waist-hip ratio, skinfold thickness, arm 
muscle measurements, and bio-impedance analysis.  These techniques are inexpensive, 
safe, non-invasive, with minimal requirement for training and subject compliance.   More 
sophisticated techniques are also available, mostly used in research settings, examples 
include near-infrared interactance, dual-energy x-ray absorptiometry (DEXA), 
densitometry (underwater weighing and air displacement plethysmography), isotope 
dilution, magnetic resonance imaging, computed tomography imaging, and whole body 
potassium scanning.  These techniques are costly, cumbersome, time-consuming, require 
specific equipment and expertise knowledge. 
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The purpose of body composition assessment is to compartmentalise the body’s 
constituents.  BMI is frequently used in clinical practice and is often considered as a 
surrogate measure of adiposity due to its positive correlation with body fat1.  However, it 
only provides a simple estimation of fat mass based on weight and height squared, lacking 
sensitivity and specificity to dissect the differences between varying compartments of body 
composition (fat mass, muscle mass and fluid volume)1.  Therefore, it does not truly reflect 
adiposity as excess body weight may be attributable to increased muscle mass and/or 
volume overload11.  In addition, it may be affected by gender, age, genetics, activity level, 
and ethnicity12. 
 
Historically, cadaver analysis is considered to be the gold standard for body composition 
assessment1.  Although it is a direct measurement and provides fundamental understanding 
of body composition, it is the most invasive method involving human dissection13.  A 
major drawback to this analysis is the requirement of deceased subjects13, limiting its 
practicality in clinical practice.  However, cadaver analyses contributed to reference data 
for developing body composition models13,14, separating body weight into two or more 
compartments13.     
 
1.1.1 The Two-Compartment Body Composition Model 
 
The two-compartment (2-C) model is the basic body composition model, consisting of fat 
mass and fat-free mass15, shown in Figure 1.1.  While fat mass includes all ether-
extractable lipids in the body16, fat-free mass is somewhat heterogeneous, comprising of all 
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1.1.2 The Three-Compartment Body Composition Model 
 
The three-compartment (3-C) model is an evolution of the 2-C model (shown in Figure 
1.1).  There are two common types of 3-C model.  Fat-free mass may be further divided 
into either:1) water and remaining fat-free solids (i.e. protein and bone mineral)13; or 2) 
bone mineral and lean tissue mass20.  The 3-C model measures body water and/or solids, 
with fat mass estimated by subtracting these from the total body weight.  The 3-C model 
assumes constant densities of fat, body solids and hydration13.  However, when patients 
present with substantially depleted protein and bone mineral masses e.g. CKD patients21,22, 
the assumed density of the bodily solids may be inaccurate, which may invalidate the 
estimation of fat mass.  DEXA scanning and phase sensitive multi-frequency bio-
impedance analysis are examples of body composition measurement techniques using the 
3-C model. 
 
1.1.3 The Four-Compartment Body Composition Model 
 
The 3-C model may be further extended to the four-compartment (4-C) model.  The 4-C or 
multi-compartment models estimate body composition by combining independent 
measurements of different body composition compartments with minimal assumptions.  
There are two common types of 4-C model: molecular and cellular compartment models13, 
shown in Figure 1.1.  In the molecular model, fat-free mass is divided into total body 
water, protein and bone mineral masses13.  The cellular model separates fat-free mass into 
extracellular solids, extracellular fluids, and body cell mass13.  Both extracellular solids 
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and extracellular fluids are constituents of fat-free mass outside cells.  While extracellular 
solids  represents bone mineral mass, extracellular fluids includes interstitial fluid and 
blood plasma13.  Body cell mass consists of skeletal muscle protein and visceral protein23, 
both of which are metabolically active19,23, hence reflecting nutritional status and signs of 
wasting19.  The cellular model is considered of greater value in CKD patients due to its 
unique ability to measure extracellular fluids and body cell mass19.  In both molecular and 
cellular compartment models, the different compartments of the fat-free mass are 
measured, with fat mass predicted by total body weight minus the sum of all the measured 
fat-free mass compartments.  The 4-C model is regarded as the most accurate measure of 
body composition, and is often used as a reference technique for development of new body 
composition methods17.  However, the techniques required for this model are technically 
challenging, costly, and not readily available in clinical settings.  Examples of 
measurement modalities for each of the 4-C model compartments include deuterium 
dilution (measurement of total body water); bromide (measurement of extracellular fluids); 
total body calcium or bone mineral content (measurement of extracellular solids); total 
body potassium (measurement of body cell mass); and DEXA scanning (measurement of 
bone mineral component). 
 
1.1.4 Characteristics of Body Composition in Kidney Transplant Recipients 
 
A greater understanding of body composition in kidney transplant recipients (KTRs) may 
provide insight into its relationships with post-transplant complications, long-term 
morbidity, mortality, and QoL outcomes.  It may also form the basis for future 
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interventional strategies aiming to improve clinical and QoL outcomes of kidney 
transplantation.  To date, there are no universally recommended methods for body 
composition assessment in KTRs.  Studies investigating the characteristics of body 
composition in KTRs employed a variety of techniques to ascertain body composition in 
this patient population.  A summary of studies reporting body composition in KTRs are 
shown in Table 1.1.    
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Table 1.1. Summary of Studies Reporting Body Composition in Kidney Transplant Recipients 
  
Study 
 
Sample 
Size 
Study Type Body 
Composition 
Measurements 
 
Study Protocol Key Findings in Relation to Body Composition Post-Transplantation 
 
Haggan 
et al24 
44 Prospective   Weight 
 DEXA 
Anthropometric 
measurements and 
body composition at 
kidney 
transplantation and 3, 
6 and 12 months 
post-transplantation. 
 
 Significant weight gain in female from baseline to 12 months post-
transplantation; but no significant weight change in male during the course 
of follow-up. 
 Total fat and lean body masses increased significantly in female from 
baseline to 12 months post-transplantation. 
 In male, total fat mass decreased significantly from baseline to 12 months 
post-transplantation; but no significant change in total lean body mass.   
 Bone mass did not change significantly in female, but decreased 
significantly from baseline to 12 months post-transplantation in male. 
 Weight gain associated with female gender. 
 Increased fat mass correlated with high energy intake. 
 Increased lean body mass associated with reduced steroid dose. 
 Bone loss associated with male gender and high doses of steroids. 
 
Heaf et 
al25 
115 Prospective  
 
 Weight 
 BMI  
 DEXA 
Anthropometric and 
DEXA measurements 
at baseline and 
repeated 3 years later. 
 
 High prevalence of overweight and obesity observed in KTRs, with 39% 
and 14% of KTRs being overweight and obese respectively. 
 No significant change in weight, BMI, lean body mass and bone weight. 
 Significant increase in fat mass. 
 Increase in fat mass associated with low fat mass at baseline, high plasma 
bicarbonate, and shorter time post-transplantation. 
 Increase in lean body mass associated with high fat mass at baseline, low 
lean body mass at baseline, reduced intakes of energy and protein, and 
increase in plasma bicarbonate. 
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Table 1.1. Summary of Studies Reporting Body Composition in Kidney Transplant Recipients (continued) 
 
Study 
 
Sample 
Size 
Study Type Body 
Composition 
Measurements 
 
Study Protocol Key Findings in Relation to Body Composition Post-
Transplantation 
 
Moreau 
et al26 
 
44 Prospective  DEXA DEXA measurements pre-
transplantation, and 
followed-up at 1, 2 and 5 
years post-transplantation. 
 
 In female, significant increase in body weight was observed from 
baseline to 5 years post-transplantation, due to significant increase 
in fat mass at 1 and 2 years post-transplantation.   
 In male, body composition remained stable and closed to baseline 
measurements during the course of follow-up period. 
 KTRs on lower corticosteroid doses developed normalised bone 
mass over the 5 years follow-up period, whereas KTRs on higher 
doses of corticosteroid developed a decreased bone mass during the 
first year post-transplantation, and then improved significantly 
thereafter back to baseline by 2 years post-transplantation.. 
 Increase in bone mass from 1 to 5 years post-transplantation was 
only significant in KTRs treated with tacrolimus. 
 
Dolgos  
et al27 
102 Prospective  DEXA DEXA measurements at 
transplantation, and 10 
weeks post-transplantation. 
 
 Fat mass increased significantly from baseline to 10 weeks post-
transplantation. 
 Fat-free mass declined significantly from baseline to 10 weeks 
post-transplantation, with no significant change in body weight. 
 Independent predictors of increased fat mass were advancing age, 
low baseline fat mass, elevated C-reactive protein, increasing 
dialysis vintage and high cumulative steroid dose. 
 High cumulative steroid dose was the only independent predictor 
of declined fat-free mass. 
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Table 1.1. Summary of Studies Reporting Body Composition in Kidney Transplant Recipients (continued) 
 
Study 
 
Sample 
Size 
Study Type Body 
Composition 
Measurements 
 
Study Protocol Key Findings in Relation to Body Composition Post-
Transplantation 
 
Harada et 
al28 
 
55 Prospective  BMI 
 Bio-impedance 
spectroscopy 
BMI and bio-impedance 
before and 1 year after 
kidney transplantation. 
 
 No significant change in BMI. 
 Total body water, percentage body muscle, and bone mass 
decreased significantly.   
 Percentage body fat increased significantly. 
 
Netto et 
al29 
 
145 Prospective  BMI 
 Skinfold 
thickness 
 Arm 
circumference 
 Arm muscle 
circumference 
 Arm muscle 
area 
 Percentage 
body fat 
 
BMI and anthropometry 
immediately after 
transplantation, and 
followed-up at 6 months 
post-transplantation. 
 
 No significant change in BMI. 
 Female displayed significantly higher muscle mass at baseline 
compared to male, measured by arm circumference, arm muscle 
circumference, and arm muscle area. 
 Percentage body fat at baseline was above the recommended levels 
in 80% of KTRs.   
 At 6 months post-transplantation, higher renal function was 
observed among normal weight compared to overweight and obese 
KTRs, despite comparable estimated glomerular filtration rate at 
baseline. 
 
Van den 
Ham et 
al30 
 
11 Prospective  DEXA DEXA measurements at 3-
4 weeks, 3- and 6- months 
post-transplantation. 
 
 At 6 months post- transplantation, weight gain is predominately 
due to an increase in fat mass. 
 Elevated fat mass was evident within 3 months post-
transplantation, this include extremity and truncal fat mass, with 
truncal region being the most prominent.  
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Table 1.1. Summary of Studies Reporting Body Composition in Kidney Transplant Recipients (continued) 
 
Study 
 
Sample 
Size 
Study Type Body Composition 
Measurements 
 
Study Protocol Key Findings in Relation to Body Composition Post-
Transplantation 
 
Miller et 
al31 
 
45 Retrospective  Weight 
 Height 
 Triceps skinfold 
thickness 
 Mid-arm muscle 
circumference 
 
Anthropometry pre- and 
post- transplantation, 
with a mean post-
transplantation follow-up 
time of 23 months. 
 Weight and weight for height increased significantly from pre- 
to post- transplantation. 
 Post-transplantation, 38% of KTRs had mid-arm muscle 
circumference below the 5th percentile, and 58% had mid-arm 
muscle circumference above the 50% percentile. 
 Following transplantation, 14% of KTRs had triceps skinfold 
thickness above the 95th percentile. 
 
Qureshi 
et al32  
 
30 Cross-
sectional 
 Skinfold 
measurements 
 Percutaneous muscle 
biopsy 
 
Post-transplant 
anthropometry and 
muscle biopsy 
measurements and 
comparisons with age-
match healthy subjects. 
 
 KTRs displayed higher percentage of body fat, triceps, 
subscapular, and total sum of skinfolds compared with healthy 
controls at 13 months post-transplantation. 
 Significant protein depletion at the cellular level in KTRs 
compared with healthy subjects at 14 days post-transplantation. 
 
Isiklar et 
al33 
 
15 Prospective  DEXA DEXA measurements 
immediately prior to 
transplantation, and 
repeated at 3 and 6 
months post-
transplantation. 
 
 Fat mass increased following transplantation, and was more 
prominent at 3 months post-transplantation.   
 Percentage body fat of the total body weight increased 
following transplantation. 
 Decreased lean body mass post-transplantation was observed in 
6 patients. 
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Table 1.1. Summary of Studies Reporting Body Composition in Kidney Transplant Recipients (continued) 
Study 
 
Sample 
Size 
Study Type Body Composition 
Measurements 
 
Study Protocol Key Findings in Relation to Body Composition Post-
Transplantation 
 
Steiger et 
al34 
 
16 Prospective  DEXA DEXA measurements 
immediately post-
transplantation, and 
followed-up at 2, 5, 11 
and 16 months after 
transplantation.  Results 
were compared with age-
, sex- and BMI- matched 
healthy controls. 
 
 Compared with healthy controls immediately post-
transplantation, lean mass of the trunk was higher in KTRs, 
lean mass of the limb was lower in KTRs, and no difference in 
fat mass was observed. 
 Compared between baseline and 16 months post-
transplantation, total fat mass increased in male KTRs 
including all sub-regions such as trunk, arms, legs, head and 
neck.   
 Compared between baseline and 16 months post-
transplantation, total fat mass remained unchanged in female 
KTRs, but head and neck fat mass was higher than healthy 
controls. 
 Body fat distribution remained constant in both sexes during 
the course of 16 months. 
 Lean mass of the trunk in KTRs decreased during early stages 
post-transplantation (between 11 and 42 days post-
transplantation) and remained constant thereafter. 
 Following the early stages post-transplantation (after 42 days 
post-transplantation), lean mass of the arms, legs, head and 
neck in KTRs increased over the observed follow-up period. 
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1.1.5 Techniques of Body Composition Assessment in this Thesis 
 
In the research studies to be discussed in this thesis (chapters 2 to 5), techniques from the 
3-C model, DEXA scanning and the multi-frequency bio-impedance analysis, were used to 
measure body composition.  Both methodologies serve as the best alternatives in terms of 
cost, convenience, equipment availability, skill requirement and quality of data. 
 
1.1.5.1 DEXA Scanning 
 
DEXA is a recognised reference method for evaluation of body composition35.  The system 
works by transmitting low-dose X-rays at two different energy levels through the 
individual, and measure the differential attenuation of the X-ray beam at these two energy 
levels to derive whole body and regional bone mineral content, fat mass and lean tissue 
mass36.  In the regions with bone, soft tissue and bone were measured, and the composition 
of soft tissue was evaluated in relation to the adjoining tissue estimates36.  In the regions 
without bone, the transmission at the two energy levels estimates fat mass and lean tissue 
mass36.   
 
1.1.5.2 Bio-impedance Analysis 
 
The bio-impedance analysis employed in the present thesis is a relatively new device 
known as the Body Composition Monitor (BCM, Fresenius Medical Care, Bad Homburg, 
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Germany).  It is a multi-frequency whole-body bio-impedance spectroscopy device that 
measures adipose tissue mass, lean tissue mass and volume status at 50 frequencies (5 – 
1,000 kHz) through electrodes placed on the wrist and ankle37.  Impedance is a measure of 
the vector sum of resistance and reactance, and is associated with the length, cross-
sectional area, and applied frequency of the conductor38.  It makes use of the principle that 
body tissues are capable of conducting low-level alternating electrical current with varying 
ease, proportional to their water and electrolyte content39.  Lean tissue mass, contains large 
amounts of water and electrolytes, is therefore highly conductive and presents low 
resistance electrical paths39.  Fat mass is anhydrous, a poor conductor of electricity, and 
hence offers high resistance electrical pathway39.  Cell membranes pose reactance to 
electrical current, opposing the flow of electrical current due to the presence of electrical 
capacitance found in cell membranes38.  Since fluid compartments (intra- and extra- 
cellular fluids) are separated by cell membranes38, high frequency current passes through 
the total body water, but low-frequency current is incapable to penetrate through cell 
membranes and therefore flows exclusively through the extracellular water39.    
 
The BCM utilises an algorithm based on a new 3-C model40, shown in Figure 1.2.  It was 
modified to reflect the presence of excess fluid accumulated due to pathological reasons40.  
The new 3-C model considered the 3 compartments as normally hydrated adipose tissue 
mass, normally hydrated lean tissue mass, and excess fluid mass40.  The hydration fractions 
within both adipose tissue mass and lean tissue mass were assumed to have zero excess 
fluid40.  Therefore, absolute excess fluid mass was determined by calculating the difference 
between the actual amount of excess fluid in the body detected by the BCM and the 
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in healthy and haemodialysis populations43, with methods frequently used in the 4-C model 
such as bromide dilution, total body potassium, deuterium dilution, DEXA scanning, air 
displacement plethysmography, and under-water weighing. 
 
1.2 Kidney Transplantation 
 
Kidney transplantation is a surgery to place a healthy kidney into a patient with end-stage 
renal failure.  It may be obtained from a deceased-donor or a living-donor.  The latter, in 
turn, is further classified as living-related or living-unrelated transplants, depending on the 
existence of a biological relationship between the donor and the recipient.  
 
1.2.1 History and Benefits of Successful Kidney Transplantation 
 
Sixty years ago, on 23rd December 1954, the first successful kidney transplantation was 
performed at the Peter Bent Brigham Hospital in Boston, USA44.  It was a living-related 
donation that occurred between identical twins44.  Since then, this operation has moved 
from a medical miracle to part of a routine clinical practice44.  Kidney transplantation is 
now considered as the preferred modality of renal replacement therapy for many patients 
with end-stage renal disease45.  Compared to remaining on the transplant waiting list, 
kidney transplantation improves long-term survival46, enhances QoL47, demonstrates cost 
benefit48, and rectifies uraemia and metabolic abnormalities contributing to an overall 
sense of well-being49.  In spite of these advantages,  the shortage of organs is corroborated 
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by a small proportion of patients on the transplant waiting list proceeding to 
transplantation, with up to 40% dying while waiting on dialysis50.  It is crucial that the best 
possible use is made of those transplanted kidneys (grafts); therefore, optimising patient 
and graft survival after transplantation is a priority in this patient group. 
 
1.3 Barriers to Successful Clinical Outcomes of Kidney Transplantation 
 
Clinical outcomes of kidney transplantation are often defined as post-transplant morbidity 
and mortality.  The most common clinical outcome measures in kidney transplantation are 
short- and long- term patient- and graft survival.  Other examples include hospitalisation 
rates, hospital re-admission rates, length of hospitalisation, delayed graft function (defined 
as dialysis requirement within the first week post-transplantation), primary non-function 
(defined as non-functioning graft within the first 6 weeks following transplantation), and 
biopsy proven acute rejection51. 
 
Short-term patient and graft survival have substantially improved over the recent decades, 
with most centres reporting both survival rates at 1 year of greater than 90%52.  However, 
long-term success has been difficult to accomplish as evident by the marginal increase in 
patient and graft survival rates over the past 15 years53.  This phenomenon is multifactorial.  
Firstly, modification of alloimmunity using immunosuppression has reduced short-term 
early acute rejection rates53, but the nephrotoxicity of immunosuppressive medication is 
known to limit long-term graft survival54.  Secondly, the use of maintenance 
immunosuppressive therapy is associated with increased risk of infection and 
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malignancy55.  Thirdly, cardiovascular disease (CVD) is a well-known long-term 
complication in KTRs56; it is the leading cause of death after transplantation and death with 
a functioning graft57. 
 
In order to improve long-term patient- and graft- survival, kidney transplantation research 
today largely focuses on immunosuppression, immunology of transplantation, and 
evaluating the risk factors and their contributions to CVD in this population.  Several other 
non-immunological aspects of kidney transplantation, which potentially contribute to 
adverse long-term outcome of KTRs, have not been fully investigated.  This thesis sought 
to explore different compartments of body composition as a non-immunological factor.  A 
greater understanding of body composition is the prerequisite for developing interventional 
strategies, aiming to improve long-term patient- and graft survival. 
 
1.3.1 Effects of Body Composition on Clinical Outcomes of Kidney Transplantation 
 
Adiposity, a potential risk factor for CVD58, has been extensively researched in the field of 
kidney transplantation.  However, majority of the studies investigating the impact of 
adiposity have used BMI solely to estimate body composition. 
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1.3.1.1 Effects of Pre-Transplant Body Composition on Clinical Outcomes of Kidney 
Transplantation 
 
Overweight and obesity are common at the time of transplantation59.  Currently, 60% of 
KTRs are overweight at the time of transplantation59, representing a 116% increase from 
198759.  With the use of BMI, there is a consensus that pre-transplant obesity predisposes 
to delayed graft function52,60-66, which in turn is associated with reduced long-term graft 
survival52,60,67.  Also, it unanimously demonstrates a negative effect on post-transplant 
surgical outcomes61-66.  However, the effects of pre-transplant obesity on long-term 
patient- and graft- survival have yielded conflicting conclusions5,52,61-66,68-72.  Such 
discrepancies may partly stem from large variations in sample size, definition of “long-
term”73, and follow-up period (2-20 years).  The inconsistent results may also reflect the 
limitation of BMI to distinguish between fat mass, lean muscle mass and volume status. 
 
Specifically, only one study to date examined the impact of pre-transplant muscle mass 
together with BMI on mortality in KTRs5.  Streja et al found that pre-transplant obesity, 
defined as higher pre-transplant BMI values above the reference range of 22 to <25 kg/m2, 
did not confer an increased risk of long-term graft loss and mortality5.  In contrast, 
sarcopenic obesity, defined as reduced estimated pre-transplant muscle mass represented 
by lower pre-transplant serum creatinine in patients with BMI ≥ 30 kg/m2, was associated 
with increased mortality and graft failure5.  These findings suggest that pre-transplant 
obesity is not associated with inferior post-transplant outcomes, but increased muscle mass 
is associated with patient- and graft- survival benefits5.  However, it is important to note 
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that the use of BMI and serum creatinine as surrogates for body composition may be 
subject to limitations5.  Indeed, a recent editorial highlighted the need to define accurate 
and practical measures of body composition that predict clinical outcomes of kidney 
transplantation74.   
 
1.3.1.2 Effects of Post-Transplant Body Composition on Clinical Outcomes of 
Kidney Transplantation 
 
Weight gain after transplantation is very common and occurs in up to 50% of KTRs75,76, 
affecting obese and non-obese patients77.  The average weight gain after transplantation is 
between 10% and 35% of body weight, with most weight gain within the first 12 months 
after transplantation75,78-80.  The characteristics of body composition in KTRs are 
summarised in Table 1.1.  In essence, it appears that much of the weight gain post-
transplant is attributed to an increase in fat mass, especially in the abdominal area30.   
 
Excessive weight gain and increased fat mass in KTRs is traditionally attributed to the 
immunosuppression treatment protocol post-transplantation.  This is due to the well-known 
hyperphagic effect of steroids and their adverse influence on adipocytes, resting energy 
expenditure, and lipid oxidation, resulting in centripetal obesity (i.e. increased fat 
deposition in the peritoneum, mediastinum, and subcutaneous sites such as face and 
neck)81.  However, recent evidence suggests that the effect of steroids on weight gain is 
controversial75,81-86, weight gain post-transplantation may be largely due to lifting of 
previous dietary restrictions, improved appetite after the correction of uraemia, and the 
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enhanced sense of well-being that occurs with transplantation49.  Other contributing factors 
for post-transplant weight gain have been identified,  including age, gender, ethnicity, pre-
transplant BMI, dialysis modality, the occurrence and treatment of rejection, and graft 
function75,78,81. 
 
Weight gain and post-transplant obesity are commonly known to be associated with 
reduced long-term patient- and graft- survival52.  Although it failed to display an 
independent relationship with risk of CVD87-90, post-transplant obesity adversely affects 
cardiovascular risk profile including hypertension, dyslipidaemia, diabetes mellitus, and 
insulin resistance, all of which are independently associated with increased risk of graft 
failure87-90.  These individual conditions also cluster as part of the metabolic syndrome, 
which is associated with increased risk of graft failure as revealed by the recent sub-
analysis of the Assessment of LEscol in Renal Transplantation (ALERT) study91.   
 
In contrast, a recent study by Kovesdy et al6 found that higher BMI was associated with 
lower mortality after adjustment for waist circumference, whereas higher waist 
circumference was associated with higher mortality after adjustment for BMI.  In addition, 
clinically obese patients with exclusive subcutaneous fat excess were found in a normal 
metabolic state and demonstrated a limited deposition of fat at visceral sites92, conferring 
reduced metabolic risk.  Further, Haggan et al24 found that increased lean tissue mass 
during the first year post-transplantation was associated with the absence of delayed graft 
function and acute rejection.  Also, recent data from a renal transplant population showed 
that lower creatinine excretion, a proxy for reduced muscle mass, was associated with 
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increased mortality and graft failure7.  These findings suggest that not only does waist 
circumference appear to be a better prognostic marker for obesity than BMI, visceral 
adiposity adversely affects kidney transplant outcomes, and increased subcutaneous fat 
and/or muscle mass may be protective against mortality risk. 
 
1.3.1.3 Potential Mechanisms for Body Composition-Mediated Post-Transplant 
Clinical Outcomes 
 
A number of mechanisms associating body composition parameters with post-transplant 
clinical outcomes have been proposed; these are summarised in Figure 1.3.  In particular, 
sarcopenic obesity, characterised by reduced muscle mass coupled with increased fat mass, 
appears to be the driving force behind the adverse events.     
 
One of the survival advantages may derive from the beneficial effects of increased muscle 
mass, which has been proposed to improve skeletal, respiratory, and cardiac muscle 
function and consequently improve muscle based-oxidative mechanism, leading to 
increased antioxidant defense6.  Correspondingly, these mechanisms may reduce the risk of 
CVD, cancer, neurodegenerative disorders, and other chronic conditions93.  Also, gelsolin, 
produced by the skeletal muscle has been shown to be associated with improved survival in 
dialysis patients6.  Although the effect of gelsolin has not been studied in kidney 
transplantation, the depletion of which may explain higher mortality risk in KTRs. 
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Specifically, visceral adipose tissue is the most metabolically active system that secretes 
adipokines (cytokines secreted by adipose tissue), and examples include chemerin, IL-6, 
visfatin, adiponectin, leptin, tumor necrosis factor-alpha (TNF-α), and resistin95.  The 
effect of adiponectin remains controversial in KTRs, with Chitalia et al finding no 
association between adiponectin and CVD risk96, but Kaisar et al reported that higher 
adiponectin levels may be protective against the development of CVD, and this 
relationship may be delineated by the positive association between adiponectin and high-
density lipoprotein levels97.  Nevertheless, hypoadiponectinemia was shown to correlate 
with inflammation in KTRs, characterised by elevated C-reactive protein (CRP) and 
hsCRP97.   
 
Raised levels of visfatin were found to correlate with inflammation and markers of 
endothelial damage in KTRs, including raised levels of hsCRP, prothrombin fragments 1 
and 2, and vascular cell adhesion molecule (VCAM)98.  Also, raised resistin levels 
correlated with markers of inflammation and endothelial dysfunction in KTRs, including 
elevated levels of hsCRP, IL-6, thrombomodulin, and VCAM99. 
 
The link between inflammation and mortality in KTRs has been previously established by 
Winkelmayer et al100.  Inflammation has been proposed to exert its downstream adverse 
sequelae via the mediation of vascular damage causing vascular inflammation, which in 
turn leads to pathogenesis of atherosclerosis in KTRs94. 
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Another suggested mechanism associated with adiposity is that adipose tissues secrete pro-
inflammatory cytokines, including TNF-α and IL-6, which sequentially activate the renin-
angiotensin-aldosterone pathway, contributing to the onset and progression of graft 
damage by sustaining cell growth, inflammation, and fibrosis52.    
 
In addition, the metabolic load of the graft increases as a result of obesity; the graft 
consequently adapts by increasing in size and glomerular filtration52.  The combining 
effect of fibrosis and glomerulomegaly are the most common histologic lesions in patients 
with obesity-related glomerulopathy, suggesting that these are important pathways leading 
to graft failure.   
 
1.4 Barriers to Successful Quality of Life Outcomes of Kidney Transplantation 
 
Whilst improving clinical outcomes of kidney transplantation through maximising patient- 
and graft- survival are of utmost importance in kidney transplantation, achievement of 
maximal QoL is also one of the major goals of transplantation101.  The World Health 
Organisation defined QoL as “individuals’ perception of their position in life in the context 
of the culture and value systems in which they live and in relation to their goals, 
expectations, standards and concerns”102.  It includes different health-related aspects from 
patients’ perspective including physical, psychological, social functioning, and overall 
well-being101.  Of importance, previous studies have shown that physical health-related 
QoL predicts long-term mortality and graft failure independently of socio-demographic 
and clinical risk factors in KTRs103-105. 
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Although it is well recognised that QoL improves following successful kidney 
transplantation compared to remaining on dialysis106,107, life after transplantation may be 
subjected to several QoL challenges104,108,109.  Previous studies have shown that female 
gender, increasing time post-transplantation, lower education level, reduced functional 
status, anaemia, comorbidity, immunosuppressive therapy, sleep disorders, fatigue and 
depression, impair post-transplant QoL110-112.  Despite this, there is a paucity of research 
addressing these factors with QoL as the endpoint.  The scarce data mainly pertains to 
minimising physical side effects of immunosuppression by converting immunosuppressive 
therapy, and reducing symptoms of depression with psychotherapy.   
 
1.4.1 Immunosuppression and Quality of Life in Kidney Transplant Recipients 
 
Modern maintenance immunosuppression therapy has improved long-term patient- and 
graft- survival, but such treatment protocol has led to medical and physical side effects, 
compromising QoL109.  Corticosteroids and calcineurin inhibitors (both tacrolimus and 
cyclosporine) continued to be the mainstream of contemporary immunosuppression.  
However, these medications are associated with physical side effects.  Corticosteroids 
commonly trigger weight gain, hirsutism, acne, cushingoid appearance, osteoporosis, and 
mood disturbance113.  Calcineurin inhibitors frequently cause hirsutism, gingival 
hyperplasia, alopecia, and hand tremors111,114-117; although substantial differences have 
been observed between tacrolimus and cyclosporin111,114-117.  Previous studies have shown 
that such immunosuppression-related physical side effects exert significant psychological 
impact on KTRs111,118, leading to non-adherence to immunosuppression treatment 
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regimens which may result in acute rejection, graft loss, hospitalisation and mortality109.  
Conversion from cyclosporin to tacrolimus demonstrated positive results in reducing 
hirsutism and gingival hyperplasia without affecting graft function119,120, potentially 
improving QoL. 
 
1.4.2 Depression and Quality of Life in Kidney Transplant Recipients 
 
Depression, although its severity and prevalence post-transplantation is lower compared to 
remaining on dialysis, it continues to be an important determinant of QoL following 
transplantation121,122.  KTRs are subjected to several mental challenges including frequent 
medical follow-up, the necessity to adhere to a complex regimen of immunosuppressive 
therapy that may generate distressing side effects, and the anxiety and fears about 
transplant rejection leading to potential graft loss123.  Of importance, depression 
independently predicts mortality in KTRs122.  On the positive side, psychotherapy has 
shown promising results in alleviating symptoms of depression in KTRs124. 
 
1.4.3 Fatigue and Quality of Life in Kidney Transplant Recipients 
 
Similar to the clinical outcomes of kidney transplantation, many other aspects which may 
impact upon QoL following transplantation have not been well investigated.  In particular, 
fatigue has received little attention in the field of kidney transplantation.  Fatigue is an 
important QoL outcome, it may be measured as part of QoL, or may be evaluated 
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independently using an assessment tool specially tailored to address the multi-dimensional 
aspects of fatigue125.    
 
Fatigue represents an important patient-reported outcome in many medical conditions126,127 
and involves physical, cognitive, emotion, and functional components128.  It is often 
medically unexplained129, persistent127, and interferes with an individual’s ability to 
function in important roles130.  As a corollary, fatigue can have a major negative impact 
upon QoL131.  In chronic dialysis patients, fatigue is frequently reported as a pervasive and 
distressing symptom132-134.  The fact that kidney transplantation improves QoL and results 
in an enhanced sense of well-being135, means that it is often assumed that fatigue no longer 
features as a major problem after transplantation, but in fact there has been very little 
research to either confirm or refute this assumption.  Only one study has specifically 
examined fatigue after transplantation112, noting that the symptom was reported in 59% of 
KTRs and that it negatively impacted on virtually every aspect of the QoL112.   
 
1.4.3.1 Effects of Body Composition on Fatigue in Kidney Transplant Recipients 
 
Body composition may be an important determinant of fatigue.  However, the effects of 
body composition on post-transplantation fatigue have not been well-investigated.  Thus 
far, only one study determined the contributors to fatigue following kidney transplantation.  
Poor sleep quality, mood disturbance, and raised BMI were identified as significant 
predictors for post-transplantation fatigue112.  However, the impact of different body 
composition compartments on fatigue was not examined and warrant further investigation. 
Chapter 1 
29 
1.5 Aims and Outline of the Thesis 
 
With this background, evidently, there are significant gaps in the current literature 
pertaining to the effects of body composition including fat mass, muscle mass and volume 
status, on both clinical and QoL outcomes in KTRs.  The studies presented in this thesis 
aim to explore the effects of different body composition compartments on morbidity and 
fatigue, the potential contributing factors to long-term patient- and graft- survival, as well 
as QoL. 
 
1.5.1 Chapter 2:  The Role of Hepcidin-25 in Kidney Transplantation 
 
Chapter 2 investigates the associations between adiposity with inflammation, hepcidin and 
haemoglobin levels in KTRs.   
  
Anaemia (or low haemoglobin level) remains a common finding post-transplantation136,137.  
Reduced haemoglobin levels are associated with short-term complications, inferior patient 
and graft survivals138-140.  Hepcidin is a peptide hormone synthesized by hepatocytes in 
response to iron repletion and acute phase inflammation141-143.  Adipose tissue also releases 
hepcidin in response to systemic inflammation 144and the local inflammatory milieu within 
the adipose tissue145.  Upon hepatic and adipocytic synthesis, hepcidin reduces intestinal 
iron absorption and sequestration142, limiting haemoglobin production.  Hepcidin may 
therefore explain the link between inflammation and reduced haemoglobin levels146,147, a 
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relationship that remains unestablished in the field of kidney transplantation.  Similarly, the 
relationship between inflammation and hepcidin has not been explored in kidney 
transplantation148.  Also, the underlying determinants of inflammation in this setting 
remain controversial.  In particular, both low and high BMI were suggested as potential 
causes of inflammation in previous studies94,149,150. 
 
The primary aims of this chapter were to determine the factors influencing hepcidin levels, 
and to establish the relationship between hepcidin and haemoglobin levels in clinically 
stable KTRs.  The secondary aims were to describe the factors associated with 
inflammation in this setting, and to assess the correlation between inflammation and 
adiposity.  This will address whether adiposity-related inflammation in KTRs is associated 
with elevated hepcidin, possibly contributing to reduced haemoglobin by dysregulation of 
iron homeostasis.  
 
1.5.2 Chapter 3:  Hypervolemia and Blood Pressure in Prevalent Kidney Transplant 
Recipients 
 
Chapter 3 focuses on the effects of hypervolemia (or volume expansion) on blood pressure 
and levels of N-terminal fragment of pro-hormone B-Type natriuretic peptide (NT-
proBNP). 
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Hypervolemia is associated with hypertension in dialysis patients151,152, but this 
relationship has not been studied in KTRs, despite the latter complication being a major 
risk factor for CVD153, the leading cause of death in KTRs. 
 
NT-proBNP, is a biologically inactive peptide, cleaved from pro-hormone B-type 
natriuretic peptide (pro-BNP) that is secreted from ventricles in response to increased 
stretch of the ventricular wall154.  NT-proBNP is an independent predictor of mortality in 
patients with end-stage renal disease155.  Recent studies have confirmed that it is marker of 
volume overload rather than cardiac dysfunction per se in maintenance dialysis patients156-
159.  However, little research has examined this relationship after transplantation, with 
limited data showing an inverse relationship between NT-proBNP levels and allograft 
function160,161. 
 
The primary objectives of this chapter were to determine the prevalence and predictors for 
hypervolemia in clinically stable KTRs, and to assess its association with post-transplant 
hypertension.  Secondly, this study sought to explore the utility of NT-proBNP as a marker 
of hypervolemia and renal dysfunction in this cohort. 
 
1.5.3 Chapter 4:  Predictors and Consequence of Fatigue in Prevalent Kidney 
Transplant Recipients 
 
Chapter 4 explores the role of muscle and fat masses on post-transplantation fatigue. 
Chapter 1 
32 
Fatigue is a common symptom following kidney transplantation112.  However, it has been 
under-investigated as discussed in Section 1.4.3.  Raised BMI was identified as a 
significant predictor for post-transplantation fatigue112, but the impact of different body 
composition compartments remains unknown.  Greater insight into fatigue severity, its 
impact on QoL, and its possible underlying causes are all prerequisites for developing 
interventions to combat this symptom.  In addition, it is important to ascertain the extent to 
which clinicians are aware of the problem. 
 
The purposes of this chapter were to determine the nature, severity, prevalence, and 
clinical awareness of fatigue in clinically stable KTRs.  Additionally, this study aimed to 
examine the impact of this symptom upon QoL, determine the associations between fatigue 
with lean tissue mass and fat mass, and to explore other potential predictors of post-
transplantation fatigue. 
 
1.5.4 Chapter 5:  Cardiovascular, Muscular and Perceptual Contributions to 
Physical Fatigue in Prevalent Kidney Transplant Recipients 
 
Chapter 5 specifically examines the mechanistic aetiology of physical fatigue in KTRs by 
evaluation of muscle mass, muscular and cardiovascular functions, and fatigue perception. 
 
Physical fatigue describes physical sensations of tiredness162, leading to physical 
underperformance163.  One of the major findings from Chapter 4 showed that physical 
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fatigue represents the dominant component of fatigue in KTRs, outweighing behavioural, 
emotional, and cognitive aspects.   
 
Conceptually, research on physical fatigue has traditionally been considered as either 
“cardiovascular”, “muscular” or “perceptual” in aetiology.  The cardiovascular model 
refers to insufficient oxygen or nutrient delivery to the muscular system, limiting oxidative 
phosphorylation and glycolysis, both of which are essential mechanisms for muscle 
contraction164.  Accordingly, fatigue with cardiovascular origin results in decreased ability 
of muscle to generate and to maintain force, hence reducing the capability to sustain 
muscle contraction, possibly contributing to physical fatigue.  The muscular model denotes 
insufficient muscle mass or reduction in muscle function, leading to failure of muscle force 
generation164-166, and/or ability to maintain a certain force or power output167, plausibly 
resulting in physical fatigue.  The perceptual theory represents the increased perception of 
effort, characterised by loss of motivation and reluctance to perform a physical task when 
perception of effort reaches a certain level.  In fatigue with perception origin, individuals 
experience heightened responses to afferent feedback from the working body, resulting in 
exhaustion164,168,169, which may be expressed as physical fatigue.   
 
Of interest, it has been recognised that mental fatigue, characterised by inability to focus 
and maintain cognitive attention, is a crucial determinant of physical limits in healthy 
individuals170-172, by heightening the perception of exertion170,171.  This phenomenon 
suggests that mental fatigue possibly contributes to physical fatigue by raising perception 
of exertion. 
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The cardinal mechanistic aetiology of physical fatigue in KTRs remained unexplored.  
Therefore, the primary objectives of this chapter were to systematically examine the 
aetiology of physical fatigue in KTRs, by measuring factors which may be mechanistically 
linked to symptoms of physical fatigue.  These include quantification of muscle mass, 
assessment of muscular and cardiovascular functions, and by evaluating perceived exertion 
during a standardised exercise protocol.  We also sought to establish the prevalence of 
physical fatigue and its impact upon QoL in clinically stable KTRs.  The key findings are 
that, physical fatigue, which adversely impacts on QoL, affects 22% of KTRs, and that 
cardiovascular and muscular factors do not contribute to the aetiology of physical fatigue.  
These observations point towards increased perception of exertion as the dominant cause 
of physical fatigue.  Such findings arising from the earlier part of this chapter led to further 
investigation to examine the role of mental fatigue, and other plausible predictors of 
heightened perception. 
 
1.5.5 Chapter 6:  General Discussion 
 
Chapter 6 addresses the major findings from the thesis, discussing the strengths and 
limitations of the aforementioned studies, the clinical implications and directions for future 
research. 
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1.5.6 Chapter 7:  Appendices 
 
Chapter 7 includes confirmation of ethical approval, and all the questionnaires used for the 
research studies presented in this thesis. 
 
1.6 Study Design and Patient Selection in this Thesis 
 
The studies presented in chapters 2 to 5 are single-centre cross-sectional pilot studies, and 
recruited KTRs from the out-patient clinic of the Queen Elizabeth Hospital Birmingham, 
United Kingdom.  In total, 139 KTRs underwent initial screening for eligibility between 
July 2010 and August 2013.  The same group of KTRs were used for each of the studies 
described in this thesis.  Generic inclusion and exclusion criteria were employed at first, 
followed by specific exclusion criteria for each chapter.  These are summarised in the flow 
diagram shown in Figure 1.4.  
 
1.7 Ethical Approval of Research Studies presented in this Thesis 
 
The studies presented in chapters 2 to 5 in this thesis were approved by the Staffordshire 
Research Ethics Committee, with Research Ethics Committee reference number of 
10/H1203/16, confirmation of favourable ethical opinion can be found under Appendices, 
Chapter 7, Sections 7.1 to 7.4.   
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CHAPTER 2:  THE ROLE OF HEPCIDIN-25 IN KIDNEY TRANSPLANTATION 
 
2.1 Abstract 
 
Background and Objectives:  Hepcidin-25 is a peptide hormone involved in iron 
absorption and homeostasis.  It is found at increased serum levels in conditions involving 
systemic inflammation, renal dysfunction, and increased adiposity.  Hepcidin may be 
involved in the pathogenesis of anaemia, but its role in kidney transplantation remains 
undefined.  The primary objectives of this study were to determine the factors influencing 
serum hepcidin levels, and to establish the relationship between hepcidin and haemoglobin 
levels in clinically stable kidney transplant recipients (KTRs).  The secondary objectives 
were to ascertain the factors associated with inflammation in this setting, and to assess the 
correlation between adiposity and inflammation.   
 
Materials and Methods: This single-centre cross-sectional study enrolled 100 clinically 
stable KTRs at least 12 months post-transplantation.  Serum hepcidin-25 level, and 
relevant demographic and laboratory data pertinent to post-transplantation anaemia, were 
measured and collected.  
 
Results:   Independent associations were observed between raised hepcidin levels and 
allograft dysfunction (reduced estimated glomerular filtration rate), inflammation (elevated 
high sensitivity C-reactive protein), iron storage (elevated transferrin saturation), and the 
use of marrow-suppressive medications (p<0.05 for all associations).  In addition, 
increased fat tissue index (whole-body multi-frequency bio-impedance spectroscopy 
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measurement) was associated with elevated hepcidin levels, but this relationship did not 
persist after adjustment for inflammation.  In turn, inflammation was associated with 
increased fat tissue index (p=0.01) and male gender (p=0.04).  Further, a non-linear 
association between serum hepcidin and haemoglobin levels was established, with 
progressive decrease in haemoglobin as hepcidin increased to 100 ng/mL, but limited 
effect thereafter (p=0.009).  This association was independent of renal dysfunction and 
female gender, both of which also displayed independent relationships with reduced 
haemoglobin level. 
 
Conclusions:  This study highlights the possible mechanisms of haemoglobin reduction in 
KTRs, and the therapeutic opportunities from understanding the role of hepcidin in this 
context.  
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2.2 Introduction 
 
Anaemia remains a common finding after kidney transplantation, occurring in 
approximately 30% of kidney transplant recipients (KTRs) beyond the first year post-
transplantation1,2.  This is not merely an incidental laboratory finding because reductions in 
haemoglobin levels have been associated with short-term complications, and inferior 
patient- and graft- survival3-5.  Furthermore, a causal role for lower haemoglobin levels 
leading to adverse events was suggested by the patients of the Correction of Anaemia and 
Progression of Renal Insufficiency in Transplant (CAPRIT) study, which demonstrated a 
slower progression of kidney disease, a lower incidence of end-stage renal failure, and an 
improved quality of life in patients targeted to higher haemoglobin concentrations with 
recombinant erythropoietin6.  However, reduced renal function and erythropoietin 
deficiency do not fully account for reduced haemoglobin levels observed in chronic kidney 
disease (CKD) or transplantation7, highlighting the importance of understanding the 
determinants of haemoglobin in this setting. 
 
An important and recently recognised component of haemoglobin homeostasis is hepcidin, 
the biologically active form of which is a 25 amino acid protein (hepcidin-25), synthesised 
by liver and adipose tissues, derived from prohepcidin, and degraded to inactive hepcidin-
208.  Hepcidin has been described as the “master regulator of iron homeostasis” with 
hepatic synthesis increasing with iron repletion.  A primary action of hepcidin-25 is the 
internalisation and subsequent degradation of ferroportin, the iron transporter found in 
duodenal enterocytes and macrophages9.  This results in reduced intestinal iron absorption, 
and iron sequestration within the reticulo-endothelial system9.  Thus, hepcidin plays a vital 
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role in protection from iron overload as there is no recognised mechanism by which iron 
excretion can be increased.  In addition, hepatic hepcidin synthesis is suppressed during 
times of increased red cell production by the marrow, thereby linking iron availability with 
requirement10.  
 
Additionally, it is recognised that hepcidin may be important in certain pathological states.  
In particular, hepatic hepcidin synthesis is increased in response to an acute phase 
inflammation11.  Adipose tissue also releases hepcidin in response to systemic 
inflammation12, and the local inflammatory milieu within the adipose tissue13.  Therefore, 
it is possible that increased hepcidin production may explain the link between 
inflammation and reduced haemoglobin levels14.  
 
CKD, and therefore kidney transplantation, presents an added complexity to these 
relationships because of the association between renal dysfunction and elevated hepcidin 
levels8,15-17.  A previous study in patients with non-transplantation CKD revealed an 
association between higher circulating hepcidin levels and lower haemoglobin levels, 
independent of renal function18.  However, it is currently unknown whether a similar 
relationship exists in KTRs.  Similarly, the described relationship between inflammation 
and hepcidin has not been established in kidney transplantation19, although this may 
provide the “missing link” between inflammation and anaemia in transplanted patients20.  
Also, there are conflicting data pertaining to the underlying determinants of inflammation 
in this setting.  In particular, both low and high body mass index (BMI) were suggested as 
potential causes of inflammation21-23. 
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The primary purpose of this study was to gain a greater understanding of the factors 
influencing serum hepcidin levels, and the relationship between hepcidin and haemoglobin 
levels in clinically stable KTRs.  Clarifying the role of hepcidin in this context is 
increasingly relevant, not only to understanding the mechanism of anaemia in 
transplantation, but also in light of emerging strategies to increase haemoglobin levels by 
antagonising the production or activity of hepcidin24,25.  The secondary aims were to 
determine the factors associated with inflammation in this setting, and to assess the link 
between adiposity and inflammation. 
 
2.3 Materials and Methods 
 
2.3.1 Study Design and Participants 
 
This prospective, observational cohort study recruited KTRs from the out-patient clinic of 
the Queen Elizabeth Hospital Birmingham, United Kingdom.  Inclusion criteria were 
KTRs with stable graft function at least 12 months post-transplantation, and with no 
previous episodes of acute allograft rejection in the 6 months prior to enrolment.  KTRs 
with defined acute or chronic inflammatory disease, such as bacterial or viral infection, 
active autoimmune disease, or neoplasia, were excluded.  KTRs on recombinant 
erythropoietin therapy were also excluded.   
 
The recruitment target of 100 patients was achieved after 114 patients had been 
approached to participate.  The main reason for decline in participation was work 
commitment (n=9), participation in other research studies (n=3), and no reason given 
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(n=2).  The study received approval from the research ethics committee, and was 
conducted in accordance with the principles of the Declaration of Helsinki. 
 
2.3.2 Data Collection 
 
The following measures were evaluated for each participant of the study. 
 
Patient demographics:  Age, gender, time post-transplantation, and diabetes status, either 
documented as a comorbidity prior to transplantation, or the presence of new onset 
diabetes after transplantation (NODAT). 
 
Other biochemical parameters were determined on the blood samples collected following a 
10-hour overnight fast:  Serum albumin, transferrin saturation (TSAT), high sensitivity C-
reactive protein (hsCRP), hepcidin-25 (see below for methodology), and estimated 
glomerular filtration rate (eGFR) using the 4-variable modification of diet in renal disease 
(MDRD) equation with serum creatinine alignment to isotope dilution mass spectrometry-
based methodology. 
 
Medication:  Use and doses of the antiproliferative agents including mycophenolate 
mofetil (MMF) or azathioprine versus neither; use of angiotensin converting enzyme 
inhibitors (ACEI) or angiotensin receptor blockers (ARB) versus neither; and use of statin 
therapy. 
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Adipose tissue mass (kg) was assessed using the whole-body multi-frequency bio-
impedance spectroscopy, known as the Body Composition Monitor (BCM, Fresenius 
Medical Care, Hamburg, Germany) as described previously26.  Adipose tissue mass was 
normalised to height (m2) subsequently, and expressed as Fat Tissue Index (FTI, kg/m2).  
Additionally, in a subset of 20 patients, dual energy X-ray absorptiometry (DEXA) 
scanning was undertaken as the “gold standard” method for fat mass estimation, thereby 
allowing method comparison with bio-impedance measurement.   
 
Documented episodes of biopsy proven prior acute rejection episodes were retrieved from 
the records of the prospectively collected institutional database.   
 
Only 4 patients admitted current tobacco use, and only 4 patients were not treated with a 
calcineurin inhibitor, and these variables were not considered for analysis. 
 
2.3.3 Analysis of Hepcidin-25 
 
The active form, hepcidin-25, was measured by surface enhanced lazer desorption / 
ionization time-of-flight mass spectrometry (SELDI-TOF-MS) using Cu2+ loaded IMAC 
ProteinChip arrays (Ciphergen Biosystems, Fremont, CA) and stable isotope-labelled 
hepcidin as an internal standard, as described previously27 and available at 
http//:www.hepcidin.bham.ac.uk. 
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2.3.4 Statistical Analysis 
 
SPSS Statistics 21 (Chicago, IL) was used for statistical analysis.  Results are expressed as 
mean ± standard deviation unless otherwise stated.  For the major regression analyses, 
there were three outcome variables (haemoglobin level, serum hepcidin concentration, and 
serum hsCRP concentration).  Each of the variables was measured on a continuous scale 
and linear regression methods were used for analysis.  Haemoglobin levels displayed a 
normal distribution, and was analysed on its original scale of measurement.  Hepcidin and 
hsCRP concentrations were both positively skewed, and were subjected to logarithmic 
transformation prior to analysis.  Therefore, the regression coefficients for these analyses 
represent the proportional, rather than absolute, change in hepcidin or hsCRP for the 
described change in the studied explanatory variable.   
 
The analyses were performed in two stages.  Initially, the separate effect of each predictor 
variables was examined in a series of univariate analyses.  Where the relationships were 
found to be non-linear, quadratic (squared) terms were added to the model in order to 
improve the capture of the relationship between variables.  Variables showing some 
evidence of association on univariate analysis (p<0.15) were subsequently and jointly 
examined in multivariate analysis.  A backwards selection procedure was performed to 
simplify the final model to include only those variables found to be statistically significant 
predictors (type I error rate ≤5%). 
 
Method comparison between the BCM and DEXA was performed by Passing-Bablok 
regression analysis, a technique specifically developed for method comparison purposes. 
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2.4 Results 
 
Patient demographics, laboratory and anthropometric data are shown in Table 2.1.  
 
Table 2.1.  Population Characteristics of the Study Cohort 
 
Age (years) 50.9 ± 13.7 
Gender, male (%) 54 
Time post-transplantation (years) 8.2 ± 6.7 
Diabetes, pre-existing or NODAT (%) 19 
Current Tobacco Use (%) 4 
Previous Biopsy Proven Acute Rejection (%) 27 
Haemoglobin (g/dL) 12.2 ± 1.5 
Serum Hepcidin (ng/mL) 43 (29-67) 
eGFR (mL/min) 44.1 ± 17.6 
hsCRP (mg/L) 2.40 (1.00-4.99) 
Transferrin Saturation (%) 25.2 ± 7.2 
Serum Albumin (g/L) 44.5 ± 3.1 
FTI (kg/m2) 14.2 ± 6.2 
Current calcineurin inhibitor use (%) 96 
Current antiproliferative use, MMF or Azathioprine (%) 86 
Current use of ACEI or ARB (%) 46 
Current use of statin (%) 32 
 
Results expressed as mean ± standard deviation, median (interquartile range), or 
percentage. 
 
Abbreviations:  NODAT=New Onset Diabetes After Transplantation; eGFR=Estimated 
Glomerular Filtration Rate; hsCRP=high sensitivity C-Reactive Protein; FTI=Fat Tissue 
Index; MMF=Mycophenolate Mofetil; ACEI=Angiotensin Converting Enzyme Inhibitor; 
ARB=Angiotensin Receptor Blocker. 
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2.4.1 Determinants of Serum Hepcidin Level 
 
Hepcidin levels are shown in Figure 2.1.   
 
Figure 2.1.  Distribution of Serum Hepcidin Levels.  Numbers of patients are shown 
with corresponding ranges of serum hepcidin. 
 
 
A summary of univariate associations are shown in Table 2.2.  When examined 
individually, higher hepcidin levels were associated with increased levels of inflammation 
(log-transformed hsCRP), the use of ACEI or ARB, the use of antiproliferative agents 
(MMF or azathioprine), increased iron stores (assessed with serum TSAT), and higher fat 
mass (assessed by FTI).  In addition, hepcidin levels were significantly associated with 
eGFR.  This association was non-linear as shown in Figure 2.2.  In general, an inverse 
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association between eGFR and hepcidin was observed, with hepcidin levels rising at eGFR 
values of less than approximately 40 mL/min, and the relationship tailed off at higher 
levels of renal function.   
 
Table 2.2.  Univariate and Multivariate Associations with Serum Hepcidin Level  
(*) Ratio reported for a 10-unit increase in explanatory variable.  (**) Ratio reported for a 5-unit increase in 
explanatory variable.  (†) Variable analysed on log scale.   
Abbreviations:  eGFR=estimated Glomerular Filtration Rate; hsCRP=high sensitivity C-Reactive Protein; 
TSAT=Transferrin Saturation; ACEI=Angiotensin Converting Enzyme Inhibitor; ARB=Angiotensin Receptor 
Blocker; MMF=Mycophenolate Mofetil; FTI=Fat Tissue Index. 
 
The final multivariate model shown in Table 2.2 confirmed the relationships between 
serum hepcidin and eGFR, log-transformed hsCRP, TSAT, the use of ACEI or ARB, and 
Variable Category Univariate 
Coefficient  
(95% CI) 
Univariate 
p-value 
Multivariate 
Coefficient 
(95% CI) 
Multivariate 
p-value 
      
*eGFR (mL/min) Linear term 0.69 (0.57, 0.84) 0.001 0.73 (0.61, 0.87) 0.001 
 Squared term 1.03 (1.01, 1.05) 0.001 1.02 (1.01, 1.03) 0.001 
      
†hsCRP (mg/L) - 1.15 (1.07, 1.24) 0.001 1.13 (1.06, 1.21) 0.001 
      
*TSAT (%)  1.25 (1.11, 1.40) 0.001 1.27 (1.15, 1.41) 0.002 
      
ACEI / ARB Yes 1.22 (1.03, 1.44) 0.02 1.18 (1.02, 1.37) 0.03 
      
MMF / 
Azathioprine 
Yes 1.31 (0.55, 3.12) 0.04 1.16 (1.03, 1.31) 0.03 
      
**FTI (kg/m2) - 1.07 (1.00, 1.14) 0.05   
      
Gender Male 0.96 (0.81, 1.14) 0.63   
      
*Age (years) - 1.00 (0.94, 1.07) 0.93   
      
**Time post-
transplantation 
(years) 
- 1.05 (0.98, 1.11) 0.14   
      
Rejection Yes 1.05 (0.85, 1.30) 0.62   
      
Diabetes status Yes 1.11 (0.89, 1.38) 0.40   
      
Albumin (g/dL)  0.99 (0.96, 1.02) 0.47   
      
Statin therapy Yes 0.96 (0.68, 1.35) 0.33   
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the use of antiproliferative agents.  These variables explained 45% of the variation in 
hepcidin levels (R2: 0.45).  After adjustment for these variables, the association between 
FTI and hepcidin level was no longer significant. 
 
Figure 2.2.  Association between Serum Hepcidin Level and Renal Function. 
 
 
In light of the association between antiproliferative co-medication and hepcidin levels, a 
subsidiary analysis of medication doses was undertaken.  No significant relationship was 
observed between azathioprine or MMF doses and serum hepcidin level (p=0.09 and 
p=0.10, respectively, in separate sub-analyses), although the analyses were limited by 
lower numbers.  Due to the varied formulations of ACEI and ARB, no sub-analysis of 
dose-relationship was undertaken for these agents. 
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2.4.2 Determinants of Inflammation 
 
Due to the observed relationship between inflammation and hepcidin, and the limited and 
conflicting data available on to the aetiology of inflammation in KTRs, particularly with 
regard to low and high BMI21-23, a secondary analysis was performed, focusing on the 
factors associated with inflammation, assessed by log-transformed hsCRP level.   
 
When examined individually, FTI was significantly associated with hsCRP.  This 
relationship was non-linear as shown in Figure 2.3.   
 
Figure 2.3.  Association between Fat Tissue Index (FTI) and Inflammation (hsCRP) 
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There was a slight increase in hsCRP as FTI increased to 20 kg/m2, with a stronger positive 
relationship between the two variables at higher FTI values.  In addition, the presence of 
diabetes (a composite of pre-transplantation diabetes and NODAT) was also associated 
with increased hsCRP levels, Table 2.3. 
 
Table 2.3.  Univariate and Multivariate Associations with high-sensitivity C-Reactive 
Protein (hsCRP) 
(*) Ratio reported for a 5-unit increase in explanatory variable.  (**) Ratio reported for a 10-unit increase in 
explanatory variable.   
Abbreviations:  FTI=Fat Tissue Index; ACEI=Angiotensin Converting Enzyme Inhibitor; 
ARB=Angiotensin Receptor Blocker; MMF=Mycophenolate Mofetil; eGFR=estimated Glomerular Filtration 
Rate. 
 
 
Variable Category Univariate 
Coefficient  
(95% CI) 
Univariate 
p-value 
Multivariate 
Coefficient 
(95% CI) 
Multivariate 
p-value 
      
*FTI (kg/m2) Linear term 0.77 (0.38, 1.56) 0.009 0.80 (0.48, 1.33) 0.01 
 Squared term 1.11 (1.06, 1.17)  1.10 (1.03, 1.17)  
      
Gender Male 0.96 (0.81, 1.14) 0.15 1.44 (1.09, 1.91) 0.04 
      
Diabetes status Yes 1.35 (1.03, 1,77) 0.03   
      
ACEI / ARB Yes 1.26 (0.89, 1.78) 0.21   
      
MMF / 
Azathioprine 
Yes 0.95 (0.58, 1.56) 0.83   
      
**eGFR (mL/min) - 0.98 (0.90, 1.07) 0.68   
      
**Age (years) - 0.94 (0.84, 1.06) 0.30   
      
*Time post-
transplantation 
(years) 
- 1.05 (0.93, 1.17) 0.45   
      
Rejection Yes 0.74 (0.50, 1.10) 0.13   
      
Statin therapy Yes 0.90 (0.62, 1.31) 0.27   
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In the multivariate model, FTI remained associated with hsCRP, and a similar relationship 
was demonstrated.  In addition, increased hsCRP levels were observed in male KTRs, 
Table 2.3.  These two variables explained 27% of the variation in hsCRP levels (R2: 0.27).  
Diabetes no longer retained significance in the multivariate model. 
 
2.4.2.1 Comparing Methods of Measurement of Adiposity: Bio-impedance Analysis 
and Dual Energy X-ray Absorptiometry Scanning 
 
In light of the association between inflammation and FTI assessed using the bio-impedance 
spectroscopy, a comparison between bio-impedance spectroscopy and DEXA assessment 
of fat mass was undertaken.  Passing-Bablok regression was used to assess the relationship 
between the 2 methods, and is shown graphically in Figure 2.4.  Although bio-impedance 
spectroscopy was associated with slightly lower absolute readings for fat mass when 
compared with DEXA scanning (as shown by the intercept of the regression line), the 2 
methods demonstrated a high degree of correlation (r=0.94).  Therefore, for the purposes 
of the current analyses, bio-impedance spectroscopy using the BCM is an appropriate and 
robust technique to determine the relationship between fat mass, adjusted to height and 
expressed as FTI, and the outcome variables assessed. 
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Figure 2.4.  Passing-Bablok regression demonstrating the Method of Comparison 
between Whole-body Multi-frequency Bio-impedance Spectroscopy and Dual Energy 
X-ray Absorptiometry (DEXA) Scanning for Estimation of Body Fat Mass 
 
 
2.4.3 Relationship between Hepcidin and Haemoglobin 
 
A significant relationship between haemoglobin and serum hepcidin levels was 
established.  This association was non-linear as shown in Figure 2.5.  In general, it 
demonstrated that lower haemoglobin levels at higher serum hepcidin levels.  This 
relationship diminished at higher serum hepcidin concentrations, with limited evidence for 
an incremental effect with hepcidin levels greater than 100 ng/mL.   
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Figure 2.5.  Association between Serum Hepcidin Level and Haemoglobin Level   
 
 
On univariate analysis, Table 2.4, lower haemoglobin levels were also associated with 
reduced renal function, inflammation (log transformed hsCRP), female gender, the use of 
either ACEI or ARB, and the use of antiproliferative immunosuppressants (MMF or 
azathioprine).  
 
After adjustment for hepcidin level, the effect of inflammation on haemoglobin level was 
no longer significant.  The final multivariate model confirmed the independent association 
between serum hepcidin and haemoglobin levels.  Reduced renal function and female 
gender were also associated with reduced haemoglobin level.  A summary of the results for 
this analysis is shown in Table 2.4, with 35% of the variation in haemoglobin level 
explained by the variables in the final model (R2: 0.35).  In addition, although not reaching 
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conventional levels of significance, there was some evidence for associations between 
lower haemoglobin level with the use of ACEI or ARB (regression coefficient: -0.36; 95% 
CI: -0.74, 0.02; p=0.06), and with the use of antiproliferative agents (regression 
coefficient: -0.30; 95% CI: -0.63, 0.04; p=0.08).  
 
Table 2.4.  Univariate and Multivariate Associations with Haemoglobin 
(*) Coefficients reported for a 20-unit increase in explanatory variable.  (**) Coefficients reported for a 10-
unit increase in explanatory variable.  (***) Coefficients reported for a 5-unit increase in explanatory 
variable.  (†) Variable analysed on log scale. 
Abbreviations:  eGFR=estimated Glomerular Filtration rate; hsCRP=high sensitivity C-Reactive Protein; 
ACEI=Angiotensin Converting Enzyme Inhibitor; ARB=Angiotensin Receptor Blocker; 
MMF=Mycophenolate Mofetil; FTI=Fat Tissue Index; TSAT=Transferrin saturation. 
 
Variable Category Univariate Beta 
Coefficient  
(95% CI) 
Univariate 
p-value 
Multivariate Beta 
Coefficient  
(95% CI) 
Multivariate 
p-value 
      
*Hepcidin (ng/mL) Linear term -1.07 (-1.42, -0.73) 0.009 -1.12 (-1.44, -0.79) 0.009 
 Squared 
term 
0.08 (0.04, 0.12)  0.09 (0.06, 0.13)  
      
**eGFR (mL/min)  - 0.31 (0.20, 0.42) 0.002 0.22 (0.12, 0.31) 0.002 
      
Gender Male 0.57 (0.16, 0.98) 0.01 0.57 (0.24, 0.90) 0.008 
      
†hsCRP (mg/L) - -0.21 (-0.38, -0.04) 0.03   
      
ACEI / ARB Yes -0.48 (-0.89, -0.07) 0.03   
      
MMF / Azathioprine Yes -0.42 (-0.70, -0.14) 0.04   
      
***FTI (kg/m2) - -0.04 (-0.21, 0.13) 0.62   
      
**Age (years) - -0.02 (-0.17, 0.13) 0.79   
      
***Time post-
transplantation 
(years) 
- -0.11 (-0.27, 0.04) 0.15   
      
Rejection Yes -0.07 (-0.60, 0.46) 0.79   
      
***TSAT (%) - -0.13 (-0.42, 0.16) 0.39   
      
Diabetes status Yes -0.33 (-0.88, 0.12) 0.23   
      
Albumin (g/dL) - -0.02 (-0.09, 0.05) 0.58   
      
Statin therapy Yes 0.06 (-0.56, 0.68) 0.44   
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2.5 Discussion 
 
The major finding of this study is the independent association between elevated serum 
hepcidin and reduced haemoglobin levels in clinically stable KTRs, with hepcidin levels 
mostly driven by systemic inflammation and reduced renal function.  Whilst the common 
explanation for low haemoglobin levels in patients with kidney disease is reduced renal 
function and erythropoietin deficiency, this does not fully explain the phenomenon7.  Even 
prior to the recent and still evolving understanding of the role of hepcidin in iron 
homeostasis and erythropoiesis, it was recognised that other factors must play a role in the 
determination of haemoglobin levels after kidney transplantation28,29.   
 
This study represents the first evidence for an independent association between raised 
serum hepcidin and reduced haemoglobin levels in this setting.  A progressive and 
clinically relevant reduction in haemoglobin was observed with increasing hepcidin levels, 
and this was independent of renal function and other relevant confounding factors.  These 
observations extend to the field of kidney transplantation, with limited data from non-
transplantation CKD showing an association between hepcidin and haemoglobin18.  This 
finding suggests that targeting transplant patients with raised hepcidin levels with therapies 
designed to antagonise hepcidin production or activity may be a useful strategy.  Currently, 
such agents remain in early phases of development, although preliminary clinical data 
appears encouraging24,25.  
 
Hepcidin levels were associated with TSAT (the marker of iron storage), reduced renal 
function, the use of marrow suppressive medication, and inflammation, which is consistent 
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with the prevailing understanding of the determinants of hepcidin levels8.  This raises the 
possibility that, at least in part, such risk factors may exert their effect on haemoglobin via 
increasing hepcidin levels.  No evidence was found for lower haemoglobin levels at the 
lower end of the spectrum of hepcidin levels, suggesting that iron deficiency was not in 
general a major mechanism for reduced haemoglobin levels in the current cohort.  
However, hepcidin may remain a valuable biomarker for identifying true iron deficiency in 
other patients, as suggested in studies of non-renal cohorts14. 
 
The observed relationship between reduced renal function and higher serum hepcidin 
levels in this study confirm and extend similar findings from non-transplantation 
cohorts8,15-17,30, and a previous study in KTRs19.  Although two recent studies in non-
transplantation CKD failed to demonstrate this association18,31, it is likely that differences 
in the characteristics of the study cohorts are responsible for these conflicting findings, in 
particular, with regard to levels of haemoglobin and inflammation, the range of renal 
function studied, and the use of comedication.  
 
An interesting and novel observation was the increase in hepcidin levels associated with 
the use of ACEI, ARB, MMF and azathioprine.  This may relate to bone marrow activity, 
which, in this setting is reduced due to a recognised effect of these medications, resulting 
in reduced inhibition of hepcidin secretion, leading to higher circulating levels.  However, 
no measurement of soluble transferrin receptor or reticulocyte count, markers of 
erythropoietic activity, was undertaken to support this hypothesis.  Nevertheless, a recent 
study of patients on haemodialysis also showed an association between renin-angiotensin 
system inhibitors and raised hepcidin levels30, in keeping with the results of this study.  
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Due to the known association between inflammation with hepcidin, and indirectly 
haemoglobin, potential factors driving such inflammation in this setting were evaluated in 
this study.  Adiposity, assessed by FTI, was independently and positively associated with 
inflammation.  Furthermore, a univariate association between FTI and hepcidin level was 
found, although such relationship did not persist when adjusted for inflammation.  This 
notion extends to the field of kidney transplantation, which supports the concept that 
adipose tissue may itself be a source of hepcidin, produced in response to the effect of 
inflammatory cytokines released by the fat tissue13.  The link between adiposity and 
inflammation is an important observation because previous studies in transplantation 
examining this association have yielded conflicting results.   
 
A sub-study of the Assessment of LEscol in Renal Transplantation (ALERT) trial showed 
that inflammation to be associated with raised BMI, a surrogate for fat mass21.  The current 
study confirms the results of the ALERT trial, and extends them to a cohort where fat mass 
was objectively evaluated using bio-impedance derived measurements, which correlated 
well with DEXA scanning, the “gold standard”.  In contrast, an association between 
inflammation and clinically-assessed undernutrition , rather than overnutrition, was found 
in another study by Molnar and colleagues22.  However, this study enrolled a mostly 
unselected cohort, and patients with known underlying chronic inflammatory conditions 
were not specifically excluded.  In the current study, and also from the ALERT trial, 
participants with known inflammatory conditions were excluded, and this may explain the 
inconsistent findings between these studies.  In addition, the cohort studied by Molnar et 
al.22 displayed significant levels of comorbidity, reduced functional status, gastro-intestinal 
symptomatology, and changes in body weight, pointing to a “sicker” population in general.  
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A third study found no association between inflammation and BMI23, but the authors 
acknowledged that small sample size and lack of a high sensitivity assay for C-Reactive 
Protein (CRP) may have reduced the power to detect an effect.   
 
Although classically thought of as a marker of liver iron storage, ferritin also represents an 
acute phase reactant and can indeed be highly correlated with serum hepcidin in transplant 
recipients32,33.  Serum ferritin was not evaluated in this study, instead, hsCRP was 
measured as the marker of inflammation, and TSAT, as the marker of circulating iron 
stores, the latter adding to the prevailing understanding of the relationship between iron 
stores and hepcidin levels as described in this study. 
 
It is acknowledged that exclusion of some KTRs from this study, including those treated 
with erythropoietin, or those with active acute or chronic inflammation, or neoplastic 
conditions, reduces the generalisability of the results to some extent.  However, for these 
reasons, it may increase the robustness of the findings by reducing certain potential 
confounders in the analysis, and this strategy is certainly in line with previous study in this 
field17.  Nevertheless, the results of the different components of this study are intuitive, 
biologically plausible, shed light on the possible mechanisms of haemoglobin reduction in 
KTRs, and point to the opportunities stemming from a greater understanding of the role of 
inflammation and hepcidin in this context.  Further prospective longitudinal follow-up of 
this cross-sectional study may add further insight into these associations.  Finally, these 
findings require confirmation in larger and independent cohorts. 
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In summary, this study describes the relationship between hepcidin, inflammation and 
adiposity in clinically stable KTRs, and demonstrates an independent association between 
elevated hepcidin and reduced haemoglobin levels in this setting.  Hepcidin antagonism 
may be a strategy for certain patients displaying reduced haemoglobin levels after kidney 
transplantation.   
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CHAPTER 3:  HYPERVOLEMIA AND BLOOD PRESSURE IN PREVALENT 
KIDNEY TRANSPLANT RECIPIENTS 
 
3.1 Abstract 
 
Background and Objectives:  The prevalence and consequences of hypervolemia in 
kidney transplant recipients (KTRs) have not been investigated.  Specifically, its impact on 
blood pressure and relationship with N-terminal fragment of prohormone B-type natriuretic 
peptide (NT-proBNP) are unknown.  The objectives of this study were to establish the 
prevalence of hypervolemia among clinically stable KTRs, investigate the predictors of 
post-transplant hypervolemia, assess its impact on blood pressure, and determine its 
relationship with NT-proBNP. 
 
Materials and Methods:  This single-centre cross-sectional study enrolled 123 clinically 
stable KTRs.  Extracellular volume status was determined by multi-frequency bio-
impedance analysis.  Mild and severe hypervolemia were defined as percentage volume 
expansion of greater than 7% and greater than 15% respectively.  Systolic blood pressure 
and diastolic blood pressure were measured, with mean arterial pressure calculated.  Serum 
NT-proBNP was quantified using a non-competitive immunoluminometric assay.  
Potential demographic, nutritional and clinical predictors of extracellular volume status, 
blood pressure and NT-proBNP levels were assessed. 
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Results:  Hypervolemia was present in 30% of KTRs, with 5% classified as severe 
hypervolemia.  Significant predictors of volume expansion were increased sodium intake, 
advancing age, and reduced fat mass (p<0.01 for all associations).  Hypervolemia was the 
only independent predictor of elevated mean arterial pressure, systolic and diastolic blood 
pressure (p<0.001 for all associations).  Raised NT-proBNP levels were independently 
associated with both hypervolemia (p=0.01) and allograft dysfunction (p=0.03). 
 
Conclusions:  Hypervolemia is unexpectedly common among clinically stable KTRs.  It is 
closely associated with elevated blood pressure.  The relationship with increased sodium 
intake signals potential therapeutic focus.  Further study is warranted to prospectively 
investigate objective measures of extracellular volume status among KTRs. 
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3.2 Introduction 
 
Hypervolemia (or volume expansion) represents isotonic expansion of the extracellular 
fluid compartment caused by abnormal retention of water and sodium, manifesting as fluid 
accumulation and swelling in the extremities or lung tissues.  It is common among patients 
with end-stage renal disease (ESRD) requiring maintenance dialysis1-4, and is associated 
with increased morbidity and mortality1-3,5.  For many of these patients, kidney 
transplantation is a preferred option of renal replacement therapy to correct metabolic 
abnormalities.  It is assumed that hypervolemia no longer represents a major problem 
following transplantation, but no study to date confirms or refutes this.     
 
In addition, hypervolemia is associated with hypertension in patients on haemodialysis2 
and peritoneal dialysis3, but this relationship has not been studied in kidney transplant 
recipients (KTRs) despite this complication arising in 75-90% of these patients6.   
 
B-type Natriuretic Peptide (BNP) is a cardiac hormone that is synthesized as an amino acid 
precursor protein and undergoes intracellular modification to a Prohormone BNP (pro-
BNP)7.  It is secreted predominately from the ventricles in response to increased stretch of 
the ventricular wall7.  Upon release into the circulation, pro-BNP is cleaved into the 
biologically active 32-amino acid C-terminal fragment BNP, and the biologically inactive 
76-amino acid N-terminal fragment (NT-proBNP)7.  NT-proBNP possesses a longer half-
life time than the biologically active counterpart, hence delivering a superior reflection of 
pathophysiological situation leading to raised BNP levels8.  Due to renal metabolism of 
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NT-proBNP, concentrations also rise with the progression of chronic kidney disease 
(CKD)9.  NT-proBNP is an independent predictor of mortality in patients with ESRD10.  
Recent studies have confirmed that it is a marker of extracellular volume overload rather 
than cardiac dysfunction per se in maintenance dialysis patients11-14.  However, little 
research has examined this relationship following transplantation, with the 2 studies 
conducted to date highlighting the inverse relationship between NT-proBNP and allograft 
function15,16. 
 
The primary objectives of this study were to determine the prevalence and predictors for 
hypervolemia in a stable kidney transplant cohort, and to assess its association with post-
transplant hypertension.  Secondly, we sought to explore the utility of serum NT-proBNP 
as a correlate of hypervolemia and renal dysfunction in this cohort.  
 
3.3 Materials and Methods 
 
3.3.1 Participants and Study Design 
 
KTRs beyond 1 year post-transplantation, with stable graft function (<10% increase in 
serum creatinine over preceding 6 months), were recruited to this cross-sectional study 
between July 2010 and April 2013.  Exclusion criteria included episodes of acute rejection 
within the last 6 months, evidence of sepsis in the last 6 weeks, known active malignancy 
or chronic infection, history of thyroid disease or adrenal insufficiency, and contra-
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indications for use of bio-impedance based body composition assessment (implanted or 
external electronic devices, metallic implants, amputations, pregnancy, and lactation).  Of 
133 patients approached, 10 did not participate (mainly due to work commitment).  The 
study was approved by the local research ethics committee, and was conducted in 
accordance with the principles of the Declaration of Helsinki. 
 
3.3.2 Data Collection 
 
3.3.2.1 Demographics and Clinical Parameters 
 
Age, gender, ethnicity, and time post-transplantation were collected from patients’ medical 
records.  Smoking status (never smoked, current and ex- smoker) was collected by 
questionnaire.  The following clinical parameters were retrieved from patients’ medical 
records:  1) presence of diabetes, either pre-transplantation (pre-DM) or new onset diabetes 
after transplantation (NODAT), 2) previous acute rejection episodes, 3) 
immunosuppressive medication usage, either prednisolone, calcineurin inhibitor or 
adjunctive antiproliferative agent, 4) use of anti-hypertensive medications, either 
angiotensin-converting-enzyme inhibitor (ACEI), angiotensin-receptor blocker (ARB), 
beta-adrenergic blocker (BAB), dihydropyridine calcium-channel blocker (CCB), or alpha-
adrenergic blocker (AAB), and 5) use of diuretic. 
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Systolic and diastolic blood pressure were measured semi-recumbent with a fully-
automatic upper-arm digital blood-pressure monitor (Spot Vital Signs ® LXi, Welch 
Allyn).  Six readings over an 8-10 minute period were taken, with the first reading ignored, 
and the mean of the remaining 5 used for analysis.  This protocol for blood pressure 
monitoring has been shown to produce measurements comparable to that derived from the 
24-hour ambulatory blood pressure monitor, the “gold standard” for the diagnosis of 
hypertension17.  Mean arterial pressure was subsequently calculated using the formula [(2 
× Diastolic Blood Pressure) + Systolic Blood Pressure] / 318.	
 
3.3.2.2 Laboratory Parameters 
 
Blood samples were collected for measurement of high-sensitivity C-reactive protein 
(hsCRP), albumin, haemoglobin, and estimated glomerular filtration rate (eGFR) derived 
using 4-variable modification of diet in renal disease equation19.  Morning urine was 
collected for assessment of albumin : creatinine ratio (ACR).  Analyses were undertaken in 
accredited hospital haematology and biochemistry laboratories.   
 
Serum NT-proBNP was measured using a non-competitive immunoluminometric assay as 
described by Khan and colleagues20.  This highly specific assay shows no cross-activity 
with atrial natriuretic peptide, BNP, or C-type natriuretic peptide20.  The inter- and intra- 
assay coefficients of variation were 2.3 and 4.8% respectively20. 
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3.3.2.3 Sodium and Fluid Intakes 
 
Sodium and fluid intakes were estimated by a 3-day food diary.  A multiple-day food diary 
provides a good estimate of individual’s sodium intake21, comparable to that derived from 
the mean 24-hour urinary sodium excretion21,22, and produces a reliable and valid record of 
fluid intake in free-living humans23.  Participants were given detailed written instructions 
on completing an accurate dietary record for a 3-day period, which included one weekend 
day, within one week prior to attending the research visit.  These instructions were 
accompanied by verbal explanation from the researcher, which included training in portion 
size estimation and documentation for both dining in and eating out.  The dietary records 
were reviewed by the researcher for accuracy and completeness at the research visit.  Data 
was entered into Dietplan6 P3 (Forestfield Software Ltd) nutrition analysis program by the 
same researcher, avoiding inter-observer variation.  Total daily intakes of fluid, energy, all 
macro- and micro- nutrients, were calculated by this program.  No patients were prescribed 
sodium-containing oral medication at the time of the study. 
 
3.3.2.4 Measurement of Body Composition and Volume Status; Definition of 
Volume Status 
 
Body composition and extracellular volume status were assessed by whole body bio-
impedance spectroscopy, the Body Composition Monitor (BCM) (Fresenius Medical Care, 
Germany).  This device has been used in dialysis patients extensively5, and has been 
validated against reference methods for volume status and body composition24.  The BCM 
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utilises an algorithm based on a 3-compartment body model to evaluate extracellular and 
intracellular fluid volumes25.  Absolute extracellular volume expansion was determined by 
calculating the difference between the actual amount of extracellular fluid in the body 
detected by the BCM and the expected amount of extracellular fluid predicted by the BCM 
under normal physiological (i.e. normovolemia) conditions5,26.  Percentage volume 
expansion (%VE) is therefore defined as: [(Absolute extracellular volume expansion × 
100) / Expected extracellular fluid volume].   
 
In a normal reference population, the 90th and the 10th percentiles of %VE is ± 7%5,27.  
Increased mortality in haemodialysis patients is observed when %VE > 15%28,29.  Hence, 
established definitions, and those used in the current study, are based on %VE, < -7.0% 
representing “hypovolemia”, within ± 7.0% indicating “normovolemia”, between 7.1% and 
15.0% denoting “mild hypervolemia”, and > 15.0% demonstrating “severe hypervolemia”. 
 
Measurements were carried out in a standard manner while the patient was lying supine in 
a flat and non-conductive bed.  The inbuilt physiological body composition model 
measures whole-body bioimpedance spectroscopy at 50 frequencies (5 to 1000 kHz) via 
electrodes placed on the wrist (proximal to the transverse) and the ankle (arch on the 
superior side of the foot) on the same side of the body.  Results for %VE, together with 
Lean Tissue Index (LTI, kg/m2) and Fat Tissue Index (FTI, kg/m2), were displayed after 
each measurement.   
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3.3.3 Statistical Analysis 
 
Statistical analyses were performed using SPSS Statistics 21 (Chicago IL).  Results were 
presented as mean ± standard deviation (SD) for normally distributed data or median 
(interquartile range, IQR) for non-normally distributed data.   
 
Unadjusted univariate relationships were evaluated with Pearson’s correlation coefficients, 
and one-way analysis of variance (ANOVA) followed by Tukey’s post-hoc test for 
multiple-group comparisons.  
 
Linear regression analysis was used to determine the associations between predictor 
variables and the continuously-distributed outcome variables, with logarithmic 
transformation of non-normally distributed data prior to analysis.  The analyses were 
performed in two stages.  Initially, the effect of each variable was examined in a series of 
univariate regression analyses.  Subsequently, the joint effect of variables demonstrating 
some evidence of association on univariate analysis (p<0.20) was examined in a 
multivariable regression analysis, using a backwards selection procedure to derive the final 
model.  A type 1 error rate ≤5% (p≤0.05) was considered significant in the final model.   
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3.4 Results 
 
3.4.1 Population Characteristics 
 
The characteristics of the studied population are shown in Table 3.1.  The mean %VE ± 
SD for the cohort was 2.6 ± 7.7%, ranging from -17.0% to +25.0%.  Based on denoted 
criteria (described in Materials and Methods), the prevalence of hypovolemia in KTRs 
was 11% (13 patients), normovolemia was 59% (73 patients), mild hypervolemia was 25% 
(31 patients displaying %VE between 7.1 and 15.0%), and 5% suffered from severe 
hypervolemia (6 patients displaying %VE >15.0%). 
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Table 3.1.  Population Characteristics 
 Characteristics 
 
Sample size n = 123 
Gender (%) Male = 56 Female = 44 
*Ethnicity (%) 
 
Caucasian = 77               
Afro-Caribbean = 5 
Asian = 16                      
Others = 2 
†Mean age (years) 50 ± 15 
‡Median time post-transplantation (years) 5 (2-11) 
§Smoking status (%) 
 
Non-smoker = 63 
Ex-smoker = 29 
Current smoker = 8 
†Mean extracellular volume status: %VE (%) 2.6 ± 7.7 
‡Median level of NT-proBNP (pmol/L) 291.0 (65.0-700.4) 
Blood pressure 
†Mean systolic blood pressure (mmHg) 
†Mean diastolic blood pressure (mmHg) 
†Mean arterial pressure (mmHg) 
 
141 ± 19 
82 ± 13 
101 ± 13 
Immunosuppressive medication usage 
Calcineurin inhibitor (%) 
Adjunctive antiproliferative agent (%) 
Prednisolone (%) 
 
79 
87 
77 
Dosage of immunosuppressive medications 
‡Median dose of Tacrolimus (mg/day) 
‡Median dose of Cyclosporin (mg/day) 
†Mean dose of Mycophenolate Mofetil (mg/day) 
†Mean dose of Azathioprine (mg/day) 
‡Median dose of Prednisolone (mg/day) 
 
4.0 (2.5-6.0) 
150 (150-200) 
987 ± 392 
77 ± 36 
5 (5-5) 
Anti-hypertensive medication usage 
ACEI / ARB (%) 
BAB (%) 
CCB (%) 
AAB (%) 
 
43 
21 
48 
39 
Diuretic medication usage 
Furosemide, exclusively (%) 
 
15 
‡Median dosage of Furosemide (mg) 40 (30-40) 
Presence of diabetes (%) Non-diabetic = 75 NODAT = 15 Pre-DM = 10 
Previous episodes of acute rejection (%) Yes = 23 No = 77 
‡Median hsCRP (mg/L) 2.4 (1.0-4.9) 
†Mean haemoglobin (g/dL) 12.6 ± 1.6 
†Mean albumin (g/L) 44.5 ± 3.2 
†Mean eGFR (mL/min) 44.2 ± 17.3 
‡Median ACR (mg/mmol) 4.4 (1.6-14.7) 
‡Median sodium intake (mg) 2725 (2131-3248) 
‡Median fluid intake (mL) 2567 (2100-3672) 
Body Composition 
Body mass index, BMI (kg/m2) 
Lean Tissue Index, LTI (kg/m2) 
Fat Tissue Index, FTI (kg/m2) 
 
27.4 ± 5.8 
13.9 ± 3.0 
13.3 ± 6.3 
†Normally distributed data, results expressed as mean ± standard deviation (SD).  ‡Non-normally distributed data, results expressed as median 
(interquartile range, IQR).   
*For the purpose of statistical analysis, the ethnicity of patients classified as “Afro-Caribbean”, “Asian” and “Others” was grouped as “Non-
Caucasian”, 77% “Caucasian” versus 23% “Non-Caucasian”.  §For the purpose of statistical analysis, smoking status was arranged into 2 
categories, “non-smoker” versus “current smoker and ex-smoker”, 63% and 37% of patients respectively. 
Abbreviations:  NT-proBNP=N-Terminal pro B-type Natriuretic Peptide; ACEI=Angiotensin-Converting-Enzyme Inhibitor; ARB=Angiotensin-
Receptor Blocker; Beta-Adrenergic Blocker; CCB=Calcium Channel Blocker; AAB=Alpha-Adrenergic Blocker; hsCRP=high-sensitivity C-
Reactive Protein; eGFR=estimated Glomerular Filtration Rate; ACR=Albumin : Creatinine Ratio; NODAT=New Onset Diabetes After 
Transplantation; Pre-DM=Presence of Diabetes Mellitus pre-transplantation.   
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Table 3.2.  Predictors of Extracellular Volume Status (Percentage Volume Expansion, 
%VE) 
 Univariate Analysis Multivariate Analysis§ 
Regression Coefficient  
(95% CI∞) 
p-value Regression Coefficient  
(95% CI∞) 
p-value 
(***) Sodium intake (mg)  1.8 (1.3, 2.3) <0.001 1.7 (1.2, 2.4) <0.001 
(***) Fluid intake (mL)  1.4 (0.6, 2.0) <0.001   
(**) Age (years)  1.9 (0.9, 2.8) <0.001 1.8 (1.0, 2.6) <0.001 
Presence of diabetes 
Non-diabetic 
NODAT 
Pre-DM  
 
0 
2.4 (-1.2, 5.9) 
10.3 (6.0, 14.7) 
 
<0.001 
 
 
 
 
 
 
Gender 
Female 
Male 
 
0 
4.3 (1.6, 7.0) 
 
0.002 
  
Use of ACEI / ARB  
No 
Yes 
 
0 
3.6 (0.9, 6.3) 
 
0.01 
  
Number of antihypertensive medications 1.6 (0.1, 3.2) 0.04   
Albumin (g/L) -0.4 (-0.8, 0.1) 0.11   
Use of diuretic (furosemide) 
No 
Yes 
 
0 
3.5 (-0.8, 7.8) 
 
0.11 
  
(*) FTI (kg/m2) -1.0 (-2.0, 0.5) 0.12 -1.4 (-2.2, -0.5) 0.002 
(*) eGFR (mL/min)  -0.3 (-0.6, 0.1) 0.19   
(ℓ) ACR (mg/mmol)  0.5 (-0.4, 1.4) 0.27   
‡Ethnicity 
Caucasian 
Non-Caucasian 
 
0 
-1.8 (-5.1, 1.5) 
 
0.29 
  
Use of prednisolone 
No 
Yes 
 
0 
-1.8 (-5.1, 1.6) 
 
0.29 
  
(*) LTI (kg/m2) -0.2 (-0.7, 0.2) 0.31   
†Smoking status 
Never smoked 
Ex-smoker / Current smoker 
 
0 
0.1 (-1.4, 4.3) 
 
0.32 
  
Use of BAB  
No 
Yes 
 
0 
0.2 (-1.3, 3.9) 
 
0.34 
  
Use of CCB 
No 
Yes 
 
0 
0.1 (-1.5, 4.1) 
 
0.34 
  
Haemoglobin (g/dL) -0.4 (-1.3, 0.5) 0.44   
Use of AAB 
No 
Yes 
 
0 
0.1 (-2.0, 3.9) 
 
0.52 
  
(*) Time post transplantation (years)  0.2 (-0.9, 1.3) 0.76   
Use of calcineurin inhibitor 
No 
Yes 
 
0 
-0.3, (-3.7, 3.1) 
 
0.85 
  
(ℓ) hsCRP (mg/L)  0.1 (-1.3, 1.4) 0.94   
Previous episodes of acute rejection 
No 
Yes 
 
0 
-0.1 (-3.4, 3.2) 
 
0.95 
  
Use of adjunctive antiproliferative 
agents 
No  
Yes 
 
0 
-0.0 (-4.6, 4.5) 
 
0.99 
  
R2 value from final model 51% 
§Results in the final multivariate regression model were presented.  ∞CI = Confidence Interval.  †For the purpose of statistical analysis, smoking status was arranged into 
2 categories, “non-smoker” versus “the combination of current smoker and ex-smoker”, 63% and 37% of patients respectively.  ‡For the purpose of statistical analysis, 
the ethnicity of patients classified as “Afro-Caribbean”, “Asian” and “Others” was grouped as “Non-Caucasian”, 77% “Caucasian” versus 23% “Non-Caucasian”.   
(*) Coefficients reported for a 5-unit increase in explanatory variable.  (**) Coefficients reported for a 10-unit increase in explanatory variable.  (***) Coefficients 
reported for a 50-unit increase in explanatory variable.   (ℓ) Variable analysed on the log scale (base 10). 
Abbreviations:  NODAT=New Onset Diabetes After Transplantation; Pre-DM=Presence of Diabetes Mellitus pre-transplantation; ACEI=Angiotensin-Converting-
Enzyme Inhibitor; ARB=Angiotensin-Receptor Blocker; FTI=Fat Tissue Index; eGFR=estimated Glomerular Filtration Rate; ACR=Albumin : Creatinine Ratio; LTI= 
Lean Tissue Index; BAB=Beta-Adrenergic Blocker; CCB=Calcium Channel Blocker; AAB=Alpha-Adrenergic Blocker; hsCRP=high-sensitivity C-Reactive Protein. 
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Table 3.3.  Predictors of Mean Arterial Pressure 
 Univariate Analysis Multivariate Analysis§ 
Regression Coefficient  
(95% CI∞) 
p-value Regression Coefficient  
(95% CI∞) 
p-value 
(*) %VE 6.6 (5.6, 7.5) <0.001 6.6 (5.6, 7.6) <0.001 
(***) Sodium intake (mg)  0.3 (0.2, 0.4) <0.001   
(**) Age (years)  2.5 (0.9, 4.1) <0.01   
Presence of diabetes 
Non-diabetic 
NODAT 
Pre-DM  
 
0 
5.6 (2.1, 9.0) 
11.2 (2.8, 19.5) 
 
<0.01 
  
Use of ACEI / ARB  
No 
Yes 
 
0 
6.7 (2.1, 11.3) 
 
<0.01 
  
Albumin (g/L) -0.9 (-1.7, -0.2) 0.01   
Gender 
Female 
Male 
 
0 
5.8 (1.1, 10.4) 
 
0.02 
  
(***) Fluid intake (mL)  0.2 (0.0, 0.3) 0.03   
Number of antihypertensive medications 2.7 (0.0, 5.4) 0.05   
‡Ethnicity 
Caucasian 
Non-Caucasian 
 
0 
5.0 (-0.5, 11.0) 
 
0.08 
  
(*) Time post transplantation (years)  1.2 (-0.6, 2.9) 0.18   
(*) FTI (kg/m2) 1.3 (-3.1, 0.6) 0.19   
Use of calcineurin inhibitor 
No 
Yes 
 
0 
3.6 (-2.2, 9.3) 
 
0.22 
  
Use of diuretic (furosemide) 
No 
Yes 
 
0 
4.0 (-2.5, 10.5) 
 
0.23 
  
Use of prednisolone 
No 
Yes 
 
0 
-2.5 (-8.1, 3.1) 
 
0.38 
  
Use of CCB 
No 
Yes 
 
0 
2.1 (-2.7, 6.8) 
 
0.39 
  
Use of BAB 
No 
Yes 
 
0 
3.2 (-2.9, 6.2) 
 
0.41 
  
(*) eGFR (mL/min)  -0.2 (-0.9, 0.5) 0.54   
Haemoglobin (g/dL) -0.5 (-2.0, 1.1) 0.56   
Use of adjunctive antiproliferative 
agents 
No  
Yes 
 
0 
2.2 (-5.3, 9.7) 
 
0.56 
  
Use of AAB 
No 
Yes 
 
0 
1.5 (-3.5, 6.5) 
 
0.56 
  
†Smoking status 
Never smoked 
Ex-smoker / Current smoker 
 
0 
1.4 (-3.5, 6.3) 
 
0.57 
  
LTI (kg/m2) -0.2 (-1.0, 0.6) 0.63   
(ℓ) hsCRP (mg/L)  1.1 (-3.8, 5.9) 0.66   
(ℓ) ACR (mg/mmol)  0.6 (-3.0, 4.3) 0.72   
Previous episodes of acute rejection 
No 
Yes 
 
0 
-0.5 (-6.1, 5.1) 
 
0.86 
  
R2 value from final model 62% 
§Results in the final multivariate regression model were presented.  ∞CI = Confidence Interval.   
†For the purpose of statistical analysis, smoking status was arranged into 2 categories, “non-smoker” versus “the combination of current smoker and ex-
smoker”, 63% and 37% of patients respectively.  ‡For the purpose of statistical analysis, the ethnicity of patients classified as “Afro-Caribbean”, “Asian” 
and “Others” was grouped as “Non-Caucasian”, 77% “Caucasian” versus 23% “Non-Caucasian”.   
(*) Coefficients reported for a 5-unit increase in explanatory variable.  (**) Coefficients reported for a 10-unit increase in explanatory variable.  (***) 
Coefficients reported for a 50-unit increase in explanatory variable.  (ℓ) Variable analysed on the log scale (base 10). 
Abbreviations:  %VE=Percentage Volume Expansion; NODAT=New Onset Diabetes After Transplantation; Pre-DM=Presence of Diabetes Mellitus pre-
transplantation; ACEI=Angiotensin-Converting-Enzyme Inhibitor; ARB=Angiotensin-Receptor Blocker; FTI=Fat Tissue Index; CCB=Calcium Channel 
Blocker; BAB=Beta-Adrenergic Blocker; eGFR=estimated Glomerular Filtration Rate; AAB=Alpha-Adrenergic Blocker; LTI= Lean Tissue Index; 
hsCRP=high-sensitivity C-Reactive Protein; ACR=Albumin : Creatinine Ratio. 
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Table 3.4.  Predictors of Systolic Blood Pressure 
 Univariate Analysis Multivariate Analysis§ 
Regression Coefficient  
(95% CI∞) 
p-value Regression Coefficient  
(95% CI∞) 
p-value 
(***) Sodium intake (mg)  0.4 (0.3, 0.6) <0.001   
(***) Fluid intake (mL)  0.2 (0.1, 0.4) <0.001   
(**) Age (years)  4.2 (2.0, 6.3) <0.001   
(*) %VE 9.7 (8.4, 11.0) <0.001 9.8 (8.5, 11.0) <0.001 
Presence of diabetes 
Non-diabetic 
NODAT 
Pre-DM  
 
0 
9.2 (4.3, 14.0) 
23.9 (12.7, 35.0) 
 
<0.001 
  
Use of ACEI / ARB  
No 
Yes 
 
0 
9.3 (2.8, 15.8) 
 
<0.01 
  
Gender 
Female 
Male 
 
0 
8.1 (1.5, 14.6) 
 
0.02 
  
Albumin (g/L) -1.1 (-2.2, -0.1) 0.03   
Number of antihypertensive medications 3.3 (-0.5, 7.0) 0.09   
‡Ethnicity 
Caucasian 
Non-Caucasian 
 
0 
5.2 (2.7, 13.1) 
 
0.20 
  
(*) FTI (kg/m2) -1.6 (-4.2, 1.1) 0.24   
(ℓ) ACR (mg/mmol)  2.9 (-2.1, 8.0) 0.25   
Use of diuretic (furosemide) 
No 
Yes 
 
0 
-4.4 (-12.3, 3.5) 
 
0.28 
  
Use of prednisolone 
No 
Yes 
 
0 
-4.4 (-12.3, 3.5) 
 
0.28 
  
LTI (kg/m2) -0.6 (-1.8, 0.5) 0.28   
(*) Time post transplantation (years)  1.2 (-1.2, 3.7) 0.31   
Haemoglobin (g/dL) -0.9 (-3.1, 1.3) 0.42   
Use of calcineurin inhibitor 
No 
Yes 
 
0 
2.6 (-5.6, 10.7) 
 
0.53 
  
Use of BAB 
No 
Yes 
 
0 
-2.1 (-4.4, 7.2) 
 
0.55 
  
Previous episodes of acute rejection 
No 
Yes 
 
0 
-2.4 (-10.3, 5.6) 
 
0.56 
  
Use of CCB 
No 
Yes 
 
0 
1.7 (-5.0, 8.4) 
 
0.62 
  
†Smoking status 
Never smoked 
Ex-smoker / Current smoker 
 
0 
1.4 (-5.5, 8.3) 
 
0.69 
  
(*) eGFR (mL/min)  -0.2 (-1.2, 0.8) 0.71   
Use of AAB 
No 
Yes 
 
0 
1.2 (-5.9, 8.3) 
 
0.74 
  
(ℓ) hsCRP (mg/L)  0.9 (-6.0, 7.8) 0.80   
Use of adjunctive antiproliferative agents 
No  
Yes 
 
0 
0.4 (-10.2, 11.0) 
 
0.95 
  
R2 value from final model 69% 
§Results in the final multivariate regression model were presented.  ∞CI = Confidence Interval.   
†For the purpose of statistical analysis, smoking status was arranged into 2 categories, “non-smoker” versus “the combination of current smoker and ex-
smoker”, 63% and 37% of patients respectively.  ‡For the purpose of statistical analysis, the ethnicity of patients classified as “Afro-Caribbean”, “Asian” 
and “Others” was grouped as “Non-Caucasian”, 77% “Caucasian” versus 23% “Non-Caucasian”.   
(*) Coefficients reported for a 5-unit increase in explanatory variable.  (**) Coefficients reported for a 10-unit increase in explanatory variable.  (***) 
Coefficients reported for a 50-unit increase in explanatory variable.   (ℓ) Variable analysed on the log scale (base 10). 
Abbreviations:  %VE=Percentage Volume Expansion; NODAT=New Onset Diabetes After Transplantation; Pre-DM=Presence of Diabetes Mellitus pre-
transplantation; ACEI=Angiotensin-Converting-Enzyme Inhibitor; ARB=Angiotensin-Receptor Blocker; FTI=Fat Tissue Index; ACR=Albumin : Creatinine 
Ratio; LTI= Lean Tissue Index; BAB=Beta-Adrenergic Blocker; CCB=Calcium Channel Blocker; eGFR=estimated Glomerular Filtration Rate; 
AAB=Alpha-Adrenergic Blocker; hsCRP=high-sensitivity C-Reactive Protein. 
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Table 3.5.  Predictors of Diastolic Blood Pressure 
 
 Univariate Analysis Multivariate Analysis§ 
Regression Coefficient  
(95% CI∞) 
p-value Regression Coefficient  
(95% CI∞) 
p-value 
(*) %VE 5.0 (3.7, 6.2) <0.001 4.9 (3.7, 6.2) <0.001 
(***) Sodium intake (mg)  0.2 (0.1, 0.3) <0.01   
Use of ACEI / ARB  
No 
Yes 
 
0 
5.3 (0.7, 9.9) 
 
0.02 
  
Albumin (g/L) -0.8 (-1.5, -0.1) 0.03   
(**) Age (years)  1.7 (0.1, 3.3) 0.04   
Presence of diabetes 
Non-diabetic 
NODAT 
Pre-DM  
 
0 
3.7 (0.2, 7.2) 
4.9 (-3.6, 13.4) 
 
0.04 
  
Gender 
Female 
Male 
 
0 
4.7 (0.0, 9.3) 
 
0.05 
  
‡Ethnicity 
Caucasian 
Non-Caucasian 
 
0 
4.9 (-0.6, 10.4) 
 
0.08 
  
Number of antihypertensive medications 2.4 (-0.3, 5.0) 0.08   
(***) Fluid intake (mL)  0.1 (-0.1, 0.2) 0.16   
Use of BAB 
No 
Yes 
 
0 
2.8 (-3.1, 4.8) 
 
0.16 
  
Use of calcineurin inhibitor 
No 
Yes 
 
0 
4.0 (-1.7, 9.6) 
 
0.16 
  
(*) Time post transplantation (years)  1.1 (-0.6, 5.6) 0.21   
†Smoking status 
Never smoked 
Ex-smoker / Current smoker 
 
0 
2.9 (-1.9, 7.7) 
 
0.23 
  
(*) FTI (kg/m2) -1.1 (-3.0, 0.7) 0.24   
Use of CCB 
No 
Yes 
 
0 
2.3 (-2.4, 7.0) 
 
0.34 
  
Use of adjunctive antiproliferative 
agents 
No  
Yes 
 
0 
3.2 (-4.1, 10.6) 
 
0.39 
  
(*) eGFR (mL/min)  -0.2 (-0.9, 0.5) 0.50   
Use of AAB 
No 
Yes 
 
0 
1.6 (-3.3, 6.5) 
 
0.53 
  
Use of diuretic (furosemide) 
No 
Yes 
 
0 
1.8 (-4.6, 8.2) 
 
0.58 
  
Use of prednisolone 
No 
Yes 
 
0 
-1.5 (-7.1, 4.0) 
 
0.59 
  
(ℓ) hsCRP (mg/L)  1.2 (-3.6, 6.0) 0.62   
(ℓ) ACR (mg/mmol)  -0.6 (-4.1, 3.0) 0.75   
Haemoglobin (g/dL) -0.2 (-1.7, 1.3) 0.77   
Previous episodes of acute rejection 
No 
Yes 
 
0 
0.4 (-5.1, 6.0) 
 
0.87 
  
LTI (kg/m2) 0.0 (-0.8, 0.8) 0.91   
R2 value from final model 35% 
§Results in the final multivariate regression model were presented.  ∞CI = Confidence Interval.   
†For the purpose of statistical analysis, smoking status was arranged into 2 categories, “non-smoker” versus “the combination of current smoker and ex-smoker”, 63% 
and 37% of patients respectively.  ‡For the purpose of statistical analysis, the ethnicity of patients classified as “Afro-Caribbean”, “Asian” and “Others” was grouped as 
“Non-Caucasian”, 77% “Caucasian” versus 23% “Non-Caucasian”.   
(*) Coefficients reported for a 5-unit increase in explanatory variable.  (**) Coefficients reported for a 10-unit increase in explanatory variable.  (***) Coefficients 
reported for a 50-unit increase in explanatory variable.  (ℓ) Variable analysed on the log scale (base 10). 
Abbreviations:  %VE=Percentage Volume Expansion; ACEI=Angiotensin-Converting-Enzyme Inhibitor; ARB=Angiotensin-Receptor Blocker; NODAT=New Onset 
Diabetes After Transplantation; Pre-DM=Presence of Diabetes Mellitus pre-transplantation; BAB=Beta-Adrenergic Blocker; FTI=Fat Tissue Index; CCB=Calcium 
Channel Blocker; eGFR=estimated Glomerular Filtration Rate; AAB=Alpha-Adrenergic Blocker; hsCRP=high-sensitivity C-Reactive Protein; ACR=Albumin : 
Creatinine Ratio; LTI= Lean Tissue Index. 
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3.4.4 NT-proBNP as a Marker of Volume Status and Allograft Function 
 
Median serum NT-proBNP level in this cohort of KTRs was 291.0 (IQR: 65.0-700.4) 
pmol/L.  NT-proBNP levels demonstrated a positively skewed distribution and underwent 
logarithmic transformation prior to parametric analysis.  On univariate analysis, higher 
%VE, lower eGFR, and reduced haemoglobin level were associated with higher values for 
NT-proBNP (Table 3.6).  In the multivariate analysis, increasing %VE (Ratio, R = 1.16; 
95% CI = 1.03, 1.29; p=0.01), decreasing eGFR (R = 0.95; 95% CI = 0.90, 0.99; p=0.03), 
and lower haemoglobin level (R = 0.74; 95% CI = 0.58, 0.96; p=0.02) retained significant 
associations with NT-proBNP.  In addition, the absence of a CCB prescription (R = 0.63; 
95% CI = 0.45, 0.89; p<0.01) and either current or previous smoking history (R = 1.46; 
95% CI = 1.04, 2.05; p=0.03) were significant predictors of raised NT-proBNP levels in 
the multivariate model.  The relationships of NT-proBNP with %VE and renal allograft 
function are demonstrated in Figure 3.5 and Figure 3.6 respectively.  A 21% of the 
variation in NT-proBNP was explained by the variables in the final multivariate model. 
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Table 3.6.  Predictors of N-Terminal of prohormone B-type Natriuretic Peptide (NT-
proBNP) 
 Univariate Analysis Multivariate Analysis§ 
Ratio  
(95% CI∞) 
p-value Ratio 
(95% CI∞) 
p-value 
(*) %VE 1.38 (1.07, 1.78) 0.01 1.16 (1.03, 1.29) 0.01 
(*) eGFR (mL/min)  0.89 (0.80, 0.99) 0.03 0.95 (0.90, 0.99) 0.03 
Hb (g/dL) 0.74 (0.57, 0.96) 0.03 0.74 (0.58, 0.96) 0.02 
Use of CCB 
No 
Yes 
 
1 
0.84 (0.53, 1.05) 
 
0.09 
 
1 
0.63 (0.45, 0.89) 
 
<0.01 
(ℓ) ACR (mg/mmol)  1.24 (0.96, 1.60) 0.10   
Use of adjunctive antiproliferative agents 
No  
Yes 
 
1 
0.85 (0.40, 1.10) 
 
0.11 
  
†Smoking status 
Never smoked 
Ex-smoker / Current smoker 
 
1 
1.16 (0.93, 1.84) 
 
0.12 
 
1 
1.46 (1.04, 2.05) 
 
0.03 
LTI (kg/m2) 0.96 (0.91, 1.02) 0.20   
(**) Age (years)  1.20 (0.91, 1.59) 0.20   
(*) Time post transplantation (years)  1.20 (0.91, 1.60) 0.20   
‡Ethnicity 
Caucasian 
Non-Caucasian 
 
1 
0.56 (0.23, 1.40) 
 
0.21 
  
Use of prednisolone 
No 
Yes 
 
1 
0.17 (0.01, 4.75) 
 
0.29 
  
(ℓ) hsCRP (mg/L)  0.83 (0.58, 1.19) 0.31   
Gender 
Female 
Male 
 
1 
0.68 (0.32, 1.47) 
 
0.33 
  
Use of AAB 
No 
Yes 
 
1 
1.09 (0.82, 1.64) 
 
0.41 
  
Presence of diabetes 
Non-diabetic 
NODAT 
Pre-DM  
 
1 
2.02 (0.69, 5.96) 
1.32 (0.37, 4.70) 
 
0.42 
  
Use of BAB 
No 
Yes 
 
1 
0.98 (0.81, 1.28) 
 
0.45 
  
Use of calcineurin inhibitor 
No 
Yes 
 
1 
1.44 (0.52, 4.01) 
 
0.48 
  
(***) Fluid intake (mL)  1.07 (0.86, 1.33) 0.53   
Number of antihypertensive medications 0.95 (0.79, 1.16) 0.63   
Alb (g/L) 1.03 (0.91, 1.17) 0.67   
Use of diuretic (furosemide) 
No 
Yes 
 
1 
1.02 (0.67, 1.67) 
 
0.81 
  
Use of ACEI / ARB  
No 
Yes 
 
1 
1.05 (0.48, 2.28) 
 
0.90 
  
(*) FTI (kg/m2) 1.01 (0.88, 1.15) 0.95   
(***) Sodium intake (mg)  1.01 (0.84, 1.20) 0.95   
Previous episodes of acute rejection 
No 
Yes 
 
1 
1.01 (0.36, 2.89) 
 
0.98 
  
R2 value from final model 21% 
§Results in the final multivariate regression model were presented.  ∞CI = Confidence Interval.   
†For the purpose of statistical analysis, smoking status was arranged into 2 categories, “non-smoker” versus “the combination of current smoker and ex-smoker”, 63% and 37% of 
patients respectively.  ‡For the purpose of statistical analysis, the ethnicity of patients classified as “Afro-Caribbean”, “Asian” and “Others” was grouped as “Non-Caucasian”, 77% 
“Caucasian” versus 23% “Non-Caucasian”.   
(*) Coefficients reported for a 5-unit increase in explanatory variable.  (**) Coefficients reported for a 10-unit increase in explanatory variable.  (***) Coefficients reported for a 50-unit 
increase in explanatory variable.   (ℓ) Variable analysed on the log scale (base 10).  
Abbreviations:  %VE=Percentage Volume Expansion; eGFR=estimated Glomerular Filtration Rate; CCB=Calcium Channel Blocker; ACR=Albumin : Creatinine Ratio; LTI= Lean 
Tissue Index; hsCRP=high-sensitivity C-Reactive Protein; AAB=Alpha-Adrenergic Blocker; NODAT=New Onset Diabetes After Transplantation; Pre-DM=Presence of Diabetes 
Mellitus pre-transplantation; BAB=Beta-Adrenergic Blocker; ACEI=Angiotensin-Converting-Enzyme Inhibitor; ARB=Angiotensin-Receptor Blocker; FTI=Fat Tissue Index. 
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3.5 Discussion 
 
This is the first study to address in detail the prevalence, predictors, and consequences of 
hypervolemia in KTRs.  Based on the previously established definition of hypervolemia, 
30% of KTRs were hypervolemic, of whom 5% suffered from severe hypervolemia.  
Despite a lower incidence when compared to continuous ambulatory peritoneal dialysis3 or 
haemodialysis30 populations, this degree of hypervolemia was unexpected, and is 
noteworthy in light of the specific selection of a clinically and biochemically stable kidney 
transplant cohort for this study.  Hypervolemia was associated with increasing sodium 
intake, highlighting an important target for intervention.  Dietary sodium restriction has not 
been formally examined in KTRs, but has gained attention in other contexts31.  The daily 
sodium intake in the current cohort of KTRs was 2725mg (118mmol), lower than 
previously reported (3588 mg/156mmol per day)18, but well above the recommendation of 
Dietary Approach to Stop Hypertension (DASH) guideline (1500-2300 mg/65-100 mmol 
per day)32.  Collectively, these findings suggest that reducing sodium intake in line with the 
DASH diet should be recommended for KTRs presented with hypervolemia. 
 
A recent study demonstrated a relationship between increased sodium intake and higher 
blood pressure, although the contribution of extracellular volume status was not evaluated 
therein18.  Whilst the results of the current study confirmed a univariate association 
between sodium intake and blood pressure, this relationship did not hold when the effect of 
extracellular volume status was taken into account.  Indeed, hypervolemia was identified as 
the only independent risk factor for elevated blood pressure, which has a recognised impact 
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upon long-term patient and graft outcomes33-35.  Although this relationship between 
hypervolemia and elevated blood pressure resonates with findings in dialysis patients2,3,36, 
this has not been previously demonstrated in KTRs.   
 
Pertinently, the American Society of Hypertension37 acknowledges the possible role of 
volume expansion and potential therapeutic role of diuretics in post-transplant 
hypertension.  Other expert review articles also recognise volume expansion as a potential 
risk factor, although remain guarded over the use of diuretic therapies38,39.  In the current 
study, the prevalence of diuretic usage was only 15%, with furosemide being the only 
diuretic prescription. No association between furosemide usage and volume status was 
observed, but this may be a reflection of “confounding by indication”.  Furthermore, the 
median dosage of furosemide in this study cohort was 40mg, a dosage which may be 
insufficient to target hypervolemia in KTRs with a mean eGFR of 44 mL/min40.  Such 
confounding may also be responsible for the association between renin-angiotensin system 
blockers (ACEI and ARB), and volume overload, mean arterial pressure, systolic and 
diastolic blood pressure, although these associations did not persist in the adjusted analysis.  
 
In regard to other determinants of extracellular volume status, an inverse association 
between fat mass and volume status was observed in the current study.   This phenomenon 
has been demonstrated in a non-transplanted population25, which now extends to the 
kidney transplant population.  Interestingly renal dysfunction was not identified as one of 
the predictors of volume status and blood pressure in this study.  However, based on the 
statistical point estimates, eGFR displayed inverse associations with volume overload, 
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mean arterial pressure, systolic and diastolic blood pressure, and the absence of statistical 
significance may reflect the study size and range of renal function encountered in this 
study, and certainly the current results do not exclude the importance of renal function in 
this setting.  
 
Based on the findings from this study, a multi-modality approach involving the DASH diet 
and increased diuretic usage may be beneficial in the treatment of volume overload and 
hypertension in KTRs.  Previous studies have shown that synergistic hypotensive effects 
were achieved when sodium restriction and diuretics were used in combination41,42.  In 
particular, the DASH diet, comprising high fruits, vegetables, whole-grains, and low-fat 
dairy products; and low fat, refined carbohydrates and sodium, has been shown to 
substantially lower blood pressure in large, randomised, controlled trials32,43,44.  It has also 
been proven to potentiate the benefits of antihypertensive medication treatment43.  Diuretic 
therapy should be titrated in accordance with volume status and blood pressure.  Crucially, 
meticulous monitoring of both volume status and blood pressure should be in place to 
ensure optimal management of hypertension in KTRs.  In particular, increasing fluid intake 
is often promoted particularly in the early period post-transplantation, yet also displayed 
univariate association with volume overload, mean arterial pressure and systolic blood 
pressure, thereby highlighting the importance of judicious assessment of extracellular 
volume in these patients.  Indeed, the findings from this study suggest that more 
widespread and accurate evaluation of extracellular volume status may facilitate the 
clinical management of KTRs, and sets the scene for interventional measures which have 
shown benefit in a recent haemodialysis-based trial45.  It is hoped that the findings of this 
study will highlight the importance of extracellular volume status assessment in the 
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management of hypertension, a tool yet to be incorporated into international guidelines 
from Kidney Disease: Improving Global Outcomes (KDIGO)46, European Renal Best 
Practice (ERBP) Work Group47 and United Kingdom Renal Association (UKRA)48. 
 
The independent association between an objective measure of hypervolemia and raised 
NT-proBNP level is a novel and noteworthy finding of this study, confirming and 
extending findings from the non-transplanted populations, predominantly patients 
undergoing dialysis11-14.  Additionally, reduced allograft function was independently 
associated with raised NT-proBNP levels, in keeping with findings from previous studies 
among KTRs15,16, due to a reduced renal clearance of NT-proBNP.  Although previous 
studies have suggested NT-proBNP as a marker of cardiac dysfunction in dialysis 
patients49,50, interpretation of these studies is limited by a lack of concomitant and 
objective measurement of volume status, and by the variation in NT-proBNP levels 
depending on the timing of blood sampling relative to dialysis treatment.  In fact, the most 
detailed study in dialysis, which employed standardised sampling times, simultaneous 
echocardiography, and bio-impedance based extracellular fluid volume measurements, 
showed that NT-proBNP was dependent on volume overload per se, rather than the 
echocardiographic parameters of cardiac dysfunction11,12.  The single study in KTRs 
addressing the relationship between echocardiography and NT-proBNP level likewise 
found no relationship between the two parameters15.  Whilst cardiac function was not 
assessed in the current study, the findings from this study certainly support the concept that 
NT-proBNP levels reflect volume status.  However, an important caveat is the high 
variability in the relationship between NT-proBNP levels and both %VE and eGFR.  This 
suggests that although NT-proBNP may be a marker of volume expansion and renal 
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dysfunction, it cannot yet be considered as an accurate surrogate for either.  The utility of 
serial NT-proBNP measurements cannot be discerned by the current study. 
 
Other factors independently associated with elevated NT-proBNP levels included smoking 
(current or ex- smoker, or both), reduced level of haemoglobin, and the absence of CCB 
prescription as an antihypertensive agent.  Although the mechanisms behind these findings 
are not fully understood and were not the focus of the present study, these results are in 
keeping with previous observations in non-transplant cohorts51-57, and reflecting the “face 
validity” of the current findings.  
 
This study has limitations that should be acknowledged.  It represents a single-centre 
experience, and validations of the findings are needed in other cohorts.  Also, transplant 
renal artery stenosis is a potential cause for post-transplant hypertension and volume 
expansion.  However, it was not systematically sought in this study due to an estimated 
prevalence of only 5-10%58, and the lack of detection is unlikely to have confounded the 
results.  The cross-sectional nature of this study is unable to establish the causal 
relationship between predictor and outcome variables.  Long-term longitudinal follow-up 
and experimental interventions are now required to robustly evaluate the impact of 
extracellular volume status on relevant end-points in kidney transplantation. 
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In summary, this is the first study to investigate the prevalence, predictors, consequences, 
and biochemical markers of hypervolemia in KTRs.  It points at potential targets for 
intervention, thereby expanding future avenues for basic and clinical research.  
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CHAPTER 4:  PREDICTORS AND CONSEQUENCES OF FATIGUE IN 
PREVALENT KIDNEY TRANSPLANT RECIPIENTS 
 
4.1 Abstract 
 
Background and Objectives:  Fatigue has been under-investigated in clinically stable 
kidney transplant recipients (KTRs).  The objectives of this study were to investigate the 
nature, severity, prevalence and clinical awareness of fatigue in medically stable KTRs, 
examine the impact of fatigue on quality of life (QoL), and explore the underlying causes 
of post-transplantation fatigue. 
 
Materials and Methods:  This single-centre cross-sectional study enrolled 106 stable 
KTRs.  Multi-Dimensional Fatigue Inventory-20 (MFI-20) was used to measure 5 fatigue 
dimensions:  General Fatigue, Physical Fatigue, Reduced Activity, Reduced Motivation, 
and Mental Fatigue.  Clinical awareness of fatigue was determined by reviewing medical 
records.  QoL was assessed by Medical Outcomes Study Short Form-36 (SF-36) 
Questionnaire.  Demographic, clinical, psychosocial and behavioural parameters were 
evaluated as fatigue predictors.  
 
Results:  Fatigue was found in 59% of KTRs.  Only 13% had this symptom documented in 
medical records.  Fatigue in KTRs was in the same range as chronically unwell patients, 
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with Physical Fatigue, Reduced Activity and Reduced Motivation approached levels 
observed in chronic fatigue syndrome.  All fatigue dimensions significantly and inversely 
correlated with QoL (p<0.001 for all associations).  Demographic predictors were male, 
older age and non-Caucasian ethnicity (p≤0.05 for all associations).  Clinical predictors 
included elevated high-sensitivity C-Reactive Protein (hsCRP, inflammation), decreased 
estimated Glomerular Filtration Rate (eGRF, graft dysfunction), and reduced Lean Tissue 
Index (LTI) (p≤0.05 for all associations).  Psychosocial and behavioural predictors were 
inferior sleep quality, anxiety and depression (p<0.01 for all associations). 
 
Conclusions:  Fatigue is common and pervasive in clinically stable KTRs.  It is strongly 
associated with reduced QoL.  This study identified modifiable fatigue predictors, and sets 
the scene for future interventional studies.  
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4.2 Introduction 
 
Fatigue is an important patient-reported outcome in many medical conditions1,2 and 
involves physical (e.g. feeling exhausted and tired), cognitive (e.g. impaired 
concentration), emotional (e.g. lack of motivation) and functional components3.  It is often 
medically unexplained4 and persistent2, and interferes with an individual’s ability to 
function in important roles (e.g. work, family, social life, self-care)5.  As a corollary, 
fatigue can have a major negative impact upon quality of life (QoL)6. 
 
In chronic dialysis patients, fatigue is frequently reported as a pervasive and distressing 
symptom7-9.  For many of these patients, kidney transplantation is the preferred modality of 
renal replacement therapy10.  Kidney transplantation increases long term survival10, 
improves QoL11, demonstrates cost benefits12, and results in enhanced sense of well-being.  
Consequently, it might be assumed that fatigue no longer feature as a major problem 
following kidney transplantation, but in fact there has been very little research to either 
confirm or refute this assumption.  Only one study has specifically examined fatigue 
following transplantation13, noting the symptom was reported in 59% of kidney transplant 
recipients (KTRs) and that it negatively impacted on virtually every aspect of the QoL13.  
Poor sleep quality, mood disturbance and raised body mass index (BMI) were identified as 
significant predictors for post-transplantation fatigue13.  However, other potentially 
modifiable contributors to fatigue such as body composition, inflammation, renal function, 
and other biochemical markers were not examined and warrant further investigation.    
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Greater insight into fatigue severity, its impact on QoL, and its possible underlying causes 
are all pre-requisites for developing interventions to combat this symptom.  In addition, it 
is also important to know the extent to which clinicians are aware of the problem.  
Therefore, the objectives of this study were to determine the nature, severity, prevalence 
and clinical awareness of post-transplantation fatigue in a clinically stable prevalent kidney 
transplant cohort.  Additionally, this study aimed to examine the impact of this symptom 
upon QoL, and to explore the predictors of post-transplantation fatigue. 
 
4.3 Materials and Methods 
 
4.3.1 Participants and Study Design 
 
Stable KTRs beyond 1 year post-transplantation, with stable graft function (<10% increase 
in serum creatinine over preceding 6 months) were recruited to this cross-sectional study 
from the renal transplant outpatient clinic at Queen Elizabeth Hospital Birmingham UK, 
between July 2010 and April 2012.  Exclusion criteria included episodes of acute rejection 
within the last 6 months, evidence of sepsis in the last 6 weeks, known active malignancy 
or chronic infection, preceding diagnosis of psychiatric disorder or chronic fatigue 
syndrome, and history of thyroid disease or adrenal insufficiency.   
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Of 114 eligible patients approached, n=6 refused to participate and n=2 did not attend the 
research visit.  Reasons for declining entry were work commitment (n=4) and participation 
in other studies (n=2).  The study was approved by the local research ethics committee, and 
was conducted in accordance with the principles of the Declaration of Helsinki. 
 
Patients attended the research visit following a 10-hour overnight fast.  The order of tests 
was standardised.  A fasting blood sampling was taken, followed by a light breakfast 
before bio-impedance body composition assessment, and self-completion of questionnaires 
under supervision of the researcher (see below). 
 
4.3.2 Fatigue Measurement 
 
Severity and nature of fatigue were determined using the MFI-20, which is a 20-item self-
report questionnaire that measures fatigue in 5 primary dimensions: General Fatigue; 
Physical Fatigue; Reduced Activity; Reduced Motivation; and Mental Fatigue.  The 
physical aspects of fatigue are captured by General Fatigue and Physical Fatigue; and the 
behavioural, emotional and cognitive aspects of fatigue are represented by Reduced 
Activity, Reduced Motivation, and Mental Fatigue14.  MFI-20 is among the most 
commonly utilized measures of fatigue in patient studies.  It shows good reliability in 
patients with end-stage renal disease15, and demonstrates validity in several medical 
conditions16.  Each fatigue dimension is assessed by 4 items, each using a 5-point Likert 
scale.  Scores for each dimension range from 4 to 20, with higher scores indicating greater 
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fatigue.  General Fatigue describes the individual’s reported functioning (e.g. “I feel 
tired”); Physical Fatigue refers to physical sensations of tiredness (e.g. “physically I feel I 
am in a bad condition”); Reduced Activity describes the reduction in activity (e.g. “I get 
little done”); Reduced Motivation describes the individual’s lack of motivation or initiative 
(e.g. “I don’t feel like doing anything”); and Mental Fatigue signifies cognitive symptoms 
such as concentration difficulties (e.g. “my thoughts easily wander”). 
 
A consensus definition for clinically meaningful fatigue is lacking.  In this study, KTRs 
were considered fatigued if scores for any dimension was ≥ upper 95th percentile for the 
general population as reported by Lin16 (General Fatigue ≥ 15; Physical Fatigue ≥ 14; 
Reduced Activity ≥ 12; Reduced Motivation ≥ 12; Mental Fatigue ≥ 13).  The present data 
were also compared with two other clinical groups, similarly derived from Lin16, namely 
patients with chronic fatigue syndrome (CFS) and patients with other chronic (> 6 months) 
diseases. 
 
Reporting of fatigue by clinicians was assessed by retrieving medical records for the 4 
clinic visits prior to participation in this study.  Medical records were reviewed in search of 
any description of fatigue or synonymous term (e.g. exhaustion; lethargy; sleepiness; 
weariness; tiredness; weakness; sluggish; and lack of energy). 
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4.3.3 Quality of Life Assessment 
 
QoL was assessed using the Medical Outcomes Study Short Form 36 (SF-36) 
questionnaire.  The SF-36 is among the most commonly used instruments to assess QoL 
and is regarded as valid and reliable in different population groups, and with both medical 
and psychiatric conditions17,18 including patients undergoing renal replacement therapy19.  
SF-36 consists of 36 questions grouped into 8 life domains:  physical functioning; social 
functioning; role limitation due to physical problems; role limitation due to emotional 
problems; mental health; energy and vitality; bodily pain; and general health perception.  
For each tested domain, item scores were coded, summed, and transformed into a scale 
from 0 (worst QoL) to 100 (best QoL) using the standard SF-36 scoring algorithm18.  As 
well as the total score for QoL, these sub-scales are subsumed under 2 subscores, i.e. 
physical health summary score and mental health summary score.  Physical health is 
represented by the physical functioning, role limitation due to physical problems, bodily 
pain, general health perception, and energy and vitality subscales of SF-36.  Mental health 
is represented by the mental health, role limitation due to emotional problems, social 
functioning, energy and vitality, and general health perception subscales of SF-3620.   
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4.3.4 Factors Associated with Fatigue 
 
4.3.4.1 Demographics and Clinical Parameters 
 
Age, gender, marital status, ethnicity, and time post-transplantation were collected from 
patients’ medical records.  Smoking status (never smoked, current smoker, ex-smoker) and 
alcohol intake (units per week) were collected by questionnaire.  Co-morbidity was 
assessed by Index of Co-Existing Disease (ICED), using the algorithm described by the 
Hemodialysis (HEMO) Study21, with data extracted from patients’ medical records.  
Presence of diabetes, either pre-transplantation (pre-DM) or new onset diabetes after 
transplantation (NODAT), prior acute rejection episodes, and immunosuppressive 
medication usage were retrieved from patients’ medical records. 
 
4.3.4.2 Laboratory Parameters 
 
Fasting blood sample was taken for analysis of high sensitive C-reactive protein (hsCRP), 
haemoglobin and estimated glomerular filtration rate (eGFR) derived using the 4-variable 
modification of diet in renal disease equation22. 
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4.3.4.3 Body Composition 
 
Body composition was assessed by multi-frequency bio-impedance spectroscopy, Body 
Composition Monitor (BCM), made by Fresenius Medical Care, Bad Homburg, Germany.  
Measurements were carried out in a standard manner while the patient was lying supine in 
a flat and non-conductive bed.  The inbuilt physiological body composition model 
measures whole-body bio-impedance spectroscopy at 50 frequencies (5 to 1000 kHz) via 
electrodes placed on the wrist (proximal to the transverse) and ankle (arch on the superior 
side of the foot).  Body composition data including Lean Tissue Index (LTI, kg/m2) and 
Fat Tissue Index (FTI, kg/m2) were displayed after each measurement.  This device has 
been validated against reference methods including dual-energy X-ray absorptiometry 
(DEXA), air displacement plethysmography and 4-compartment modelling23 
 
4.3.4.4 Self-Reported Outcome Measures 
 
4.3.4.4.1 Anxiety and Depression 
 
Anxiety and Depression were assessed using the Hospital Anxiety and Depression Scale 
(HADS)24.  HADS was developed to identify anxiety and depression among patients in 
non-psychiatric hospital settings.  It has been validated against clinical diagnoses of 
anxiety and depression25 including patients with end-stage renal disease26.  HADS is a self-
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administered 14-item scale, with 7 items measuring anxiety and 7 items measuring 
depression.  Items were scored on a 4-point scale ranging from 0 to 3.  The sum-scores for 
anxiety and depression range from 0 to 21, with higher scores indicating higher levels of 
anxiety or depression. 
 
4.3.4.4.2 Sleep Quality 
 
Sleep quality was assessed by the Pittsburgh Sleep Quality Index (PSQI)27.  The PSQI is 
valid, reliable and widely used27,28.  In particular, it demonstrated reliability and validity in 
KTRs29.  PSQI consists of a 24-item questionnaire measuring sleep disturbances during the 
previous month in 7 dimensions:  subjective sleep quality, sleep latency, sleep duration, 
habitual sleep efficiency, sleep disturbances, use of sleep medication, and day-time 
dysfunction.  Each dimension generates a component score, ranging from subscale scores 0 
to 3.  The addition of the 7 component scores yields a global score of subjective sleep 
quality ranging from 0 to 21, with higher scores indicating worsening subjective sleep 
quality. 
 
4.3.5 Statistical Analysis 
 
Statistical analysis was performed using SPSS Statistics 21 (Chicago, IL).  Results are 
presented as mean ± standard deviation (SD) or median (interquartile range, IQR).  
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Independent sample t-tests were used to compare continuous variables, and Pearson 
correlation coefficients to assess relationship. 
 
Linear regression analysis was used to determine predictor variables associated with 
different domains of fatigue.  The analyses were performed in two stages.  Initially, the 
effect of each variable was examined in a series of univariate analyses.  Subsequently, the 
joint effect of variables was examined in a multivariate analysis, using a backwards 
selection procedure to derive the final model.  A type 1 error rate ≤5% (p≤0.05) was 
considered significant.  Results for General Fatigue, Physical Fatigue and Reduced 
Activity revealed normal distributions and were analysed on the original scale of 
measurement.  Results for Reduced Motivation and Mental Fatigue demonstrated 
positively skewed distributions and underwent logarithmic transformation prior to analysis.  
In the multivariate regression analyses, only the explanatory variables with univariate p-
values of <0.20 were included.  The figures reported in Tables 4.5, 4.6, 4.7, 4.8 and 4.9, 
were regression coefficients or odds ratios, and their corresponding confidence intervals.    
The regression coefficients and odds ratios describe the change in fatigue for the described 
increase (or category) of the predictor variable. 
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4.4 Results 
 
4.4.1 Patient Characteristics 
 
The characteristics of the studied population are shown in Table 4.1. 
 
4.4.2 Relationship between Different Domains of Fatigue 
 
The correlations between different domains of fatigue are shown in Table 4.2. 
 
Table 4.2:  Correlation between Different Domains of Fatigue 
Pearson correlation (r); p-value for each correlation 
 General 
Fatigue 
Physical 
Fatigue 
Reduced 
Activity 
Reduced 
Motivation 
Mental 
Fatigue 
General 
Fatigue  
 r=0.74; 
p<0.001 
r=0.68; 
p<0.001 
r=0.65; 
p<0.001 
r=0.46; 
p<0.001 
Physical 
Fatigue  
r=0.74; 
p<0.001 
 r=0.76; 
p<0.001 
r=0.69; 
p<0.001 
r=0.34; 
p<0.001 
Reduced 
Activity 
r=0.68; 
p<0.001 
r=0.76; 
p<0.001 
 r=0.62; 
p<0.001 
r=0.32; 
p=0.001 
Reduced 
Motivation 
r=0.65; 
p<0.001 
r=0.69; 
p<0.001 
r=0.62; 
p<0.001 
 r=0.46; 
p<0.001 
Mental 
Fatigue  
r=0.46; 
p<0.001 
r=0.34; 
p<0.001 
r=0.32; 
p=0.001 
r=0.46; 
p<0.001 
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Table 4.1:  Population Characteristics 
 Characteristics 
 
Sample size n = 106  
†Mean age 51 ± 14 years 
Gender  56% Male; 44% Female 
Marital status Single 21%; Married 71%; 
Divorced/Widowed 8%  
Immunosuppressive medication usage 
Calcineurin inhibitor 
 
Adjunctive antiproliferatives 
 
 
Prednisolone 
 
89%  
(55% Tacrolimus, 34% Cyclosporin) 
87% 
(58% Mycophenolate Mofetil, 29% 
Azathioprine) 
74%  
Dosage of immunosuppressive medications 
‡Median dose of Tacrolimus 
‡Median dose of Cyclosporin 
†Mean dose of Mycophenolate Mofetil 
†Mean dose of Azathioprine  
†Mean dose of Prednisolone 
 
4.0 (2.5-6.0) mg/day 
150 (150-200) mg/day 
987 ± 392 mg/day 
77 ± 36 mg/day 
5.2 ± 1.0 mg/day 
*Ethnicity 
Caucasian 
Afro-Caribbean  
Asian 
Other 
 
76% 
7% 
15% 
2% 
‡Median time post transplantation 6.5 (3.0-14.0) years 
‡Median alcohol intake per week 0.0 (0.0-3.0) units 
Smoking status 
Never smoked  
Current smoker  
Ex-smoker 
 
63% 
7% 
30% 
†**Mean ICED score (co-morbidity) 
Score = 1 
Score = 2 
Score = 3 
2.1 ± 0.4 
2% 
85% 
13% 
†Mean haemoglobin 12.6 ± 1.6 g/dl 
‡Median hsCRP 2.5 (1.0-4.9) mg/l 
†Mean eGFR 43.9 ± 18.5 ml/min 
Body composition 
†Mean LTI 
†Mean FTI 
 
13.9 ± 3.0 kg/m2 
14.2 ± 6.2 kg/m2 
HADS 
‡Median anxiety score 
‡Median depression score 
 
6.0 (2.5-9.5) 
3.0 (1.0-7.0) 
PSQI  
†Mean global score 
 
7.2 ± 4.1 
†Normally distributed data, results expressed as mean ± SD.   ‡Non-normally distributed data, results expressed as median (IQR).   
*For the purpose of the statistical analysis, the ethnicity of 2% of patients classified as “Other” was grouped as “Caucasian”.  **For the purpose of the 
statistical analysis, ICED scores were arranged into 2 categories (≤2 versus >2, 87% and 13% of patients respectively). 
Abbreviations:  ICED=Index of Coexisting Disease; hsCRP=high-sensitivity C-Reactive Protein; eGFR=estimated Glomerular Filtration Rate; LTI=Lean 
Tissue Index; FTI=Fat Tissue Index; HADS=Hospital Anxiety and Depression Scale; PSQI=Pittsburgh Sleep Quality Index. 
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4.4.3 Nature, Severity and Prevalence of Fatigue 
 
The nature and severity of fatigue are shown in Table 4.3, alongside normative data 
obtained from Lin’s study16.  Comparison of the MFI-20 subscales indicated that 
significant differences were found between the following dimensions:  General Fatigue and 
Reduced Activity (p=0.002); General Fatigue and Reduced Motivation (p<0.001); General 
Fatigue and Mental Fatigue (p<0.001); Physical Fatigue and Reduced Activity (p=0.002); 
Physical Fatigue and Reduced Motivation (p<0.001); Physical Fatigue and Mental Fatigue 
(p<0.001); Reduced Activity and Reduced Motivation (p<0.001); Reduced Activity and 
Mental Fatigue (p<0.001).  The differences between the following dimensions were not 
statistically significant:  General Fatigue and Physical Fatigue (p=0.881); Reduced 
Motivation and Mental Fatigue (p=0.801).  In summary, physical aspects of fatigue 
(General Fatigue and Physical Fatigue) in KTRs were scored significantly higher than 
behavioural, emotional and cognitive aspects of fatigue (Reduced Activity, Reduced 
Motivation and Mental Fatigue).  Overall, the mean MFI-20 scores in KTRs exceeded the 
mean scores found in the general population and were comparable with the mean scores 
reported by chronically unwell patients.  In fact, the mean scores for Physical Fatigue, 
Reduced Activity and Reduced Motivation approached the mean values reported by CFS 
patients. 
 
Based on the dichotomous classification of fatigue (≥ upper 95th percentile for the general 
population, see Materials and Methods), a total of 63 patients (59%) reported fatigue on 
at least one MFI-20 subscale.  Of these 63 patients, 24% experienced General Fatigue, 
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38% displayed Physical Fatigue, 35% demonstrated Reduced Activity, 29% indicated 
Reduced Motivation, and 25% revealed Mental Fatigue.  Importantly, only 8 patients 
(13%) had complaints of fatigue documented in medical records.   
 
Table 4.3:  Nature and Severity of Fatigue 
Mean Fatigue Score ± SD by Dimensions 
 Transplant 
Patients 
 
Healthy 
Population† 
Chronically 
Unwell Patients† 
 
CFS-like 
Patients† 
 
General 
Fatigue  
 
11.78 ± 4.05 8.42 ± 3.59 12.84 ± 3.84 16.38 ± 2.73 
Physical 
Fatigue  
 
11.73 ± 4.74 7.77 ± 3.36 10.39 ± 3.76 13.63 ± 3.79 
Reduced 
Activity  
 
10.69 ± 4.70 6.76 ± 2.67 9.06 ± 3.75 11.32 ± 4.37 
Reduced 
Motivation 
 
9.36 ± 3.61 6.82 ± 2.91 9.29 ± 3.35 11.95 ± 3.53 
Mental 
Fatigue  
 
9.67 ± 4.54 7.23 ± 3.07 10.98 ± 4.00 13.77 ± 3.77 
†Original unpublished normative data provided by Lin et al16. 
Abbreviation:  CFS=Chronic Fatigue Syndrome 
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4.4.4 Fatigue and Quality of Life 
 
As shown in Table 4.4, all dimensions of fatigue (General Fatigue, Physical Fatigue, 
Reduced Activity, Reduced Motivation and Mental Fatigue) were significantly and 
inversely correlated with all aspects of QoL including SF-36 physical health, SF-36 mental 
health and SF-36 total score.  To exclude the confounding effect of the SF-36 “energy and 
vitality” subscale, which is a general measure of fatigue within the SF-3630, results were 
reanalysed after removal of this subscale, results were comparable after this exclusion 
(shown in parentheses in Table 4.4). 
 
Table 4.4:  Association between Fatigue and Quality of Life 
 SF-36  
Physical Health 
 
SF-36  
Mental Health 
SF-36 
Total Score 
General 
Fatigue  
 
†r=-0.68; p<0.001 
*(r=-0.62; p<0.001) 
†r=-0.70; p<0.001 
*(r=-0.63; p<0.001) 
†r=-0.68; p<0.001 
*(r=-0.64; p<0.001) 
Physical 
Fatigue  
 
†r=-0.78; p<0.001 
*(r=-0.74; p<0.001) 
†r=-0.71; p<0.001 
*(r=-0.65; p<0.001) 
†r=-0.74; p<0.001 
*(r=-0.72; p<0.001) 
Reduced 
Activity  
 
†r=-0.72; p<0.001 
*(r=-0.69; p<0.001) 
†r=-0.67; p<0.001 
*(r=-0.62; p<0.001) 
†r=-0.71; p<0.001 
*(r=-0.68; p<0.001) 
Reduced 
Motivation 
 
†r=-0.66; p<0.001 
*(r=-0.64; p<0.001) 
†r=-0.69; p<0.001 
*(r=-0.66; p<0.001) 
†r=-0.69; p<0.001 
*(r=-0.68; p<0.001) 
Mental 
Fatigue  
 
†r=-0.33; p<0.001 
*(r=-0.29; p<0.01) 
†r=-0.49; p<0.001 
*(r=-0.48; p<0.001) 
†r=-0.42; p<0.001 
*(r=-0.41; p<0.001) 
†Correlation and p-value derived from comparisons between all domains of fatigue and all SF-36 subscales in the analysis.   
*Correlation and p-value in parentheses derived from comparisons between all domains of fatigue and SF-36 excluding “energy and 
vitality” subscale in the analysis. 
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4.4.5 Factors Predicting Dimensions of Fatigue 
 
Linear regression analyses, to identify predictors of each fatigue dimension, were 
performed in 3 stages.  First, univariate analyses tested the predictive value of each 
parameter individually.  Second, multivariate analyses tested the independent prediction of 
all parameters.  Third, the multivariate analysis was repeated excluding the patient-
reported outcome data (HADS and PSQI), thereby focusing on clinical, anthropometric 
and laboratory parameters. 
 
4.4.5.1 General Fatigue 
 
The univariate analyses are shown in Table 4.5.  In multivariate analysis, only depression 
(β=2.8; 95% CI=1.9, 3.7; p<0.001) and inferior sleep quality (β=1.1; 95% CI=0.2, 1.9; 
p=0.01) were independently associated with General Fatigue (Figure 4.1 and Figure 4.2).  
Repeating the multivariate analysis excluding HADS and PSQI revealed that increasing 
time post-transplantation (β=0.6; 95% CI=0.0, 1.1; p=0.04), inflammation (β=1.8; 95% 
CI=0.3, 3.3; p=0.02), and renal dysfunction (β=-0.4; 95% CI=-0.8, 0.0; p=0.04) were 
independently associated with increasing General Fatigue. 
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Table 4.5:  Results of Univariate and Multivariate Analyses for General Fatigue 
 Univariable Analysis 
 
Multivariable Analysis†,© Multivariable Analysis§,© 
Regression 
Coefficient  
(95% CI*) 
P-value Regression 
Coefficient 
(95% CI*) 
P-value Regression 
Coefficient 
(95% CI*) 
P-value 
aDepression 3.3 (2.5, 4.2) <0.001 2.8 (1.9. 3.7) <0.001   
aSleep quality 2.3 (1.4, 3.1) <0.001 1.1 (0.2, 1.9) 0.01   
aAnxiety 2.0 (1.3, 2.8) <0.001     
aTime post-
transplantation (years) 
0.8 (0.3, 1.4) 0.004  
 
 0.6 (0.0, 1.1) 0.04 
chsCRP (mg/L) 2.2 (0.6, 3.8) 0.008   1.8 (0.3, 3.3) 0.02 
aFTI (kg/m2) 0.8 (0.2, 1.5) 0.009     
beGFR (ml/min) -0.5 (-0.9, -0.1) 0.02   -0.4 (-0.8, 0.0) 0.04 
bAge (years) 0.6 (0.1, 1.1) 0.03     
LTI (kg/m2) -0.3 (-0.5, 0.0) 0.05   -0.2 (-0.5, 0.0) 0.07 
Alcohol intake (unit) -0.2 (-0.5, 0.0) 0.06     
Use of calcineurin 
inhibitor 
None 
Cyclosporin 
Tacrolimus 
 
 
0 
0.1 (-0.6, 2.7) 
-0.2 (-2.3, 0.1) 
 
0.06 
    
ICED 
≤2 
>2 
 
0 
2.1 (-0.3, 4.5) 
 
0.08 
    
Use of prednisolone 
No 
Yes 
 
0 
-0.1 (-3.0, 0.6) 
 
0.19 
    
Presence of diabetes 
None 
Pre-DM 
NODAT 
 
0 
2.0 (-0.6, 4.5) 
-0.8 (-3.0, 1.5) 
 
0.23 
    
Haemoglobin (g/dL) -0.2 (-0.7, 0.3) 0.37     
Use of adjunctive 
antiproliferatives 
None 
Mycophenolate Mofetil 
Azathioprine 
 
 
0 
-0.2 (-3.1, 0.0) 
0.1 (-0.8, 1.8) 
 
 
0.45 
    
Previous episodes of 
acute rejection 
No 
Yes 
 
 
0 
0.8 (-1.8, 3.3) 
 
 
0.56 
    
Marital status 
Single 
∞Married 
◊Divorced/Widowed 
 
0 
0.2 (-0.4, 3.4) 
-0.2 (-5.3, 0.6) 
 
0.65 
    
Ethnicity 
Caucasian 
Asian 
Afro-Caribbean 
 
0 
0.8 (-1.4, 3.0) 
-0.6 (-3.8, 2.6) 
 
0.71 
    
Smoking status 
Never smoked 
Current smoker 
Ex-smoker 
 
0 
0.0 (-1.5, 1.8) 
0.1 (-2.7, 4.8) 
 
0.75 
    
Gender  
Female 
Male 
 
0 
-0.2 (-1.8, 1.4) 
 
0.85 
    
R2 value from final model 
 
41% 19% 
†All predictor variables were included in multivariable analysis. 
§Patient-reported outcomes (HADS and PSQI) were excluded in multivariable analysis. 
©Results in the final multivariable regression model were presented. 
*CI = Confidence Interval 
∞“Living with partner” was classified under the “Married” category. 
◊“Separated” was classified under the “Divorced/Widowed” category. 
aCoefficients reported for 5-
unit increase in explanatory 
variable. 
bCoefficients reported for 10-
unit increase in explanatory 
variable. 
cVariable analysed on log 
scale (base 10) 
 
 
Chapter 4 
 
124 
 
 
 
 
 
 
Figure 4.1:  Association between General Fatigue and Depression 
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Figure 4.2:  Association between General Fatigue and Sleep Quality 
 
 
4.4.5.2 Physical Fatigue 
 
The univariate analyses are shown in Table 4.6.  In the multivariate model, depression 
(β=3.2; 95% CI=2.3, 4.1; p<0.001), renal dysfunction (β=-0.7; 95% CI=-1.4, -0.5; 
p<0.001; Figure 4.3), inflammation (β=1.4; 95% CI=0.0, 2.7; p=0.05), reduced LTI (β=-
0.5; 95% CI=-0.8, -0.3; p<0.001; Figure 4.4) and male (β=2.4; 95% CI=0.9, 4.0; p=0.003) 
were independently associated with Physical Fatigue.  Repeating the multivariate analysis 
excluding HADS and PSQI showed that renal dysfunction (β=-0.8; 95% CI=-1.2, -0.4; 
p<0.001), inflammation (β=2.6; 95% CI=1.0, 4.1; p=0.002), increasing time post-
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transplantation (β=0.7; 95% CI=0.2, 1.3; p=0.01), reduced LTI (β=-0.6; 95% CI=-0.9, -0.3; 
p<0.001), and male (β=3.1; 95% CI=1.2, 5.0; p=0.001) were independently associated with 
Physical Fatigue. 
 
Figure 4.3:  Association between Physical Fatigue and Estimated Glomerular 
Filtration Rate (eGFR) 
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Table 4.6:  Results of Univariate and Multivariate Analyses for Physical Fatigue 
 Univariable Analysis 
 
Multivariable Analysis†,© Multivariable Analysis§,© 
Regression 
Coefficient 
(95% CI*) 
P-value Regression 
Coefficient 
(95% CI*) 
P-value Regression 
Coefficient 
(95% CI*) 
P-value 
aDepression 4.1 (3.2, 5.1) <0.001 3.2 (2.3, 4.1) <0.001   
beGFR (ml/min) -0.9 (-1.4, -0.5) <0.001 -0.7 (-1.4, -0.5) <0.001 -0.8 (-1.2, -0.4) <0.001 
chsCRP (mg/L) 3.6 (1.8, 5.4) <0.001 1.4 (0.0, 2.7) 0.05 2.6 (1.0, 4.1) 0.002 
aTime post-transplantation 
(years) 
1.2 (0.6, 1.9) <0.001   0.7 (0.2, 1.3) 0.01 
aSleep quality 2.3 (1.2, 3.3) <0.001     
aAnxiety 2.1 (1.1, 3.0) <0.001     
aFTI (kg/m2) 1.4 (0.7, 2.1) <0.001     
bAge (years) 0.8 (0.2, 1.5) 0.01     
Use of calcineurin inhibitor 
None 
Cyclosporin 
Tacrolimus 
 
0 
0.9 (0.8, 4.5) 
-0.8 (-3.0, -0.4) 
 
0.01 
 
    
ICED 
≤2 
>2 
 
0 
3.2 (0.5, 5.9) 
 
0.02 
 
 
   
Alcohol intake (unit) -0.2 (-0.6, 0.0) 0.04     
LTI (kg/m2) -0.3 (-0.6, -0.0) 0.05 -0.5 (-0.8, -0.3) <0.001 -0.6 (-0.9, -0.3) <0.001 
Use of prednisolone 
No 
Yes 
 
0 
-0.2 (-3.8, 0.3) 
 
0.09 
    
Haemoglobin (g/dL) -0.5 (-1.0, 0.1) 0.11     
Gender  
Female 
Male 
 
0 
1.5 (-0.4, 3.3) 
 
0.12 
 
0 
2.4 (0.9, 4.0) 
 
0.003 
 
0 
3.1 (1.2, 5.0) 
 
0.001 
Presence of diabetes 
None 
Pre-DM 
NODAT 
 
0 
1.7 (-1.3, 4.8) 
-0.6 (-3.3, 2.0) 
 
 
0.44 
    
Use of adjunctive 
antiproliferatives 
None 
Mycophenolate Mofetil 
Azathioprine 
 
 
0 
-0.2 (-3.6, 0.1) 
0.1 (-1.1, 1.9) 
 
 
0.58 
    
Previous episodes of acute 
rejection 
No 
Yes 
 
 
0 
-0.6 (-3.6, 2.4) 
 
 
0.69 
    
Marital status 
Single 
∞Married 
◊Divorced/Widowed 
 
0 
0.1 (-1.0, 3.5) 
-0.1 (-5.3, 1.8) 
 
0.69 
    
Smoking status 
Never smoked 
Current smoker 
Ex-smoker 
 
0 
0.1 (-3.1, 6.0) 
0.1 (-0.7, 1.3) 
 
0.85 
    
Ethnicity 
Caucasian 
Asian 
Afro-Caribbean 
 
0 
-0.5 (-3.1, 2.1) 
-0.6 (-4.3, 3.2) 
 
0.91 
    
R2 value from final model 
 
58% 41% 
†All predictor variables were included in multivariable analysis. 
§Patient-reported outcomes (HADS and PSQI) were excluded in multivariable analysis. 
©Results in the final multivariable regression model were presented. 
*CI = Confidence Interval 
∞“Living with partner” was classified under the “Married” category. 
◊“Separated” was classified under the “Divorced/Widowed” category. 
aCoefficients reported for 5-
unit increase in explanatory 
variable. 
bCoefficients reported for 10-
unit increase in explanatory 
variable. 
cVariable analysed on log scale 
(base 10) 
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Figure 4.4:  Association between Physical Fatigue and Lean Tissue Index (LTI) 
 
4.4.5.3 Reduced Activity 
 
The univariate analyses are shown in Table 4.7.  In the multivariate model, depression 
(β=3.4; 95% CI=1.9, 3.7; p<0.001), inflammation (β=2.7; 95% CI=1.2, 4.1; p<0.001; 
Figure 4.5), and increasing age (β=0.7; 95% CI=0.2, 1.1; p=0.003) were independent 
predictors for Reduced Activity.  Following exclusion of HADS and PSQI, inflammation 
(β=3.8; 95% CI=2.2, 5.4; p<0.001), increasing comorbidity (β=3.4; 95% CI=1.0, 5.7; 
p=0.006), increasing time post-transplantation (β=0.6; 95% CI=0.0, 1.2; p=0.04), and 
increasing age (β=0.6; 95% CI=0.2, 1.1; p=0.04) were independently associated with 
Reduced Activity.   
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Table 4.7:  Results of Univariate and Multivariate Analyses for Reduced Activity 
 Univariable Analysis 
 
Multivariable Analysis†,© Multivariable Analysis§,© 
Regression 
Coefficient 
(95% CI*) 
P-value Regression 
Coefficient 
(95% CI*) 
P-value Regression 
Coefficient 
(95% CI*) 
P-value 
aDepression 4.1 (3.1, 5.0) <0.001 3.4 (1.9, 3.7) <0.001   
chsCRP (mg/L) 4.2 (2.5, 5.9) <0.001 2.7 (1.2, 4.1) <0.001 3.8 (2.2, 5.4) <0.001 
aSleep quality 2.3 (1.2, 3.3) <0.001     
aAnxiety 1.8 (0.9, 2.7) <0.001     
ICED 
≤2 
>2 
 
0 
4.7 (2.1, 7.4)  
 
0.001 
   
0 
3.4 (1.0, 5.7) 
 
0.006 
aFTI (kg/m2) 1.2 (0.5, 1.9) 0.001     
aTime post-transplantation 
(years) 
1.0 (0.4, 1.7) 0.002 
 
  0.6 (0.0, 1.2) 0.04 
Use of calcineurin inhibitor 
None 
Cyclosporin 
Tacrolimus 
 
0 
0.2 (-0.2, 3.6) 
-0.3 (-4.3, -0.3) 
 
0.005 
    
bAge (years) 0.8 (0.2, 1.4) 0.01 0.7 (0.2, 1.1) 0.003 0.6 (0.2, 1.1) 0.04 
beGFR (ml/min) -0.5 (-0.9, 0.0) 0.06     
Gender  
Female  
Male 
 
0 
1.6 (-0.2, 3.4) 
 
0.08 
    
Alcohol intake (unit) -0.2 (-0.5, 0.0) 0.12     
LTI (kg/m2) -0.2 (-0.5, 0.1) 0.14     
Presence of diabetes 
None 
Pre-DM 
NODAT 
 
0 
0.0 (-1.5, 2.4) 
-1.6 (-4.2, 1.0) 
 
0.21 
    
Haemoglobin (g/dL) -0.2 (-0.8, 0.4) 0.50     
Smoking status 
Never smoked 
Current smoker 
Ex-smoker 
 
0 
0.0 (-1.5, 2.4) 
0.1 (-3.0, 5.4) 
 
0.54 
    
Use of prednisolone 
No 
Yes 
 
0 
-0.1 (-2.6, 1.5) 
 
0.62 
    
Marital status 
Single 
∞Married 
◊Divorced/Widowed 
 
0 
0.1 (-1.0, 3.5) 
-0.1 (-5.2, 1.8) 
 
0.70 
    
Previous episodes of acute 
rejection 
No 
Yes 
 
 
0 
-0.6 (-3.6, 2.4) 
 
 
0.71 
    
Ethnicity 
Caucasian 
Asian 
Afro-Caribbean 
 
0 
0.6 (-2.0, 3.2) 
0.7 (-3.0, 4.5) 
 
0.85 
    
Use of adjunctive 
antiproliferatives 
None 
Mycophenolate Mofetil 
Azathioprine 
 
 
0 
-1.6 (-3.3, 0.4) 
0.0 (-1.3, 1.6) 
 
 
0.85 
    
R2 value from final model 
 
52% 34% 
†All predictor variables were included in multivariable analysis. 
§Patient-reported outcomes (HADS and PSQI) were excluded in multivariable analysis. 
©Results in the final multivariable regression model were presented. 
*CI = Confidence Interval 
∞“Living with partner” was classified under the “Married” category. 
◊“Separated” was classified under the “Divorced/Widowed” category. 
aCoefficients reported for 5-
unit increase in explanatory 
variable. 
bCoefficients reported for 10-
unit increase in explanatory 
variable. 
cVariable analysed on log scale 
(base 10) 
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Figure 4.5:  Association between Reduced Activity and high-sensitivity C-Reactive 
Protein (hsCRP) 
 
 
4.4.5.4 Reduced Motivation 
 
The univariate models are shown in Table 4.8.  In the multivariate analysis, depression 
(Odds Ratio = 1.40; CI=1.30, 1.52; p<0.001), renal dysfunction (Odds Ratio = 0.96; 
CI=0.93, 1.00; p=0.03), and reduced LTI (Odds Ratio = 0.98; CI=0.96, 1.00; p=0.05) were 
associated with Reduced Motivation independently.  Following exclusion of HADS and 
PSQI, increasing time post-transplantation (Odds Ratio = 1.07; CI=1.01, 1.13; p=0.02), 
renal dysfunction (Odds Ratio = 0.95; CI=0.92, 0.99; p=0.02), and inflammation (Odds 
Ratio = 1.22; CI=1.05, 1.43; p=0.01) were independent predictors for Reduced Motivation. 
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Table 4.8:  Results of Univariate and Multivariate Analyses for Reduced Motivation 
 Univariable Analysis 
 
Multivariable Analysis†,© Multivariable Analysis§,© 
Odds Ratio  
(95% CI*) 
P-value Odds Ratio  
(95% CI*) 
P-value Odds Ratio  
(95% CI*) 
P-value 
aDepression 1.44 (1.32, 1.56) <0.001 1.40 (1.30, 1.52) <0.001   
aSleep quality 1.25 (1.14, 1.36) <0.001     
aAnxiety 1.23 (1.14, 1.33) <0.001     
aTime post-
transplantation (years) 
1.09 (1.03, 1.16) 0.003   1.07 (1.01, 1.13) 0.02 
beGFR (ml/min) 0.94 (0.90, 0.98) 0.005 0.96 (0.93, 1.00) 0.03 0.95 (0.92, 0.99) 0.02 
chsCRP (mg/L) 1.26 (1.07, 1.48) 0.006   1.22 (1.05, 1.43) 0.01 
aFTI (kg/m2) 1.09 (1.02, 1.16) 0.008     
Use of calcineurin 
inhibitor 
None 
Cyclosporin 
Tacrolimus 
 
 
1 
1.27 (1.02, 1.30) 
0.79 (0.70, 0.99) 
 
 
0.02 
    
ICED 
≤2 
>2 
 
1 
1.30 (1.02, 1.66) 
 
0.03 
    
bAge (years) 1.06 (1.00, 1.12) 0.05     
Alcohol intake (unit) 0.83 (0.81, 1.00) 0.06     
LTI (kg/m2) 0.98 (0.95, 1.00) 0.10 0.98 (0.96, 1.00) 0.05   
Use of prednisolone 
No 
Yes 
 
1 
0.85 (0.83, 1.01) 
 
0.10 
    
Gender  
Female 
Male 
 
1 
1.00 (0.85, 1.17) 
 
0.12 
    
Use of adjunctive 
antiproliferatives 
None 
Mycophenolate Mofetil 
Azathioprine 
 
 
1 
0.87 (0.84, 1.02) 
1.14 (0.98, 1.29) 
 
 
0.19 
    
Haemoglobin (g/dL) 0.98 (0.93, 1.03) 0.34     
Marital status 
Single 
∞Married 
◊Divorced/Widowed 
 
1 
0.99 (0.91, 1.09) 
0.84 (0.79, 1.02) 
 
0.39 
    
Presence of diabetes 
None 
Pre-DM 
NODAT 
 
1 
0.99 (0.76, 1.29) 
0.90 (0.72, 1.14) 
 
 
0.69 
    
Ethnicity 
Caucasian 
Asian 
Afro-Caribbean 
 
1 
1.03 (0.94, 1.09) 
0.90 (0.82, 1.12) 
 
0.79 
    
Smoking status 
Never smoked 
Current smoker 
Ex-smoker 
 
1 
0.98 (0.76, 1.28) 
0.90 (0.82, 1.12) 
 
0.86 
    
Previous episodes of 
acute rejection 
No 
Yes 
 
 
1 
0.98 (0.76, 1.28) 
 
 
0.91 
    
R2 value from final model 
 
47% 19% 
†All predictor variables were included in multivariable analysis. 
§Patient-reported outcomes (HADS and PSQI) were excluded in multivariable analysis. 
©Results in the final multivariable regression model were presented. 
*CI = Confidence Interval 
∞“Living with partner” was classified under the “Married” category. 
◊“Separated” was classified under the “Divorced/Widowed” category. 
aOdds ratios reported for 5-unit 
increase in explanatory 
variable. 
bOdds ratios reported for 10-
unit increase in explanatory 
variable. 
cVariable analysed on log scale 
(base 10) 
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4.4.5.5 Mental Fatigue 
 
Finally, the univariate analyses predicting Mental Fatigue are shown in Table 4.9.  In the 
multivariate model, only anxiety was independently associated with fatigue (Odds Ratio = 
1.36; CI=1.24, 1.49; p<0.001; Figure 4.6).  A borderline effect of ethnicity was found 
(Odds Ratio = 1.42; CI=1.01, 1.99; p=0.05).  When the multivariate analysis was repeated 
excluding the HADS and PSQI results, no predictor variables retained statistical 
significance.  
 
Figure 4.6:  Association between Mental Fatigue and Anxiety 
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Table 4.9:  Results of Univariate and Multivariate Analyses for Mental Fatigue 
 Univariable Analysis 
 
Multivariable Analysis†,© Multivariable Analysis§,© 
Odds Ratio 
(95% CI*) 
P-value Odds Ratio 
(95% CI*) 
P-value Odds Ratio 
(95% CI*) 
P-value 
aAnxiety 1.34 (1.22, 1.47) <0.001 1.36 (1.24, 1.49) <0.001   
aDepression 1.36 (1.20, 1.53) <0.001     
aSleep quality 1.17 (1.04, 1.32) 0.01     
Ethnicity 
Caucasian 
Asian 
Afro-Caribbean 
 
1 
1.27 (0.97, 1.68) 
1.16 (0.78, 1.73) 
 
0.19 
 
1 
1.20 (0.95, 1.52) 
1.42 (1.01, 1.99) 
 
0.05 
  
chsCRP (mg/L) 1.12 (0.91, 1.38) 0.28     
Smoking status 
Never smoked 
Current smoker 
Ex-smoker 
 
1 
0.90 (0.87, 1.04) 
0.97 (0.79, 1.22) 
 
0.29 
    
beGFR (ml/min) 0.97 (0.92, 1.03) 0.33     
Alcohol intake (unit) 0.91 (0.88, 1.01) 0.36     
Use of calcineurin 
inhibitor 
None 
Cyclosporin 
Tacrolimus 
 
 
1 
1.18 (0.94, 1.24) 
0.93 (0.91, 1.04) 
 
 
0.51 
    
Marital status 
Single 
∞Married 
◊Divorced/Widowed 
 
1 
0.90 (0.85, 1.05) 
1.06 (0.89, 1.22) 
 
0.55 
    
Use of prednisolone 
No 
Yes 
 
1 
0.95 (0.88, 1.07) 
 
0.59 
    
Use of adjunctive 
antiproliferatives 
None 
Mycophenolate Mofetil 
Azathioprine 
 
 
1 
0.88 (0.87, 1.03) 
1.05 (0.95, 1.09) 
 
 
0.60 
    
aFTI (kg/m2) 1.02 (0.94, 1.11) 0.64     
Haemoglobin (g/dL) 1.01 (0.95, 1.08) 0.64     
ICED 
≤2 
>2 
 
1 
0.94 (0.69, 1.27) 
 
0.67 
    
Previous episodes of 
acute rejection 
No 
Yes 
 
 
1 
0.93 (0.67, 1.29) 
 
 
0.67 
    
Gender  
Female 
Male 
 
1 
0.97 (0.79, 1.18) 
 
0.74 
    
bAge (years) 0.99 (0.93, 1.06) 0.84     
LTI (kg/m2) 1.00 (0.97, 1.04) 0.88     
aTime post-
transplantation (years) 
1.00 (0.93, 1.08) 0.91     
Presence of diabetes 
None 
Pre-DM 
NODAT 
 
1 
0.96 (0.69, 1.33) 
0.96 (0.72, 1.28) 
 
0.93 
    
R2 value from final model 
 
32% - 
†All predictor variables were included in multivariable analysis. 
§Patient-reported outcomes (HADS and PSQI) were excluded in multivariable analysis. 
©Results in the final multivariable regression model were presented. 
*CI = Confidence Interval 
∞“Living with partner” was classified under the “Married” category. 
◊“Separated” was classified under the “Divorced/Widowed” category. 
aCoefficients reported for 5-
unit increase in explanatory 
variable. 
bCoefficients reported for 10-
unit increase in explanatory 
variable. 
cVariable analysed on log 
scale (base 10) 
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4.5 Discussion 
 
This study aimed to investigate the nature, severity, prevalence and clinical awareness of 
post-transplantation fatigue, to determine the association between fatigue and QoL, and to 
identify main predictors of post-transplantation fatigue.  The results revealed that, in 
clinically stable KTRs without evidence of intercurrent disease, fatigue is common, severe, 
and clinically under-appreciated.  It has a close association with inferior QoL.  These 
results confirm and significantly extend the findings of the single previous study on post-
transplantation fatigue13, and advances understanding of the possible determinants of 
fatigue by showing associations with anthropometric and clinical variables not previously 
evaluated.  Depression, anxiety, inferior sleep quality, inflammation, reduced muscle mass, 
and renal dysfunction were identified as risk factors, forming potential targets for future 
interventional studies. 
 
The significant correlations between different domains of fatigue suggest that treatment of 
behavioural, emotional and cognitive aspects of fatigue may improve physical aspects of 
fatigue, or vice versa.  However, a recent study provides experimental evidence that mental 
fatigue limits exercise tolerance in humans via higher perception of effort rather than 
cardiorespiratory and musculoenergetic mechanisms31, implying that the overall focus of 
fatigue management should be on the behavioural, emotional and cognitive aspects.   
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Compared with normative data from healthy population16,32, KTRs suffer from higher 
levels of fatigue on all dimensions.  In comparison with normative data from Lin et al16, 
fatigue levels in KTRs were similar to “chronically unwell” patients, defined as having 
chronic (≥ 6 months) unwellness with or without fatigue, but not meeting criteria for 
CFS16.  Indeed, severity in certain domains, such as Physical Fatigue, Reduced Activity 
and Reduced Motivation, approached that of CFS16, further highlighting the burden of 
fatigue in KTRs.  Of note, the level of Mental Fatigue was higher in KTRs compared with 
cancer patients with mild anaemia undergoing chemotherapy32, and chronic heart failure 
patients with and without anaemia33.  Also, KTRs suffer from higher levels of Physical 
Fatigue, Reduced Activity and Reduced Motivation compared to cancer patients without 
anaemia32.  Physical aspects of fatigue outweighed behavioural, emotional and cognitive 
aspects, resembling findings in liver transplant recipients34.   
 
Using a dichotomous fatigue definition, 24-38% of participants reported fatigue in at least 
one of the five dimensions, and 59% in any dimension.  This prevalence is comparable to 
that found by Rodrigue13 using the one-dimensional “Fatigue Symptom Inventory”.  
Despite the high prevalence, only 13% of patients had fatigue documented in medical 
records prior to participation in this study, suggesting that this symptom is either under-
reported or under-acknowledged.  Furthermore, the close correlation between all fatigue 
domains and QoL resonates with the clinical and social relevance of this symptom.   
 
The assessment of multiple domains of fatigue, and the measurement from the clinically 
validated HADS extends the findings of Rodrigue13 where fatigue severity significantly 
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correlated with a composite mood score incorporating depression, vigour, anger, 
confusion, anxiety and fatigue itself.  The current study highlights the specific, 
independent importance of depression as a risk factor for all dimensions of fatigue except 
for Mental Fatigue.  This exception is surprising as previous study on multiple sclerosis 
(MS) related fatigue found that depression was related to Mental Fatigue35,36.  However, 
depression and Mental Fatigue can occur independently or simultaneously37, and this 
phenomenon has been demonstrated in stroke patients37 .  Many symptoms for depression 
and Mental Fatigue overlap, but the core symptoms are different.   The lack of association 
in this study may be explained by the distinction between the core symptoms.  Depression 
is an illness or mood disorder with a variety of symptoms, the most defining being an 
inexplicable, enduring feeling of sadness, and loss of positive effect38.  The collective 
symptoms may not manifest as Mental Fatigue, which is a psychobiological state caused 
by prolonged periods of demanding cognitive activity such as concentration, attention and 
increased mental load31.  In Mental Fatigue, mental effort can only be sustained for a short 
time-frame, and recovery period is disproportionally long37.  Accompanying symptoms 
include irritability, sensitivity to stress, concentration difficulties, and emotional 
instability37.  Anxiety was a significant predictor for Mental Fatigue, similar to other 
chronic conditions such as MS36.  KTRs are subjected to several mental challenges, 
including fears about transplant rejection and the necessity to adhere to a complex regimen 
of immunosuppression therapy that may generate distressing side effects39.  To an extent, 
the unpredictable clinical course post-transplantation is reminiscent of the relapsing and 
remitting nature of MS.  While acknowledging the limitations of cross-sectional data to 
make causal inferences, the present results are in line with evidence showing that 
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psychological interventions addressing disease-related anxiety and depression per se may 
yield added benefit in modifying fatigue. 
 
While inferior sleep quality may intuitively be expected to have a pervasive and broad 
effect on multiple aspects of fatigue13, a significant association was only observed for the 
General Fatigue dimension.  This finding suggests that mere sleep difficulties do not 
explain a large spectrum of the fatigue complaints in KTRs, and interventions aiming to 
improve sleep quality may have limited effect on fatigue. 
 
An important caveat with the interpretation of the associations between self-reported data, 
such as depression, sleep difficulties and symptoms of fatigue is that common-method 
variance may partly drive the observed associations, and may account for 25% of shared 
variance40.  In common-method variance, patients high in negative effect (i.e. negative 
mood) perceive, remember and report more physical and psychological symptoms, and 
report those symptoms to be more severe than patients with a less negative mood41.  
Additionally, individual items on questionnaires measuring fatigue, depression or sleep 
problems tend to show conceptual overlap, which further enhances co-variation.  While 
these would not render self-reports unimportant, and neither would refute that sleep and 
depression may have strong bidirectional links with fatigue, potential interpretational 
difficulties may result.  Therefore, this study’s objective and detailed anthropometric and 
biochemical data represents an important extension of the previous study in the field13.  
When multivariate regression analysis excluded adjustment for mood and sleep, reduced 
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LTI, renal impairment and inflammation were identified as potentially reversible 
predictors. 
 
The association between inflammation and fatigue is particularly notable as the studied 
cohort consisted of clinically stable KTRs, without overt evidence of ongoing acute or 
chronic inflammatory conditions.  Evidence from studies of healthy volunteers, elderly 
populations and other disease groups have shown that inflammatory cytokines possess 
potent neurological effects and are mediators of fatigue13,42-45.  Modifying inflammation 
may therefore represent an attractive target in future studies. 
 
The independent association between physical fatigue and reduced LTI is intuitively 
plausible, but not previously reported in KTRs.  It replicates results from cancer-related 
fatigue46, and fatigue associated with end-stage renal disease on haemodialysis47,48.  
Reduced muscle mass coupled with increased fat mass (“sarcopenic obesity”) is a common 
characteristic of body composition following kidney transplantation49.  Despite significant 
univariate associations between FTI and different dimensions of fatigue (General Fatigue, 
Physical Fatigue, Reduced Activity and Reduced Motivation), this relationship did not 
hold when adjusted for inflammation, suggesting inflammation as the driver for fatigue, 
rather than adiposity per se.  This study advances understanding from Rodrigue et al13 
where raised BMI (a proxy for fat mass) was identified as a predictor of fatigue, but 
detailed anthropometric and inflammatory evaluation was not undertaken.   However, it is 
possible that the systemic low-grade inflammation present in obesity triggers adipocyte 
release of pro-inflammatory cytokines50, this in turn accelerates muscle catabolism51, 
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leading to muscle wasting51.  The current study suggests that lifestyle interventions with a 
strong focus on increased physical activity and dietary modification aiming to reverse this 
phenotype should be valuable for patients displaying symptoms of fatigue.  Apart from 
promoting favourable changes in body composition, lifestyle modification is particularly 
important in light of the inverse associations between all domains of fatigue and SF-36 
physical health subscale, which is a representation of self-perceived physical functioning.  
Recent studies reported that self-perceived physical functioning is significantly and 
positively correlated with physical activity level52,53.  Although physical activity level was 
not measured in the current study, this finding suggests that striving to be physically active 
enhances functional capacity and improves self-perception of physical functioning, leading 
to improved fatigue and QoL. 
 
Although fatigue is a common and important symptom for patients on dialysis7,8, the 
present results show, for the first time, a relationship between allograft dysfunction and 
physical fatigue in KTRs.  Clinical strategies exist to improve allograft function54 and 
fatigue may represent an important patient-reported outcome in future interventional 
studies.   
 
Other non-modifiable, but important, risk factors for varying domains of fatigue included 
male, older age, ethnicity, comorbidity, and increasing time post-transplantation.  
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The lack of association between haemoglobin level and fatigue is unsurprising as the 
results from the Trial to Reduce cardiovascular Events with Aranesp Therapy (TREAT) 
study55 only showed a small improvement in fatigue with haemoglobin normalisation, 
using recombinant erythropoietin in non-transplant, diabetic, chronic kidney disease. 
 
The use of immunosuppressive medication was not associated with fatigue in KTRs.  Of 
relevance, no link between immunosuppression and fatigue was seen in previous studies of 
liver transplant recipients34 and KTRs13.    
 
This study has limitations that should be acknowledged.  It is a single-centre study with a 
small sample size.   The progression and regression of fatigue over time could not be 
evaluated due to the study design of cross-sectional nature.  The results may not be 
representative of “sicker” patients within the transplanted population.  It is recognised that 
hyperparathyroidism occurs in a substantial proportion of KTRs (17%)56, with fatigue as a 
possible manifestation.  Regrettably, serum parathyroid hormone concentrations were not 
measured in this study.   
 
Whilst kidney transplantation is associated with a variety of benefits compared with 
dialysis, this study shows that fatigue remains a common and relevant problem in 
otherwise stable KTRs.  As the medical complexity of KTRs increases, it is important not 
to lose sight of important patient-reported outcomes such as fatigue.  This study 
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demonstrates potential targets for intervention, and future research should focus on 
evaluating the effectiveness and impact of such interventions upon fatigue and QoL. 
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CHAPTER 5:  CARDIOVASCULAR, MUSCULAR AND PERCEPTUAL 
CONTRIBUTIONS TO PHYSICAL FATIGUE IN PREVALENT KIDNEY 
TRANSPLANT RECIPIENTS 
 
5.1 Abstract 
 
Background and Objectives:  Physical fatigue is a debilitating and common symptom in 
clinically stable kidney transplant recipients (KTRs).  This study investigates the aetiology 
of physical fatigue in this setting through examinations of muscle mass, muscular and 
cardiovascular functions, and perceived exertion.  The prevalence of physical fatigue, its 
association with quality of life (QoL), and the predictors of perceived exertion, were also 
evaluated.   
 
Materials and Methods:  This single-centre cross-sectional study enrolled 55 KTRs.  
Physical fatigue was measured using Multi-Dimensional Fatigue Inventory-20.  QoL was 
assessed using Medical Outcomes Study Short Form-36.  Muscle mass was quantified 
using dual-energy x-ray absorptiometry.  Muscular function was assessed by jumping 
mechanography.  Cardiovascular function (maximal oxygen consumption and oxygen 
pulse) was estimated during submaximal exercise test, with perceived exertion determined 
using age-adjusted Borg scale-ratings.  Potential demographic, clinical, nutritional, 
psychosocial and behavioural predictors of perceived exertion were assessed.   
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Results:  Of clinical importance, increased perceived exertion was the only independent 
predictor of physical fatigue (p=0.001).  Physical fatigue occurred in 22% of KTRs, and 
negatively impacted QoL (p<0.001).  Predictors of heightened perception included mental 
fatigue, anxiety, new-onset diabetes after transplantation, absence of cyclosporine, and 
very light alcohol intake (p<0.05 for all).   
 
Conclusion:  Physical fatigue in KTRs is associated with increased perceived exertion.  
This study identified predictors of perception, paving the way for future interventions.  
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5.2 Introduction 
 
Fatigue is the subjective sensation of profound and persistent tiredness, weakness, and lack 
of energy1,2.  It is a complex and multi-dimensional phenomenon involving physical, 
cognitive, and emotional components that interfere with individuals’ abilities to function 
normally2,3.  Fatigue is a prevalent patient-reported outcome among kidney transplant 
recipients (KTRs), occurring in up to 59% of these patients3-5 and substantially impacting 
upon quality of life (QoL)4,5.  Yet it is clinically under-recognised and often untreated4.   
 
Physical fatigue describes physical sensations of tiredness6, leading to physical 
underperformance7.   It represents the dominant component of fatigue in KTRs, 
outweighing behavioural, emotional, and cognitive aspects4.  It is found in 38% of KTRs, 
impacting all aspects of QoL4.   
 
Conceptually, research on physical fatigue has traditionally been considered as either 
“cardiovascular”, “muscular”, or “perceptual” in aetiology.  The cardiovascular model 
refers to insufficient cardiovascular oxygen or nutrient delivery to the muscular system, 
limiting oxidative phosphorylation and glycolysis, both of which are essential mechanisms 
for muscle contraction8.  Accordingly, fatigue with cardiovascular origin results in 
decreased ability of muscle to generate and to maintain force, hence reducing the capability 
to sustain muscle contraction, possibly contributing to physical fatigue.  The muscular 
model denotes insufficient muscle mass or reduction in muscle function, leading to failure 
of muscle force generation8-10, and/or inability to maintain a certain force or power 
output11, plausibly resulting in physical fatigue.  The perceptual theory represents the 
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increased perception of effort, characterised by loss of motivation and reluctance to 
perform a physical task when perception of effort reaches a certain level.  In fatigue with 
perceptual origin, individuals experience heightened responses to afferent feedback from 
the working body, resulting in exhaustion8,12,13, which may be expressed as physical 
fatigue.   
 
Of interest, it has been recognised that mental fatigue, characterised by inability to focus 
and maintain cognitive attention, is a crucial determinant of physical limits in healthy 
individuals14-16, by heightening the perception of exertion14,15.  This phenomenon suggests 
that mental fatigue possibly contributes to physical fatigue by raising perception of 
exertion.   
 
The cardinal mechanistic aetiology of physical fatigue in KTRs remained unexplored.   
Therefore, the primary objectives of this study were to systematically examine the 
aetiology of physical fatigue in KTRs, by measuring factors which may be mechanistically 
linked to symptoms of physical fatigue.  These include quantification of muscle mass, 
assessment of muscular and cardiovascular functions, and by evaluating perceived exertion 
during a standardised exercise protocol.  We also sought to establish the prevalence of 
physical fatigue and its impact on QoL in clinically stable KTRs.  The key findings are 
that, physical fatigue, which adversely impacts on QoL, affects 22% of KTRs, and that 
cardiovascular and muscular factors do not contribute to the aetiology of physical fatigue.  
These observations point towards increased perception of exertion as the dominant cause 
of physical fatigue.  Such findings arising from the earlier part of this study led to further 
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investigation to examine the role of mental fatigue, and other plausible predictors of 
heightened perception.   
 
5.3 Materials and Methods 
 
5.3.1 Participants and Study Design 
 
Prevalent KTRs were recruited from the renal transplant outpatient clinic at Queen 
Elizabeth Hospital Birmingham UK, between August 2011 and August 2013.  Inclusion 
and exclusion criteria are detailed in Table 5.1.  Age and gender-matched healthy subjects 
(control group A) were recruited from Queen Elizabeth Hospital Birmingham and 
University of Birmingham, UK.  However, control group A did not perform jumping 
mechanography (described below), and consequently, jumping mechanography data from 
KTRs were compared with normative data from 146 healthy subjects (control group B) 
collected for a study of muscle and ageing17. 
 
The study was approved by the local research ethics committee, and was conducted in 
accordance with the principles of the Declaration of Helsinki. 
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Table 5.1.  Inclusion and Exclusion Criteria  
Inclusion Criteria 
 KTRs beyond 1 year post-transplantation 
 Stable graft function (<10% increase in serum creatinine over the preceding 6 
months) 
Exclusion Criteria 
 Inability to provide written informed consent 
 Episodes of acute rejection within the last 6 months  
 Evidence of sepsis in the last 6 weeks 
 Known active malignancy or chronic infection 
 History of thyroid disease of adrenal insufficiency 
 Evidence of unstable angina (occurring at rest, severe and of new onset, or 
crescendo pattern) 
 Evidence of acute coronary syndrome in the last 6 months 
 Moderate or severe aortic stenosis (mean transvalvular gradient of >25mmHg or 
valve area of <1.5cm2 on echocardiogram) 
 Immobility 
 Pregnancy 
 
 
5.3.2 Protocol Overview 
 
Patients attended the research visit in the morning following an overnight rest and a light 
breakfast (260kcal and 12g protein).  Upon arrival and prior to initiating the research 
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protocol, the testing procedures including the blood test, the use of different 
questionnaires, tools and equipment were explained to the participants.   
 
The order of tests was standardised.  First, blood sampling was undertaken.  Self-
completion of questionnaires (Multi-Dimensional Fatigue Inventory-20, Hospital Anxiety 
and Depression Scale, Pittsburgh Sleep Quality Index, and Medical Outcomes Study Short 
Form-36) followed, and then dual-energy x-ray absorptiometry scanning and jumping 
mechanography were undertaken.  Finally, participants rested for one-hour prior to 
performing an incremental submaximal exercise test, which included a measure of exertion 
estimated using the Borg Rating of Perceived Exertion (RPE) scale. 
 
5.3.3 Multi-Dimensional Fatigue Inventory and Definitions of Physical and Mental 
Fatigue 
 
Severity of physical and mental fatigue were determined subjectively using the Multi-
Dimensional Fatigue Inventory-20 (MFI-20), a 20-item self-report questionnaire 
measuring fatigue in 5 dimensions including physical and mental fatigue.  Both physical 
and mental fatigue were assessed by 4 items, each using a 5-point Likert scale.  Scores for 
both physical and mental fatigue ranged from 4-20, with higher scores indicating greater 
fatigue.  It demonstrates reliability in patients with end-stage renal disease18, and proves 
validity in several medical conditions19. 
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The prevalence of physical fatigue was determined based on the previously established 
definition of physical fatigue, with fatigue defined as ≥95th percentile for healthy 
subjects4,19 (control group A). 
 
5.3.4 Quality of Life Assessment  
 
QoL was assessed using the Medical Outcomes Study Short Form-36 (SF-36).  The SF-36 
consists of 36 questions grouped into 8 life domains: physical functioning; social 
functioning; role limitation due to physical problems; role limitation due to emotional 
problems; mental health; energy and vitality; bodily pain; and general health perception.  
For each tested domain, item scores were coded, summed, and transformed into a scale 
from 0 (worst QoL) to 100 (best QoL) using the standard SF-36 scoring algorithm20.  As 
well as the total score for QoL, these sub-scales are subsumed under 2 subscores, i.e. 
physical health summary score and mental health summary score.  Physical health is 
represented by the physical functioning, role limitation due to physical problems, bodily 
pain, general health perception, and energy and vitality subscales.  Mental health is 
represented by the mental health, role limitation due to emotional problems, social 
functioning, energy and vitality, and general health perception subscales21.  The SF-36 is 
among the most commonly used instruments to assess QoL, and is regarded as valid and 
reliable in different population groups, including patients undergoing renal replacement 
therapy22. 
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5.3.5 Dual-Energy X-ray Absorptiometry Scanning 
 
Dual-Energy X-ray Absorptiometry (DEXA) Scanning provided measures of whole-body 
lean tissue mass (LTM), lower limb lean tissue mass (LLTM), and fat mass (FM)23,24.  
Prior to DEXA scanning, body weight was measured for individualised estimation of the 
most appropriate acquisition mode.  Scan acquisition was carried out by trained personnel.  
Analysis and reporting of the scans were performed by a single trained bone densitometry 
clinical scientist.  Coefficients of variation were <3% for body composition assessment in 
the local laboratory.   
 
Both LTM and LLTM were normalised to height squared (Ht2) to account for differences 
in body size:  Normalised LTM or LLTM = (LTM or LLTM / Ht2). 
 
5.3.6 Jumping Mechanography 
 
The Leonardo Mechanography Ground Reaction Force Platform, software version 4.2 
(Novotec Medical GmbH, Pforzheim, Germany) was used to assess lower limb muscle 
power, an indication of muscular function.  Participants performed three two-legged 
counter movement jump (CMJ) on the force platform with freely-moving arms.  A one-
minute rest interval was incorporated between each jump.  Participants were instructed to 
jump as high as possible, producing maximum elevation of centre of mass.  The jump with 
the highest automatic peak detection was selected for data analysis.  The coefficient of 
variation of muscle power measurement using Jumping Mechanography is 3.6%25 .   
 
 
Chapter 5   
155 
Peak power of the vertical movement was computed by the system as the product of force 
and velocity25-29, which subsequently provides an important outcome parameter, the peak 
power normalised to total body mass (BM):  Peak Power adjusted to BM = Peak Power 
from CMJ / BM.  In particular, given that jumping mechanography predominately 
investigates kinetic factors of lower limb muscle function (i.e. mechanical power) in both 
paediatric and adult populations30,31, peak power was also adjusted to LLTM:  Peak Power 
adjusted to LLTM = Peak Power from CMJ / LLTM. 
  
5.3.7 Incremental Submaximal Exercise Test 
 
Cardiovascular function, represented by maximal oxygen consumption (VO2max) and 
oxygen pulse (O2 pulse), were measured by performing a submaximal incremental exercise 
test on an electrically braked cycle ergometer (Lode Corival, Cranlea, UK). 
 
The exercise protocol was preceded and followed by a two-minute warm-up and cool-
down period at 10 watts (W).  The test started at 25W, and the work rate increased by 25W 
at three-minute intervals until voluntary exhaustion or the end of three-minutes at 75W.  
Participants were encouraged verbally to maintain a cadence of ≥65 revolutions per 
minute.   
 
During the exercise protocol, participants were required to have a nose-clip fitted, and 
breathe through a mouthpiece attached to a two-way non-rebreathing valve, which is 
connected to a metabolic cart with a breath-by-breath online gas collection system 
(MOXUS Modular Metabolic System, AET Technologies, Pittsburgh, USA).  The 
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MOXUS demonstrates validity and reliability compared with the “Douglas bag method”, 
the gold standard32.  Calibration procedures were performed on the MOXUS metabolic cart 
prior to exercise testing in accordance with the manufacturer instructions.  Ventilation and 
expired gas were collected continuously and analysed every 30 seconds, calculating 
oxygen consumption (VO2).  The coefficient of variation for VO2 measurement is 3.0%32.  
Heart rate (HR) was monitored continuously (Polar Vantage, Kempele, Finland) and 
recorded every 30 seconds. 
 
The VO2 and HR measurements were averaged over the final minute of each of the three-
minute workloads (25W, 50W and 75W).  Consequently, VO2max was estimated by linear 
regression, extrapolating VO2 to the age-predicted maximum HR:  Age-predicted 
Maximum HR = 205.8 – (0.685 × Age)33-35.  It is known that estimated VO2max correlates 
highly with measured VO2max when calculated with this approach36.  An example of the 
linear regression is shown in Figure 5.1, the mean r2 of the linear regression for the studied 
cohort is 0.97 (ranged from 0.86 to 1.00).  
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seconds of each minute of the exercise test, where participants reported an instantaneous 
RPE by pointing at the scale. 
 
For comparisons to be made between different subjects and exercise conditions, the Borg 
RPE scale should be related to a standardised workload.  This may be possible if the cohort 
is homogenous, but in the present study, there are differences in age, gender, body size, 
and levels of cardiovascular fitness.  There were also variations in the workload achieved 
among participants.  To overcome these issues, RPE index (RPEindex) was adopted, in 
which the actual RPE at the end of the exercise protocol (or volitional fatigue) was 
compared to the expected RPE based on the subject’s HR at that time as a fraction of 
estimated age-predicted maximum HR and assuming that RPE would be 20 at maximum 
heart rate.  The RPEindex allows for differences in body size, fitness and age, it is therefore 
a true reflection of the subject’s sense of effort relative to other people. 
 
The derivation is summarised below: 
 
RPEindex = (Actual RPE / Expected RPE of 20) × (Estimated Age-predicted Maximum 
HR / Actual HR at exhaustion or end of exercise) 
 
5.3.9 Demographic, Clinical, Psychosocial and Behavioural Data Collection 
 
Age, gender, marital status, ethnicity, and time post-transplantation were collected from 
patients’ medical records.  Smoking status (never smoked, current smoker, ex-smoker) and 
alcohol intake (units per week) were enquired by questionnaire.  Co-morbidity was 
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assessed by Index of Co-Existing Disease (ICED), using the algorithm described by 
Hemodialysis (HEMO) Study39, with data extracted from patients’ medical records.  
Presence of diabetes, either pre-transplantation (pre-DM) or new-onset diabetes after 
transplantation (NODAT), prior acute rejection episodes, and immunosuppressive 
medication usage were retrieved from patients’ medical records.   
 
Blood sampling was undertaken for analysis of high-sensitivity C-reactive protein 
(hsCRP), haemoglobin, and creatinine-derived estimated glomerular filtration rate (eGFR) 
using the 4-variable modification of diet in renal disease equation40.     
 
Symptoms of anxiety and depression were assessed using Hospital Anxiety and Depression 
Scale (HADS).  It has been validated against clinical diagnosis of anxiety and depression 
including patients with end-stage renal disease41,42.  HADS is a self-administered 14-item 
scale, with 7 items measuring anxiety and 7 items measuring depressive symptoms.  Items 
were scored on a 4-point scale ranging from 0 to 3.  The sum-scores for anxiety and 
depression range from 0 to 21, with higher scores indicating increased symptoms of 
anxiety and depression.   
 
Sleep Quality was assessed by the Pittsburgh Sleep Quality Index (PSQI).  It is valid, 
reliable and widely used43,44.  In particular, it demonstrated reliability and validity in 
KTRs45.  PSQI consists of a 24-item questionnaire measuring sleep disturbances during the 
previous month, and generates a global score of subjective sleep quality ranging from 0 to 
21, with higher scores indicating worsening subjective sleep quality. 
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5.3.10 Statistical Analysis 
 
Statistical analyses were performed using SPSS Statistics 21 (Chicago, IL).  Unless 
otherwise stated, results were presented as mean ± standard deviation (SD) for normally 
distributed data, or median (interquartile range, IQR) for non-normally distributed data.  
Data with positively skewed distribution were given a logarithmic transformation prior to 
analysis.  Pearson correlation coefficient was used to assess relationships.  Independent-
samples t-test was used to compare differences of continuous variables between groups.     
 
Linear regression analysis was used to determine the association between predictor 
variables and the continuously-distributed outcome variables.  There were two outcomes 
variables in this study, physical fatigue and RPEindex.  Both variables were found to be 
normally distributed, and were analysed on its original scale of measurement.  The 
analyses were performed in two stages.  Initially, the effect of each variable was examined 
in a series of univariate regression analyses.  Subsequently, the joint effect of variables 
demonstrating some evidence of association in univariate analyses (p<0.20) was examined 
in a multivariate regression analysis, using a backward selection procedure to derive the 
final model.  A type 1 error rate ≤5% (p≤0.05) was considered significant in the final 
model. 
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5.4 Results 
 
The characteristics of KTRs are shown in Table 5.2.  Comparison of population 
characteristics between KTRs and healthy control subjects (control groups A and B) are 
shown in Table 5.3.   
 
Table 5.3.  Comparison of Basic Population Characteristics between Kidney 
Transplant Recipients (KTRs), Control Group A and Control Group B 
 KTRs 
 
Control Group A 
 
Control Group B p-value 
Sample size 
 
n = 55 n = 41 n = 146 --------- 
Gender (%) 
 
Male = 58 Male = 57 Male = 52              a0.61 
†Mean age (years)  
 
†46 ± 14 †56 ± 10 †51 (range 18-82) b0.18 
†Mean or ‡Median weight (kg) 
 
‡73.0 (64.2-88.5) †76.6 ± 15.0 ‡66.7 (60.1-76.5)  b0.59 
†Mean height (m) 
 
†1.70 ± 0.10 †1.71 ± 0.09 †1.73 ± 0.09 b0.20 
†Mean or ‡Median BMI (kg/m2) 
 
†26.8 ± 5.1 ‡24.8 (23.6-27.9) ‡22.4 (19.0-27.1) b0.21 
 
†Normally distributed data, results expressed as mean ± standard deviation (SD), unless otherwise stated.  ‡Non-normally 
distributed data, results expressed as median (interquartile range, IQR). 
aCochran’s Q test was used to test differences on the dichotomous dependent variable between 3 groups. 
bKruskal-Wallis One-Way Analysis of Variance (ANOVA) was used to test differences of the continuous variable 
between groups. 
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Table 5.2.  Population Characteristics for Kidney Transplant Recipients 
 Characteristics 
 
Sample size n = 55 
Gender (%) Male = 58 
†Mean age (years) 46 ± 14 
Ethnicity (%) Caucasian = 80 
Asian = 13 
Afro-Caribbean = 5 
Others = 2 
Marital status (%) Single = 22 
Married = 67 
Divorced/Widowed = 11                                
Alcohol intake (units per week) 2 (0-3)  
Smoking status (%) Non-smoker = 60 
Current smoker = 11 
Ex-smoker = 29 
‡Median time post-transplantation (years) 2 (1-7)  
Previous episodes of acute rejection (%) Yes = 7 
No = 93 
Immunosuppressive medication usage 
Calcineurin inhibitor (%) 
Adjunctive antiproliferative agent (%) 
Prednisolone (%) 
 
93 
87 
86 
Dosage of immunosuppressive medications 
†Mean dose of tacrolimus (mg/day) 
†Mean dose of cyclosporine (mg/day) 
†Mean dose of mycophenolate mofetil (mg/day) 
†Mean dose of azathioprine (mg/day) 
‡Median dose of prednisolone (mg/day) 
 
5.8 ± 3.2 
184 ± 47 
1147 ± 456 
85 ± 36 
5.3 (5.0-5.0) 
Physical fatigue 
†Mean MFI-20 score 
MFI-20 score ≥95th percentile of control group A 
 
10 ± 4 
22 
Mental fatigue  
†Mean MFI-20 score 
MFI-20 score ≥95th percentile of control group A 
 
10 ± 5 
20 
Quality of Life 
†Mean total score 
†Mean physical health summary score 
†Mean mental health summary score 
 
77 ± 18 
73 ± 20 
77 ± 18 
Body composition (DEXA measurements) 
†Mean LTM (kg) 
 
†Mean LTM adjusted to Ht2 (kg/m2) 
 
†Mean LLTM (kg) 
 
†Mean LLTM adjusted to Ht2 (kg/m2) 
 
†Mean FM (kg) 
 
50.7 ± 11.5        
[Male: 58.0 ± 9.6; Female: 41.2 ± 4.9] 
17.5 ± 2.5          
[Male: 18.7 ± 2.4; Female: 15.8 ± 1.6] 
16.0 ± 3.7          
[Male: 18.1 ± 3.1; Female: 13.4 ± 2.4]  
5.5 ± 0.9            
[Male: 5.8 ± 0.8; Female: 5.0 ± 0.8] 
23.2 ± 8.9          
[Male: 22.2 ± 9.3; Female: 24.5 ± 8.6] 
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Table 5.2.  Population Characteristics for Kidney Transplant Recipients (continued) 
 Characteristics 
 
Jumping mechanography 
†Mean muscle power from CMJ (W) 
 
†Mean muscle power per BM from CMJ (W/kg) 
 
†Mean muscle power per LLTM from CMJ (W/kg)  
 
2641 ± 756        
[Male: 3008 ± 727; Female: 2171 ± 493] 
35 ± 7                
[Male: 37 ± 8; Female: 32 ± 6] 
169 ± 31            
[Male: 172 ± 33; Female: 166 ± 29] 
Incremental submaximal exercise test  
†Mean VO2max (ml/min/kg) 
 
†Mean O2 Pulse (ml/beat) 
 
†Mean O2 Pulse (ml/beat/kg BM) 
 
†Mean O2 Pulse (ml/beat/kg LTM) 
 
27.7 ± 10.4        
[Male: 30.1 ± 9.7; Female: 21.9 ± 5.0] 
16.8 ± 5.8          
[Male: 21.6 ± 7.4; Female: 12.0 ± 4.2] 
0.22 ± 0.07        
[Male: 0.26 ± 0.08; Female: 0.18 ± 0.06] 
0.35 ± 0.14        
[Male: 0.39 ± 0.13; Female: 0.31 ± 0.14] 
Borg scale 
†Mean RPEindex 
 
1.0 ± 0.3            
[Male: 0.9 ± 0.3; Female: 1.0 ± 0.2]  
Presence of diabetes (%) Non-diabetic = 73         
NODAT = 14          
Pre-DM = 13 
Co-morbidity 
‡Median ICED score 
 
2 (2-2) 
HADS 
†Mean anxiety score 
†Mean depression score 
 
8 ± 5  
4 ± 3 
PSQI 
†Mean global score 
 
6 ± 3 
‡Median hsCRP (mg/L) 1.67 (0.61-3.96) 
†Mean Hb (g/dL) 12.6 ± 1.5 
†Mean eGFR (mL/min)  49.4 ± 12.9 
 
†Normally distributed data, results expressed as mean ± standard deviation (SD).  ‡Non-normally distributed data, results 
expressed as median (interquartile range, IQR).   
Abbreviations:  MFI-20=multi-dimensional fatigue inventory-20; DEXA=dual energy x-ray absorptiometry; LTM=lean tissue 
mass; Ht2=height squared; LLTM=lower limb lean tissue mass; FM=fat mass; CMJ=single two-legged counter movement jump; 
VO2maxest=estimated maximal oxygen consumption; O2 pulse =oxygen pulse; BM=total body mass; RPEindex=rating of 
perceived exertion index; ICED=index of co-existing disease; HADS=hospital anxiety and depression scale; PSQI=Pittsburgh 
sleep quality index; hsCRP=high-sensitivity c-reactive protein; Hb=haemoglobin; eGFR=estimated glomerular filtration rate; 
NODAT=new onset diabetes after transplantation; Pre-DM=pre-existing diabetes mellitus. 
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Table 5.4.  Predictors for Mechanistic Aetiology of Physical Fatigue 
 Univariate Analysis Multivariate Analysisa 
Regression 
Coefficient  
(95% CIb) 
p-value Regression 
Coefficient  
(95% CIb) 
p-value 
RPEindex 
 
5.7 (2.2, 9.2) 0.001 5.7 (2.2, 9.2) 0.001 
c0.0 (-7.8, 7.9) 
d0.0 (-0.2, 0.3) 
c0.99 
d0.73 
VO2max (ml/min/kg) 
 
-0.1 (-0.2, 0.0) 0.09   
c-0.2 (-0.5, 0.2) 
d0.0 (-0.0, 0.0) 
c0.34 
d0.69 
O2 Pulse (ml/beat) 
 
3.5 (-4.1, 11.2) 0.21   
c-5.5 (-19.2, 12.1) 
d0.1 (-0.8, 0.9) 
c0.39 
d0.77 
O2 Pulse (ml/beat/kg BM) 
 
2.5 (-2.7, 11.4) 0.20   
c-5.7 (-16.2, 9.8) 
d0.2 (-0.5, 0.4) 
c0.22 
d0.68 
O2 Pulse (ml/beat/kg LTM) 
 
4.7 (-3.1, 12.6) 0.23   
c-6.5 (-23.1, 10.1) 
d0.0 (-0.6, 0.6) 
c0.43 
d0.88 
LTM adjusted to Ht2 (kg/m2) 
 
0.1 (-0.4, 0.5) 0.75   
c0.8 (-0.4, 2.0) 
d0.0 (-0.0, 0.1) 
c0.29 
d0.51 
LLTM adjusted to Ht2 (kg/m2) 
 
-0.4 (-1.6, 0.8) 0.48   
c0.8 (-1.9, 3.4) 
d-0.0 (-0.1, 0.1) 
c0.57 
d0.83 
‡CMJ, absolute power (W) 
 
-0.1 (-0.2, 0.1) 0.33   
c0.0 (-0.3, 0.2) 
d0.0 (-0.0, 0.0) 
c0.91 
d0.94 
†CMJ, power per BM (W/kg) 
 
-0.1 (-0.2, 0.1) 0.31   
c-1.1 (-5.2, 2.4) 
d-0.0 (-0.1, 0.1) 
c0.52 
d0.41 
†CMJ, power per LLTM (W/kg) 
 
-0.1 (-0.3, 0.1) 0.28   
c-1.5 (-5.8, 2.8) 
d-0.1 (-0.3, 0.1) 
c0.47 
d0.24 
R2 value from final model 28% 
aResults in the final multivariate regression model were presented.  
bCI = Confidence Interval. 
cResults of interaction analysis moderated by the effect of gender. 
dResults of interaction analysis moderated by the effect of age. 
†Coefficients reported for a 10-unit increase in explanatory variable. 
‡Coefficients reported for a 100-unit increase in explanatory variable. 
Abbreviations:  RPEindex=rating of perceived exertion index; VO2maxest=estimated maximal oxygen consumption; O2 
pulse=oxygen pulse; BM=total body mass; LTM=lean tissue mass; Ht2=height squared; LLTM=lower limb lean tissue mass; 
CMJ=single two-legged counter movement jump. 
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Table 5.5.  Predictors of Rating of Perceived Exertion Index (RPEindex) 
 Univariate Analysis Multivariate Analysisa 
Beta Coefficient, β 
(95% CIb) 
p-value Beta Coefficient, β 
(95% CIb) 
p-value 
Presence of diabetes 
Non-diabetic 
NODAT 
Pre-DM 
 
0 
0.3 (0.0, 0.5) 
0.6 (-0.2, 1.4) 
 
0.02 
 
0 
0.2 (0.0, 0.5) 
0.2 (-0.0, 0.5) 
 
0.04 
Use of calcineurin inhibitor 
None 
Cyclosporine 
Tacrolimus 
 
0 
-0.3 (-0.5, -0.1) 
-0.1 (-0.3, 0.2) 
 
0.03 
 
0 
-0.4 (-0.6, -0.2) 
-0.0 (-0.3, 0.3) 
 
0.03 
†Age (years)  0.1 (0.0, 0.2) 0.04   
†Mental fatigue (MFI-20 score) 0.3 (0.1, 0.5) 0.04 0.5 (0.1, 0.9) 0.03 
†Alcohol intake (units per week) -0.4 (-1.1, -0.0) 0.04 -0.6 (-1.1, -0.1) 0.03 
†Anxiety (HADS score) 0.5 (0.1, 0.8) 0.04 0.4 (0.1, 0.7) 0.04 
†Depression (HADS score) 0.5 (0.0, 0.1) 0.05   
Use of prednisolone 
No 
Yes 
 
0 
-0.4 (-0.9, 0.1) 
 
0.10 
  
Co-morbidity (ICED score) 0.9 (-0.4, 2.2) 0.18   
Previous episodes of acute rejection
No 
Yes 
 
0 
-0.4 (-1.1, 0.2) 
 
0.20 
  
Time post transplantation (years)  0.1 (-0.2, 0.4) 0.35   
Marital status 
Married 
Single 
Divorced / Widowed 
 
0 
0.2 (-0.6, 0.2) 
-0.0 (-0.2, 0.1) 
 
0.46 
  
cEthnicity 
Caucasian 
†Non-Caucasian 
 
0 
0.4 (-0.2, 3.8) 
 
0.48 
  
Gender 
Female 
Male 
 
0 
0.1 (-0.2, 0.5) 
 
0.51 
  
†FM (kg) 0.1 (-0.2, 0.3) 0.55   
Smoking status 
Never smoked 
†Ex-smoker 
Current smoker 
 
0 
0.5 (-1.6, 2.4) 
0.1 (-7.3, 7.6) 
 
0.66 
  
†Haemoglobin (g/dL) 0.3 (-0.9, 1.5) 0.66   
†PSQI (global score) 0.1 (-0.5, 0.6) 0.77   
†eGFR (mL/min) 0.0 (-0.1, 0.2) 0.82   
ℓhsCRP (mg/L) 0.0 (-0.3, 0.4) 0.94   
Use of adjunctive antiproliferative 
agents 
None 
†Mycophenolate mofetil 
Azathioprine 
 
0 
-0.2 (-4.3, 0.4) 
0.0 (-0.3, 0.3) 
 
 
0.98 
  
†LTM (kg) 0.00 (-0.2, 0.2) 0.99   
R2 value from final model 38% 
aResults in the final multivariate regression model were presented.  bCI = Confidence Interval. 
cFor the purpose of statistical analysis, the ethnicity of patients classified as “Afro-Caribbean”, “Asian” and “Others” was grouped as “Non-Caucasian”, 80% 
“Caucasian” versus 20% “Non-Caucasian”. 
† Coefficients reported for a 10-unit increase in explanatory variable.  ℓVariable analysed on the log scale (base 10). 
Abbreviations:  HADS=hospital anxiety and depression scale; NODAT=new onset diabetes after transplantation; Pre-DM=pre-existing diabetes mellitus; MFI-
20=multi-dimensional fatigue inventory-20; ICED=index of co-existing disease; FM=fat mass; PSQI=Pittsburgh sleep quality index; eGFR=estimated glomerular 
filtration rate; hsCRP=high-sensitivity C-reactive protein; LTM=lean tissue mass. 
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In the multivariate analysis, age and depression did not retain significance, but the 
remaining variables persisted as showing statistically significant relationships with 
RPEindex (Table 5.5).  38% of the variation in perceived exertion was explained by the 
variables in the final multivariate model (R2: 38%). 
 
5.5 Discussion 
 
This is the first study to systematically investigate the potential aetiology of physical 
fatigue in KTRs, which may be mechanistically linked to symptoms of physical fatigue.  
This study reveals important findings.  First, physical fatigue is unrelated to muscular and 
cardiovascular factors, but rather, it is driven by increased perception of exertion during 
exercise.  The findings of the current study confirm physical fatigue as a common and 
disabling symptom among KTRs, negatively impacting on QoL3-5.  In turn, mental fatigue 
significantly associated with such heightened perception of effort.  Whilst novel to 
transplantation, these results resonate with findings from other populations, whereby 
heightened perception limits exercise capacity in healthy trained individuals47 and diabetic 
patients48, and mental fatigue impairs physical performance through increased perception 
of effort rather than limiting musculoenergetic or cardiorespiratory functions14,15.  
 
Similar to all aspects of fatigue assessment using the MFI-20 questionnaire, physical 
fatigue scores varied widely within both KTRs and control groups.  Based on an 
established definition of physical fatigue (≥95th percentile for healthy control subjects)4,19, 
22% of KTRs experienced this symptom.  It was somewhat lower than previously reported 
(38%)4, possibly due to stringent exclusion criteria employed in this study for ethical and 
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safety issues.  Also, KTRs who were eligible for entry into this study might have declined 
participation at enrolment due to the likely discomfort arising from the exercise test and the 
possibility of physical difficulty encountered with the vertical jump test.  For these reasons, 
variations in the characteristics of the studied populations may explain the differences in 
the prevalence of physical fatigue.  Indeed, the mean physical fatigue score for KTRs 
(10±4) was comparable to “chronically unwell” patients (10±4) reported by Lin19.  This, 
together with the adverse associations on all aspects of QoL, indicates the severity of the 
problem. 
 
Varied disease processes or lack of physical activity may result in muscle atrophy.  In these 
circumstances, muscles work at a relatively high work-load and hence fatigue rapidly.  
However, in this cohort of KTRs, there was no association between physical fatigue with 
either whole body LTM or LLTM.  Certainly, muscle mass per se may not be the crucial 
factor, the ability of musculature to generate force and movement arguably may be of 
greater importance.  Interestingly, the results from the jumping mechanography studies 
showed no association between muscular power and physical fatigue.  In support of these 
results in the KTRs group, muscle mass and power were similar to gender-specific healthy 
control subjects, with muscle mass data comparable to previous literature in this field49,50. 
 
Reduced aerobic fitness from disease or inactivity may lead to physical fatigue.  VO2max 
is the conventional measure of cardiovascular fitness, and its prognostic utility is well-
established in research and clinical settings51,52.  VO2max is frequently estimated from a 
submaximal exercise test.  However, there are 2 caveats to this approach.  Firstly, 
estimation of maximum HR in relation to age may be unreliable33,53.  Secondly, body 
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weight-adjusted VO2max can be misleading due to inter-individuals’ variability in body 
composition.  An alternative, but complimentary measure of O2 pulse has recently 
emerged51,52, which, during exercise is predominately determined by cardiac stroke volume 
and peripheral oxygen extraction, thereby reflecting cardiovascular function more 
accurately51,52,54.  Both male and female KTRs had numerically lower VO2max and O2 
pulse compared to healthy controls, although only statistically significant in females.  
These results are comparable to findings from previous studies in this field49,50,55,56.  Of 
relevance, however, neither VO2max nor O2 pulse were associated with physical fatigue in 
the analysis.  The difference in cardiovascular fitness between KTRs and healthy subjects 
is perhaps unsurprising, but the underlying reasons for the variation were not the focus of 
the current study.   
 
Using the Borg scale in healthy subjects, the RPE during exercise is linearly related to the 
actual work rate, measured by oxygen uptake or HR36, ranging from a RPE of 6 at rest to 
20 corresponding to age-predicted maximum HR.  In this study, it was found that at the 
end of the exercise protocol, the RPE scores from KTRs were significantly higher than 
healthy control subjects, with both based on HR relative to age-adjusted maximum HR.  
This indicates that at the same relative work rate, KTRs had greater perception of exertion.  
Importantly, RPEindex in KTRs correlated significantly with physical fatigue, consistent 
with a heightened perception of exertion.  The final multivariate analysis model suggests 
that this contribution explains 28% of physical fatigue experienced by KTRs.   
 
The mechanisms by which perception of effort influences physical performance has been 
previously proposed by Marcora and colleagues using the Brehm’s theory of motivation14.  
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In this theory, individuals opt to withdraw from a task when it is perceived to be too 
difficult, or the effort required exceeds the individuals’ willingness to perform57.  During 
the decision-making process, individuals are suspected to have lowered their level of task 
difficulty for withdrawal58,59.  Impaired physical performance is a common feature in 
KTRs60-62, since physical fatigue represents a transient decrease in muscular performance, 
this may be seen as failure to generate and to maintain optimal physical performance.  
Therefore, the Brehm’s theory of motivation may be extrapolated in this setting.   In 
addition, there is evidence that disorders of the brainstem, dopaminergic systems and 
endogenous opiates may affect decision making57-59,63,64.  In particular, increasing 
dopamine release in the brain through dopaminergic-modulating agent, is associated with 
reduced perceived fatigue and increased perceived QoL in chronic fatigue syndrome65.  
This may be applicable to KTRs with physical fatigue as an important-patient reported 
outcome.   
 
Of importance, a caveat with the interpretation of the associations between self-report data, 
such as symptoms of physical and mental fatigue, perceived exertion, anxiety and 
depression, is that common method variance may partly drive the observed associations 
and may account for 25% of shared variance66.  In common method variance, patients high 
in negative effect (i.e. negative mood) perceive, remember, and report more physical and 
psychological symptoms, and report those symptoms to be more severe than patients with 
less negative mood67.  Although these would not render self-reports unimportant, potential 
interpretational difficulties may result.   
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Factors associated with heightened perceived exertion in the adjusted analysis included 
low alcohol intake, lack of cyclosporin prescription, NODAT, mental fatigue, and anxiety.  
Interestingly, other commonly studied clinical and demographic variables, including 
eGFR, haemoglobin and hsCRP, showed no association with perception of effort.  
 
Overall, this study cohort consisted of very light drinkers (2 units a week), and previous 
studies have shown that light to moderate alcohol consumption is associated with improved 
cognitive function68,69, with both social and physiological factors playing potential roles68-
71.  Absence of cyclosporin was also an independent predictor of perceived exertion.  The 
exact mechanism remains unclear, although an animal study demonstrated that 
cyclosporine A preserves brain mitochondrial function that is associated with improved 
motor and cognitive behaviour72.  Previous study have shown that higher cognition is 
closely associated with improved visual perception73, however, it is unclear whether visual 
perception shares similar mechanisms as perceived exertion during exercise.  Although 
these associations may be biologically plausible, at present, such correlations were only 
supported by weak rationale in the literature, possibly representing a type I statistical error.  
 
Fatigue in diabetes is likely to be caused by the interplay of physiological, psychological 
and lifestyle-associated factors74.  It is interesting that pre-DM was not associated with 
increased perceived exertion, a plausible explanation for the differences between NODAT 
and pre-DM is that KTRs with NODAT may experience exaggerated psychological 
distress having to cope with yet another disease state and requiring a novel diabetes 
treatment regimen.   
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KTRs displayed considerable mental fatigue, with an MFI-20 score of 10±5, comparable to 
“chronically unwell” patients reported by Lin19 (11±4).  Further, mental fatigue was an 
independent predictor of increased perception of exertion.  This novel data in KTRs is 
reminiscent of that from Marcora in a non-transplant cohort14 who showed mental fatigue 
decreases physical performance via increased perception of effort, without affecting 
conventional physiological variables such as stroke volume, oxygen uptake, blood 
pressure, or lactate levels14.  However, it should be noted that mental fatigue was measured 
by self-report questionnaire in this study, whereas mental fatigue was induced 
experimentally by a 90-minute computer-based cognitive task in Marcora’s study14, it is 
unclear whether the two methodologies characterised equivalent effects.  If common 
mechanisms exist, it is possible that increased perception of exertion is an aspect of mental 
fatigue in KTRs, contributing to symptoms of physical fatigue. 
 
Mean anxiety score for KTRs in this study (8±5 on HADS) is considered mild anxiety75, 
and was independently associated with increased perception of exertion.  Depression also 
displayed a univariate association with perception.  These observations have been noted 
previously in non-transplant studies76,77, supporting the findings of this study.  Anxious and 
depressed individuals are less attuned to interpret bodily sensations including fatigue 
during physical activity77, with physiological responses to exercise “linked” 
inappropriately to catastrophic cognitions in such individuals.   
 
This study has limitations that should be acknowledged.  It is a pilot study that represents a 
single-centre experience, and validations of the findings are needed in larger cohorts.  The 
observational and cross-sectional nature of the study design indicates that the direction of 
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the causality between predictor and outcome variables cannot be defined.  However, the 
findings are intuitive and biologically plausible, and are in many aspects compatible with 
findings from other disease states and the general population.  Despite this, there is a 
possibility that the large number of correlational analyses performed may lead to type I 
statistical error, especially where associations were supported by weak rationale in the 
literature.  Similarly, absence of associations between certain variables should not be 
treated without reservations due to a pilot study with a small sample size, implicating an 
inherently high probability of type II statistical error.  Finally, it is important to 
acknowledge that KTRs are often prescribed antihypertensive medications that exert 
cardioactive effects, specifically the negative chronotropic effect of beta adrenergic 
blockers and calcium-channel blockers which would have influenced measurements of HR 
in this study.   
 
In conclusion, this study suggests that physical fatigue in KTRs is not affected by muscular 
and cardiovascular factors, but rather, it is caused by increased perception of exertion 
influenced by mental fatigue and anxiety.  Improving physical fitness or strength per se is 
unlikely to improve physical fatigue, and other strategies such as cognitive behavioural 
therapy or centrally-acting pharmacological therapies may be more appropriate.  
Undoubtedly, physical fatigue represents a frequent and important patient-reported 
outcome.  The findings of this study set the scene for future interventional research and 
therapeutic strategies. 
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CHAPTER 6:  GENERAL DISCUSSION 
 
6.1 Overview of the Thesis 
 
The studies presented in Chapters 2 to 5 of this thesis explored the associations between 
different body composition compartments with morbidity (low haemoglobin, elevated 
blood pressure) and fatigue, the potential contributing factors to long-term patient- and 
graft- survival, as well as quality of life (QoL).  There are significant gaps in the current 
literature on this area of research.  A greater understanding of the relationships between 
different body composition compartments with morbidity, mortality, and QoL outcomes 
may provide insight into future interventional strategies, ultimately improving clinical and 
QoL outcomes in kidney transplant recipients (KTRs).      
 
Chapters 2 and 3 focused on clinical outcomes in clinically stable kidney transplant 
recipients (KTRs).  Chapter 2 assessed the association between adiposity and 
inflammation, and its relationship with elevated hepcidin and reduced haemoglobin levels.  
Chapter 3 determined the effects of hypervolemia on blood pressure and levels of N-
terminal fragment of pro-hormone B-Type natriuretic peptide (NT-proBNP). 
 
Chapters 4 and 5 attended to fatigue, an important QoL outcome in medically stable 
KTRs.  Whilst Chapter 4 explored the role of muscle mass and adiposity on post-
transplantation fatigue; Chapter 5 specifically examined the potential mechanisms of 
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physical fatigue by evaluation of muscle mass, muscular function, cardiovascular function, 
and fatigue perception. 
 
6.2 Summary of the Major Findings Pertaining to Body Composition 
 
The crucial finding of this thesis is that different body composition compartments exert 
varying effects on clinical and QoL outcomes in KTRs.   
 
6.2.1 Associations between Adiposity with Inflammation, Hepcidin and 
Haemoglobin Levels in Kidney Transplant Recipients 
 
As shown in Chapter 2, increased fat mass was independently and positively associated 
with inflammation.  This is an important observation as previous studies in kidney 
transplantation yielded conflicting conclusions1-3.  Further, a univariate association 
between fat mass and hepcidin level was found, but this association did not persist when 
adjusted for inflammation.  This notion extends to the field of kidney transplantation, 
which supports the concept that adipose tissue may itself be a source of hepcidin, produced 
in response to the effect of inflammatory cytokines released by the fat tissue4.  However, a 
relationship between adiposity and haemoglobin level was not established.  Since 
independent correlations were observed between inflammation and raised hepcidin level, 
and between elevated hepcidin and reduced haemoglobin levels, it remains a possibility 
that adiposity-related inflammation in KTRs is associated with elevated hepcidin, 
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contributing to reduced haemoglobin in KTRs by dysregulation of iron homeostasis.  The 
absence of such associations may suggest a type II statistical error.  Though not evaluated 
in the current study, the proposed mechanism may potentially impact on patient- and graft- 
survivals5-7. 
 
6.2.2 Effects of Hypervolemia on Blood Pressure and Levels of N-Terminal 
Fragment of Pro-hormone B-Type Natriuretic Peptide in Kidney Transplant 
Recipients 
 
As revealed by Chapter 3, hypervolemia was identified as an independent risk factor for 
elevated mean arterial, systolic and diastolic blood pressure, which has a recognised impact 
upon long-term patient- and graft- outcomes8-10.  While the relationship between 
hypervolemia and elevated blood pressure resonates with findings in dialysis patients11-13, 
it has not been previously demonstrated in KTRs and reflects novelty in this setting.  In 
addition, the independent association between the objective measure of hypervolemia and 
raised NT-proBNP level is another novel and noteworthy observation of this study.  
Although the impact of elevated NT-proBNP level in KTRs remains undetermined, it is an 
independent predictor of mortality in patients with end-stage renal disease (ESRD)14.  The 
relationship between hypervolemia and raised NT-proBNP level confirms and extends 
findings from the non-transplant populations, predominately patients undergoing dialysis15-
18.   
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6.2.3 The Role of Muscle Mass and Fat Mass on Post-transplantation Fatigue 
 
As presented in Chapter 4, while significant univariate associations were observed 
between fat mass and different dimensions of fatigue, including general fatigue, physical 
fatigue, reduced activity, and reduced motivation; these relationships did not hold when 
adjusted for inflammation, suggesting that inflammation is a driver for fatigue rather than 
adiposity per se.  This study advances understanding previously built upon from a study in 
this field19, where raised body mass index (BMI), a proxy for fat mass, was identified as a 
predictor of fatigue, but detailed anthropometric and inflammatory evaluation was not 
undertaken.  However, it is possible that the systemic low-grade inflammation present in 
obesity triggers adipocyte release of proinflammatory cytokines20; this in turn accelerates 
muscle catabolism21, leading to muscle wasting21.  Reduced muscle mass coupled with 
increased fat mass (i.e. sarcopenic obesity) is a common characteristic of body composition 
after kidney transplantation22.  Such proposed mechanisms support another major finding 
in Chapter 4, where decreased muscle mass independently predicts two domains of 
fatigue, physical fatigue and reduced activity.  In particular, the independent association 
between physical fatigue and reduced muscle mass is intuitively plausible, but not 
previously reported in KTRs.  It replicates results from cancer-related fatigue23, and fatigue 
associated with ESRD on haemodialysis24,25.  Of important note, the negative associations 
between different domains of fatigue and all aspects of post-transplantation QoL shown in 
Chapter 4 have important implications.  In order to improve QoL in KTRs, fatigue, an 
important patient-reported outcome, and its potential determinants including reduced 
muscle mass, deserve more attention from clinical and research perspectives.  This will be 
discussed under Section 6.3.3.4.   
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6.2.4 Potential Mechanistic Aetiology of Physical Fatigue in Kidney Transplant 
Recipients by Evaluation of Muscle Mass, Muscular and Cardiovascular 
Functions, and Fatigue Perception 
 
Although Chapter 4 showed that reduced muscle mass significantly correlated with 
fatigue in clinically stable KTRs, such an association did not persist in Chapter 5 when the 
potential mechanisms of physical fatigue were evaluated by measurements of muscle mass, 
muscular strength, cardiovascular function and fatigue perception. 
 
It is biologically plausible that varied disease processes or lack of physical activity may 
result in muscle atrophy26-28.  In these circumstances, muscles work at relatively high 
work-load and hence fatigue rapidly.  However, in the studied cohort of clinically stable 
KTRs, there was no association between physical fatigue with either whole body or lower 
limb lean tissue mass.  Certainly, muscle mass per se may not be the crucial factor, the 
ability of musculature to generate force and movement may arguably be of greater 
importance.  Interestingly, the results from the jumping mechanography studies showed no 
association between muscular power and physical fatigue.  In support of these results, 
muscle mass and muscular power in KTRs were similar to that of age- and gender- 
matched healthy control subjects, with muscle mass data comparable to previous literature 
in this field29,30.  
 
Such discrepancy between Chapter 4 and Chapter 5 may be explained to a certain degree 
by selection effects.  In contrast with Chapter 4, the study described in Chapter 5 
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employed stringent exclusion criteria.  In addition to such criteria specified in Chapter 4, 
including episodes of acute rejection within the past six months, evidence of sepsis in the 
last 6 weeks, active malignancy or chronic infection, preceding diagnosis of psychiatric 
disorder or chronic fatigue syndrome, and history of thyroid disease or adrenal 
insufficiency; Chapter 5 employed additional exclusion criteria due to ethical and safety 
reasons.  Chapter 5 excluded KTRs with evidence of unstable angina, acute coronary 
syndrome in the last 6 months, moderate or severe aortic stenosis, immobility and 
pregnancy.  Furthermore, KTRs who were eligible for entry into the study reported in 
Chapter 5 might have declined participation at enrolment, due to the likely discomfort 
arising from the exercise test and the possibility of physical difficulty encountered with the 
vertical jump test, although qualitative data would be needed to assess this speculation.  
For these reasons, variations in the characteristics of the studied cohorts between the two 
chapters may explain the differences in the findings.    
   
6.3 Other Important Findings of the Thesis 
 
In addition to body composition, the research studies presented in Chapters 2 to 5 of this 
thesis yielded other valuable findings, these are summarised in the following sections. 
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6.3.1 Chapter 2:  The Role of Hepcidin-25 in Kidney Transplantation 
 
This study presented in Chapter 2 represents the first evidence for an independent 
association between raised serum hepcidin and reduced haemoglobin levels in otherwise 
well and clinically stable KTRs, with hepcidin levels mostly driven by systemic 
inflammation and reduced renal function. 
 
6.3.1.1 Association between Hepcidin and Haemoglobin Levels in Kidney 
Transplant Recipients 
 
A progressive and clinically relevant reduction in haemoglobin level was observed with 
increasing hepcidin level.  This association was independent of renal function and other 
potential confounding factors.  Limited data exist from non-transplantation chronic kidney 
disease (CKD)31, showing a positive association between hepcidin and haemoglobin 
levels31, these observations now extend to the field of kidney transplantation.   
 
6.3.1.2 Independent Predictors of Hepcidin Levels in Kidney Transplant Recipients 
 
In addition to the positive and independent association between hepcidin and inflammation 
as discussed in Section 6.2.1, hepcidin levels were independently associated with increased 
transferrin saturation (the marker of iron storage), reduced renal function, and the use of 
marrow suppressive medication.  Such associations are consistent with the prevailing 
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understanding of the determinants of hepcidin levels32.  It raises the possibility that, at least 
partially, the identified risk factors may exert their effect on haemoglobin by means of 
elevating hepcidin levels.   
 
6.3.1.2.1 Transferrin Saturation and Hepcidin Levels in Kidney Transplant 
Recipients 
 
Although increased transferrin saturation was associated with raised hepcidin levels, no 
evidence was found for lower haemoglobin levels at the lower end of the spectrum of 
hepcidin levels, suggesting that iron deficiency was not in general a major mechanism for 
reduced haemoglobin levels in the current cohort.  However, hepcidin may remain a 
valuable biomarker for identifying true iron deficiency, as suggested in studies of non-
renal cohorts33. 
 
6.3.1.2.2 Allograft Function and Hepcidin Levels 
 
The observed relationship between renal function and higher hepcidin levels in this study 
confirms and extends similar findings from non-transplantation cohorts32,34-37, and a 
previous study in KTRs38.  However, it contradicts with two recent studies in non-
transplantation CKD31,39, it is likely that differences in patient characteristics are 
responsible for these conflicting findings, in particular, with regard to levels of 
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haemoglobin and inflammation, the range of renal function studied, and the use of co-
medication. 
 
6.3.1.2.3 Marrow Suppressive Medications and Hepcidin Levels 
 
An interesting and novel observation was the increase in hepcidin levels associated with 
the use of angiotensin-converting-enzyme inhibitor, angiotensin receptor blocker, 
mycophenolate, and azathioprine.  These associations may be explained by the recognised 
effect of these medications on reducing bone marrow activity, possibly decreasing 
erythropoiesis, leading to reduced inhibition of hepcidin secretion, resulting in higher 
circulating levels.  However, measurements of soluble transferrin receptor or reticulocyte 
count, and markers of erythropoietic activity, were not undertaken to support this 
hypothesis.  Nevertheless, a recent study in the haemodialysis setting showed an 
association between renin-angiotensin system inhibitors and raised hepcidin levels37, in 
keeping with the results of this study. 
 
6.3.1.3 Chapter Summary, Clinical Implications and Future Directions of Chapter 2 
 
In summary, Chapter 2 highlighted the possible mechanisms of haemoglobin reduction in 
KTRs, and the therapeutic opportunities from understanding the role of hepcidin in this 
context.  This finding suggests that targeting KTRs with raised hepcidin levels using 
therapies designed to antagonise hepcidin production or activity may be a useful strategy.  
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Currently, such agents remain in early phases of development, although preliminary 
clinical data appear encouraging40,41. 
 
Although Chapter 2 did not establish a relationship between adiposity and haemoglobin 
level, as discussed, independent associations were observed between adiposity and 
inflammation, between inflammation and elevated hepcidin, and between raised hepcidin 
and reduced haemoglobin levels.  It remains a possibility that adiposity-related 
inflammation in KTRs may be associated with elevated hepcidin, contributing to decreased 
haemoglobin by dysregulation of iron homeostasis.  Further prospective longitudinal 
follow-up of this cross-sectional cohort may add further insight into these associations.  
Also, these findings require replication in larger independent cohorts. 
  
6.3.2 Chapter 3:  Hypervolemia and Blood Pressure in Prevalent Kidney Transplant 
Recipients 
 
The study described in Chapter 3 is the first to address in detail the prevalence, predictors, 
and consequences of hypervolemia in KTRs.   
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6.3.2.1 Prevalence of Hypervolemia in Prevalent Kidney Transplant Recipients 
 
Based on the previously established definition of hypervolemia, 30% of KTRs were 
hypervolemic, of whom 5% suffered from severe hypervolemia.  Despite a lower incidence 
when compared with continuous ambulatory peritoneal dialysis12 or haemodialysis42 
populations, this degree of hypervolemia was unexpected, and is noteworthy in light of the 
specific selection of a clinically and biochemically stable cohort of KTRs for this study.   
 
6.3.2.2 Dietary Sodium Intake and Hypervolemia in Kidney Transplant Recipients 
 
Hypervolemia was associated with increasing sodium intake, highlighting an important 
target for intervention.  Dietary sodium restriction has not been formally examined in 
KTRs, but has gained attention in other context43.  The daily sodium intake in the current 
cohort of KTRs was 2,725 mg (118 mmol), lower than previously reported (3,588 mg or 
156 mmol per day)44, but well above the recommendation of Dietary Approach to Stop 
Hypertension (DASH) guideline (1,500 – 2,300 mg or 65 – 100 mmol per day)45. 
 
6.3.2.3 Dietary Sodium Intake and Blood Pressure in Kidney Transplant Recipients 
 
A recent study in KTRs demonstrated a relationship between increased sodium intake and 
higher blood pressure, but the contribution of extracellular volume status was not evaluated 
therein44.  Although the results of the current study confirmed a univariate association 
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between sodium intake and blood pressure, this relationship did not hold when the effect of 
extracellular volume status was taken into account. 
 
6.3.2.4 Diuretic Usage and Hypervolemia in Kidney Transplant Recipients 
 
It is important to note that, in the current study, the prevalence of diuretic usage was only 
15%, with furosemide being the only diuretic prescription.  No association between 
furosemide usage and volume status was observed, but this may be a reflection of 
“confounding by indication”.  Further, the median dosage of furosemide in this study was 
40 mg, a dosage which may be insufficient to target hypervolemia in KTRs with a mean 
estimated glomerular filtration rate (eGFR) of 44 mL/min46.   
 
6.3.2.5 Fat Mass and Hypervolemia in Kidney Transplant Recipients 
 
In regard to other determinants of extracellular volume status, an inverse association 
between fat mass and volume status was observed in the current study.  This phenomenon 
has been demonstrated in non-transplanted population47,48 which now extends to KTRs.  
The underlying mechanism remains unclear, further studies are necessary to delineate such 
observation.  However, it is also possible that, in clinical practice, volume overload often 
accompanies obesity49 and/or the physical appearance of obese patients may be clinically 
misclassified as volume overload48.  Therefore, obese KTRs may be more likely to receive 
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adequate or surplus treatment of volume status.  As a result, this finding may be 
confounded by clinical practice. 
 
6.3.2.6 Hypervolemia and N-Terminal Fragment of Pro-hormone B-Type 
Natriuretic Peptide in Kidney Transplant Recipients 
 
In addition to the independent association between hypervolemia and raised NT-proBNP 
as described in Section 6.2.2, reduced allograft function was another independent predictor 
of raised NT-proBNP levels.  This is in keeping with findings from previous studies among 
KTRs50,51, due to reduced renal clearance of NT-proBNP.52  However, an important caveat 
is the high variability in the relationship between NT-proBNP levels with both percentage 
volume expansion and eGFR.  This suggests that NT-proBNP may be a marker of volume 
expansion and renal dysfunction, it cannot yet be considered as an accurate surrogate for 
either.  The utility of serial NT-proBNP measurements cannot be discerned by the current 
study. 
 
6.3.2.7 Chapter Summary, Clinical Implications and Future Directions of Chapter 3 
 
In summary, Chapter 3 showed that hypervolemia is unexpectedly common among 
clinically stable KTRs, and is closely associated with elevated blood pressure and raised 
NT-proBNP levels.  The findings from this study suggest that meticulous monitoring of 
both volume status and blood pressure should be in place to ensure optimal management of 
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hypertension in KTRs.  It is hoped that the findings of this study will highlight the 
importance of extracellular volume status assessment in the management of hypertension, a 
tool yet to be incorporated into international guidelines from Kidney Disease: Improving 
Global Outcomes53, European Renal Best Practice Work Group54, and the United Kingdom 
Renal Association55.   
 
The relationship between increased sodium intake and hypervolemia signals potential 
nutritional focus.  In addition, inadequate diuretics usage may contribute to the high 
prevalence of hypervolemia.  Based on the findings from this study, a multi-modality 
approach involving the DASH diet and increased diuretic usage may be beneficial in the 
treatment of volume overload and hypertension in KTRs.  Long-term longitudinal follow-
up and experimental interventions, such as DASH diet and increased diuretic usage, are 
now required to evaluate its impact on extracellular volume status.  Also, future studies 
should examine the impact of extracellular volume status on relevant end points in kidney 
transplantation.   
 
6.3.3 Chapter 4:  Predictors and Consequences of Fatigue in Prevalent Kidney 
Transplant Recipients 
 
Chapter 4 revealed that, in clinically stable KTRs, fatigue in common, severe, and 
clinically under-appreciated.  It has a close association with inferior QoL.  In addition to 
reduced muscle mass already discussed in Section 6.2.3, other independent predictors of 
post-transplantation fatigue include depression, anxiety, inferior sleep quality, 
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inflammation, and renal dysfunction.  These findings form the potential targets for future 
interventional studies. 
 
6.3.3.1 Nature of Fatigue in Prevalent Kidney Transplant Recipients 
 
Compared with healthy population56,57, KTRs suffer from higher levels of fatigue on all 
dimensions, and were indeed similar to “chronically unwell” patients56.  Further, severity 
in certain domains, such as physical fatigue, reduced activity, and mental fatigue, 
approached that of chronic fatigue syndrome56, highlighting the burden of fatigue in KTRs.  
Of relevance, physical aspects of fatigue outweighed behavioural, emotional, and cognitive 
aspects, resembling findings in liver transplant recipients58.  Also, the significant 
associations between different domains of fatigue suggest that treatment of behavioural, 
emotional, and cognitive aspects of fatigue may improve physical aspects of fatigue or vice 
versa.   
 
6.3.3.2 Prevalence and Clinical Awareness of Fatigue in Prevalent Kidney 
Transplant Recipients 
 
The prevalence of fatigue in the current cohort of KTRs is 59%, comparable with a single 
previous study in this field19.  Despite the high prevalence, only 13% of patients had 
fatigue documented in medical records prior to participation in this study, suggesting that 
this symptom is either under-reported or under-acknowledged. 
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6.3.3.3 Independent Predictors of Fatigue in Prevalent Kidney Transplant 
Recipients 
 
Depression was highlighted as the specific, independent predictor of four fatigue 
dimensions, including general fatigue, physical fatigue, reduced activity and reduced 
motivation.  Anxiety was identified as a significant predictor of mental fatigue, similar to 
other chronic conditions such as multiple sclerosis59.  KTRs are subjected to several mental 
challenges, including fears about transplant rejection and the necessity to adhere to a 
complex regimen of immunosuppression therapy that may generate distressing side 
effects60. 
 
Inferior sleep quality may intuitively be expected to have a pervasive and broad effect on 
multiple aspects of fatigue19.  However, a significant association was only observed for the 
dimension of general fatigue.  
 
The association between inflammation and fatigue is particularly notable as the studied 
cohort consisted of clinically stable KTRs, without overt evidence of ongoing acute or 
chronic inflammatory conditions.  Evidence from studies of healthy volunteers, elderly 
populations, and other disease groups has shown that inflammatory cytokines possess 
potent neurological effects and are mediators of fatigue19,61-64.  
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Although fatigue is a common and important symptom for patients on dialysis65,66, the 
results from the current study showed, for the first time, a relationship between allograft 
dysfunction and physical fatigue in KTRs. 
 
6.3.3.4 Chapter Summary, Clinical Implications and Future Directions of Chapter 4 
 
In summary, Chapter 4 showed that, in clinically stable KTRs, fatigue is common, severe, 
and clinically under-appreciated.  It has a close association with inferior QoL. 
 
The findings from this study suggest that psychological interventions addressing disease-
related anxiety and depression per se may be beneficial in improving symptoms of 
fatigue67.  Inferior sleep quality was associated with only one domain of fatigue, 
suggesting that mere sleep difficulties do not explain a large spectrum of fatigue 
complaints in KTRs, and interventions aiming to improve sleep quality may have limited 
effect on fatigue. 
 
Reduced muscle mass coupled with increased fat mass (i.e. sarcopenic obesity) is a 
common characteristic of body composition in KTRs22, and systemic low-grade 
inflammation is a hallmark of obesity20.  The findings from Chapter 4 suggest that 
lifestyle intervention focusing on increasing physical activity and dietary modification 
aiming to reverse this phenotype should be valuable for patients displaying symptoms of 
fatigue. 
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Additionally, clinical strategies exist to improve allograft function68 and fatigue may 
represent an important patient-reported outcome in future interventional studies. 
 
6.3.4 Chapter 5:  Cardiovascular, Muscular and Perceptual Contributions to 
Physical Fatigue in Prevalent Kidney Transplant Recipients 
 
The study described in Chapter 5 is the first study to systematically investigate the 
potential aetiology of physical fatigue in KTRs, and reveal important findings.  As already 
discussed in Section 6.2.4, physical fatigue is unrelated to muscular and cardiovascular 
factors, but rather, it is driven by increased perception of exertion during exercise.  The 
findings of Chapter 5 confirm physical fatigue as a common and disabling symptom 
among KTRs, occurring in 22% in the studied cohort, negatively impacting on QoL19,69,70.   
 
6.3.4.1 Perceived Exertion and Physical Fatigue in Kidney Transplant 
Recipients 
 
Physical fatigue in KTRs is driven by increased perception of exertion during exercise.  
Such findings arising from the earlier part of this study led to the further investigation of 
the plausible predictors of heightened perception.  In turn, mental fatigue significantly 
associated with such heightened perception of effort.  Whilst novel to transplantation, these 
results resonate with findings from other populations, whereby heightened perception 
limits exercise capacity in healthy trained individuals71 and diabetic patients72, and mental 
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fatigue impairs physical performance through increased perception of effort rather than 
limiting musculoenergetic and cardiorespiratory functions73,74. 
 
The mechanisms by which perception of exertion influences physical performance has 
been previously proposed by Marcora and colleagues using the Brehm’s theory of 
motivation73.  In this theory, individuals opt to withdraw from a task when it is perceived 
to be too difficult, or the effort required exceeds the individuals’ willingness to perform75.  
During the decision-making process, individuals are suspected to have lowered their level 
of task difficulty for withdrawal76,77.  Impaired physical performance is a common feature 
in KTRs78-80, since physical fatigue represents a transient decrease in muscular 
performance, this may be seen as failure to generate and to maintain optimal physical 
performance.  Therefore, the Brehm’s theory of motivation may be extrapolated in this 
setting.  In addition, there is evidence that disorders of the brainstem, dopaminergic 
systems and endogenous opiates may affect decision making75-77,81,82.  In particular, 
increasing dopamine release in the brain through dopaminergic-modulating agent, is 
associated with reduced perceived fatigue and increased perceived QoL in chronic fatigue 
syndrome83.  This may be applicable to KTRs with physical fatigue as an important 
patient-reported outcome.   
 
Of importance, a caveat with the interpretation of the associations between self-report data, 
such as symptoms of physical and mental fatigue, perceived exertion, anxiety and 
depression, is that common method variance may partly drive the observed associations 
and may account for 25% of shared variance84.  In common method variance, patients high 
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in negative effect (i.e. negative mood) perceived, remember, and report more physical and 
psychological symptoms, and report those symptoms to be more severe than patients with 
less negative mood85.  Although these would not render self-reports unimportant, potential 
interpretational difficulties may result. 
 
6.3.4.2 Predictors of Perceived Exertion in Kidney Transplant Recipients 
 
In addition to mental fatigue as already discussed in Section 6.3.4.1, other factors 
associated with heightened perceived exertion included new onset diabetes after 
transplantation (NODAT), low alcohol intake, lack of cyclosporin prescription, and 
anxiety.  Interestingly, other commonly studied clinical and demographic variables, 
including estimated glomerular filtration rate, Hb and inflammation, showed no association 
with perception of effort. 
 
Fatigue in diabetes is likely to be caused by the interplay of physiological, psychological 
and lifestyle-associated factors86.  It is interesting to note that pre-existing diabetes was not 
associated with perceived exertion.  A plausible explanation for the differences between 
NODAT and pre-existing diabetes is that KTRs with NODAT may experience exaggerated 
psychological distress having to cope with yet another disease state and requiring a novel 
diabetes treatment.   
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The associations between raised perceived exertion with low alcohol intake and lack of 
cyclosporin prescription may be biologically plausible.  However, at present, such 
correlations were supported by weak rationale in the literature87-92, possibly representing a 
type I statistical error.   
 
Finally, anxiety independently associated with increased perception of exertion; and 
depression displayed a univariate association with perception.   These observations have 
been noted previously in non-transplant studies93,94, supporting the findings of this study.  
Anxious and depressed individuals are less attuned to interpret bodily sensations including 
fatigue during physical activity94, possibly with physiological response linked 
inappropriately to catastrophic cognitions in such individuals. 
 
6.3.4.3 Chapter Summary, Clinical Implications and Future Directions of Chapter 5 
 
In summary, Chapter 5 suggested that physical fatigue in KTRs is caused by perceived 
exertion influenced by mental fatigue and anxiety.  The findings from this chapter suggest 
that improving physical fitness or strength per se is unlikely to improve physical fatigue.  
Other strategies such as cognitive behavioural therapy or centrally-acting pharmacological 
therapies may be appropriate.  Undoubtedly, physical fatigue represents a frequent and 
important patient-reported outcome.  The results from this chapter set the scene for future 
interventional research and therapeutic strategies. 
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6.4 Limitations of the Thesis 
  
This thesis has limitations that should be acknowledged.  All studies described in 
Chapters 2 to 5 represent single-centre experience.  The cross-sectional nature of the study 
design in these chapters inherently means that the direction of the causality between 
predictor and outcome variables cannot be defined. 
 
In addition, all studies described in Chapters 2 to 5 were pilot observational studies in 
nature.  As such, power calculations were not conducted.  Various associations have been 
established, supported by explanations which are biologically plausible, and are in many 
aspects compatible with findings from other disease states and the general population.  
These associations were further reinforced by statistically significant p-values, and hence, 
in general, the probability of type 1 statistical error remains low.  Nevertheless, type I 
statistical errors may still exist especially in associations supported by weak rationale in 
the literature.  Of importance, the absence of associations between certain variables should 
not be treated without reservations due to studies with small sample sizes, implicating an 
inherently high probability of type II statistical error.  Future studies with larger cohorts are 
necessary to validate the conclusions drawn from the current pilot studies, in addition to 
minimising any type II or type I statistical errors. 
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6.5 Conclusion 
 
To conclude, the studies presented in this thesis identified potential predictors of post-
transplantation morbidity and fatigue, the potential contributing factors to long-term 
patient- and graft- survival, as well as QoL.  In particular, different body composition 
compartments exert varying effects on inflammation, blood pressure, NT-proBNP level, 
and fatigue.  The findings from this thesis set the scene for future interventional research 
and therapeutic strategies. 
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7.5 Section 1:  General Questions about You 
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Section 1:  General Questions about You 
 
1 What is your date of birth? 
  
            
      Day  Month  Year  
 
 
2 Are you a male or a female?  (Please tick) 
  
      Male   Female   
 
 
3 What is your current marital status?  (Please tick) 
  
       Married / living with partner   
       Widowed   
       Divorced   
       Separated   
       Single   
 
 
4 Which of these ethnic groups do you consider you belong to?   
(Please tick) 
  
  White British   Pakistani  
  White Irish   Bangladeshi  
  Black Caribbean   Chinese  
  Black African   Mixed  
  Indian   Other  
  
If other, please define: ............................................................................................. 
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5 Which of the following best describes your working status?   
(Pleas tick)  
  
    Working full time   
    Working part time   
    Semi-retired   
    Retired   
    Working in the home   
    Not working (due to ill health or disability)   
    Unemployed but seeking work   
    Student   
 
If you have already left full time education or your training scheme:   
 
6 How old were you when you left full time education or your training scheme 
(whichever was later)?  
           
           
           Years of age  
 
 
7 Do you have any of the following qualifications?   (Please tick all that apply) 
      
   School leaving certificate   
   CSE   
   GCE ‘O’ Level or GCSE   
   Technical College Exams / City and Guilds   
   Completed Apprenticeship   
   Higher National Diploma (HND)   
   ‘A’ Level, Highers   
   Trade Certificates   
   Teaching Diploma, NHC   
   University Degree   
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8 Which of the following best describes your use of tobacco products?   
(Please tick)  
         
      Never smoked   
      Currently smoking   
      Former smoker   
 
 
If you are a current or a former smoker: 
 
9 How many of the following tobacco products do you smoke / did you smoke 
a day?  (If none, please put zero “0” in the box.)  
         
        Cigarettes 
        Cigars 
        Pipe 
 
 
If you are a current or a former smoker: 
 
10 At what age did you start to smoke? 
         
        Years of age 
 
 
If you are a former smoker: 
 
11 At what age did you stop? 
        Years of age 
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With regards to caffeine intake, how many cups of each of the following drinks 
might you have in a normal week?  (If none, please put zero “0” in the box.) 
 
  How Many?  
12 Coffee  Cups 
13 Tea  Cups 
 
 
With regards to alcohol intake, how many measures of each of the following 
drinks might you have in a normal week?  (If none, please put zero “0” in the 
box.) 
 
  How Many?  
14 Wine  Small Glasses 
15 Fortified Wine (e.g. port or sherry)  Small Glasses 
16 Beer (e.g. lager, stout, bitter)  Pints 
17 Cider  Pints 
18 Spirits  Pub measure (25cl) 
19 Liqueurs (e.g. Tia Maria, Baileys)  Pub measure (25cl) 
 
 
During a normal day of the week, how much time do you usually spend 
sitting?  (Please tick) 
 
20 Never  
21 0 to 4 hours a day  
22 5 to 9 hours a day  
23 10 to 14 hours a day  
24 All day  
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With regards to physical activity, how often during the last year did you do the 
physical activities listed below? 
(Please tick) 
 
  Never 
 
0 to 2 
hours a 
week 
3 to 4 
hours a 
week 
 
5 to 9 
hours a 
week 
10 to 14 
hours a 
week 
More 
than 15 
hours a 
week 
25 Walking 
 
 
      
26 Jogging or 
running 
 
      
27 Swimming 
 
 
      
28 Cycling 
 
 
      
29 Exercise or 
dance classes 
 
      
30 Housework 
 
 
      
31 Gardening 
 
 
      
32 Other, please 
specify 
…………………. 
      
 
 
  
 
 
 
 
7.6 Section 2:  Medical Outcomes Study Short Form-36 (SF-36) 
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Section 2:  Questions about your General Health (SF-36 QoL) 
 
 
1 In general, would you say your health is:  (Please tick) 
      Excellent   
      Very good   
      Good    
      Fair   
      Poor   
 
 
2 Compared to one year ago, how would you rate your health in general now: 
 (Please tick)  
    Much better than one year ago   
    Somewhat better than one year ago   
    About the same   
    Somewhat worse now than one year ago   
    Much worse than one year ago   
 
 
The following questions are about activities you might do during a typical day.  
DOES YOUR HEALTH NOW LIMIT YOU IN THESE ACTIVITIES?   
If so, how much does it limit you?  (Please tick) 
 
   Yes, 
limited a 
lot. 
Yes, 
limited a 
little. 
No, not 
limited at 
all. 
      
3 Vigorous activities, such as running, lifting 
heaving objects, participating in strenuous 
sports such as playing golf. 
    
    
    
4 Moderated activities, such as moving a 
table, pushing a vacuum cleaner, or 
bowling. 
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The following questions are about activities you might do during a typical day.  
DOES YOUR HEALTH NOW LIMIT YOU IN THESE ACTIVITIES?   
If so, how much does it limit you?  (Please tick) 
 
   Yes, 
limited a 
lot. 
Yes, 
limited a 
little. 
No, not 
limited at 
all. 
      
5 Lifting or carrying groceries.     
    
    
6 Climbing several flights of stairs. 
  
 
    
7 Climbing one flight of stairs. 
 
 
    
8 Bending, kneeing or stopping. 
 
 
    
9 Walking more than a mile. 
 
 
    
10 Walking half a mile. 
 
 
    
11 Walking 100 yards. 
 
 
    
12 Bathing and dressing yourself.   
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During the past 4 weeks, have you had any of the following problems with your 
work or other daily activities as a result of your physical health?  (Please tick) 
 
  Yes 
 
No 
13 Cut down on the amount of time you spent on work or 
other activities. 
  
14 Accomplished less than you would like. 
 
  
15 Were limited in the kind of work or other activities. 
 
  
16 Had difficulty performing the work or other activities (e.g. it 
took extra effort) 
  
 
 
During the past 4 weeks, have you had any of the following problems with your 
work or other daily activities as a result of any emotional problems (such as 
feeling depressed or anxious)?  (Please tick) 
 
  Yes 
 
No 
17 Cut down on the amount of time you spent on work or 
other activities. 
  
18 Accomplished less than you would like. 
 
  
19 Didn’t do work or other activities as carefully as usual. 
 
  
 
 
 
 
 
 
 
Quality of Life & Fatigue Questionnaires Version 3.0           Version Date: 08-12-2010 
 
251 
20 During the past 4 weeks, to what extent has your physical health or emotional 
problems interfered with your normal social activities with family, friends, 
neighbours or groups?  (Please tick) 
 
 
         
    Not at all   
    Slightly   
    Moderately   
    Quite a bit   
    Extremely   
 
 
21 How much bodily pain have you had during the past 4 weeks?   
 (Please tick)    
    None   
    Very mild   
    Mild   
    Moderate   
    Severe   
    Very severe   
 
 
22 During the past 4 weeks, how much did pain interfere with your normal work 
(including work both outside the home and housework)?   
(Please tick) 
 
 
    Not at all   
    A little bit   
    Moderately   
    Quite a bit   
    Extremely   
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These questions are about how you feel and how things have been with you 
during the past 4 weeks.  Please indicate the answer that closest describe the 
way you have been feeling.  How much time during the past 4 weeks:   
(Please tick) 
   All the 
time 
Most of 
the 
time 
A good 
bit of 
the 
time 
Some 
of the 
time 
A little 
of the 
time 
None 
of the 
time 
         
23 Have you felt full of life? 
 
 
       
       
24 Have you been a nervous 
person? 
 
       
       
25 Have you felt so down in 
the dumps that nothing 
could cheer you up? 
       
       
       
26 Have you felt calm and 
peaceful? 
 
       
       
27 Have you had a lot of 
energy? 
 
       
       
28 Have you felt 
downhearted and low? 
 
       
       
29 Have you felt worn out? 
 
 
       
       
30 Have you been a happy 
person? 
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These questions are about how you feel and how things have been with you 
during the past 4 weeks.  Please indicate the answer closest describe the way 
you have been feeling.   
How much time during the past 4 weeks: 
(Please tick) 
   All the 
time 
Most of 
the 
time 
A good 
bit of 
the 
time 
Some 
of the 
time 
A little 
of the 
time 
None 
of the 
time 
         
31 Have you felt tired? 
 
 
 
 
       
       
32 Have your physical health 
or emotional problems 
interfered with your social 
activities (like visiting 
friends, relatives, etc.)? 
       
      
      
      
      
 
How TRUE or FALSE is each of the following statements for you?  (Please tick) 
 
  Definitely 
true 
Mostly 
true 
Not sure Mostly 
false 
Definitely 
false 
33 I seem to get ill more 
easily than other people. 
     
34 I am as healthy as 
anybody I know. 
     
35 I expect my health to get 
worse. 
     
36 My health is excellent.  
 
    
 
  
 
 
 
 
7.7 Section 3:  Multi-Dimensional Fatigue Inventory-20 (MFI-20) 
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Section 3:  Questions about how you have been feeling over the 
past few days (MFI-20) 
 
We would like to get an idea of how you have been feeling over the last few days.  
If you think any of these statements are entirely true, please tick the box for “1” on 
the extreme left.  The more you disagree with the statement, the more you can tick 
the box in the direction of “no, that is not true”.  Please do not miss out a statement.   
 
 
  Yes, 
that is 
true. 
   No, 
that is 
not 
true. 
  1 
 
2 3 4 5 
1 I feel fit. 
 
     
2 Physically I feel only able to do 
a little. 
     
3 I feel very active. 
 
     
4 I feel like doing all sort of nice 
things. 
     
5 I feel tired. 
 
     
6 I think I do a lot in a day. 
 
     
7 When I am doing something, I 
can keep my thoughts on it. 
     
8 Physically I can take on a lot. 
 
     
9 I dread having to do things. 
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  Yes, 
that is 
true. 
   No, 
that is 
not 
true. 
  1 
 
2 3 4 5 
10 I think I do very little in a day. 
 
     
11 I can concentrate well. 
 
     
12 I am rested. 
 
     
13 It takes a lot of effort to 
concentrate on things. 
     
14 Physically I feel I am in a bad 
condition. 
     
15 I have a lot of plans. 
 
     
16 I tire easily. 
 
     
17 I get little done. 
 
     
18 I don’t feel like doing anything. 
 
     
19 My thoughts easily wander. 
 
     
20 Physically I feel I am in 
excellent condition. 
     
 
 
 
 
 
  
 
 
 
 
7.8 Section 4:  Hospital Anxiety and Depression Scale (HADS) 
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Section 4:   Questions about how you have been feeling during the 
past week?  (HADS) 
 
The next questions are designed to help us know how you feel in further detail.  
Please tick the reply which comes closest to how you have been feeling in the 
past week? 
 
1 I feel tense or wound up. 
  
       Most of the time   
       A lot of the time   
       Time to time, occasionally    
       Not at all   
 
 
2 I still enjoy things I used to enjoy. 
  
       Definitely as much   
       Not quite as much   
       Only a little   
       Hardly at all   
 
 
3 I get a sort of frightened feeling as if something awful is about to happen. 
  
       Very definitely and quite badly   
       Yes, but not too badly   
       A little, but doesn’t worry me   
       Not at all   
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4 I can laugh and see the funny side of things. 
  
       As much as I always could   
       Not quite as much now   
       Definitely not so much now   
       Not at all   
 
 
5 Worrying thoughts go through my mind. 
  
       A great deal of the time   
       A lot of the time   
       From time to time but not too often   
       Only occasionally    
 
 
6 I feel cheerful. 
  
       Not at all   
       Not often   
       Sometimes   
       Most of the time   
 
 
7 I can sit at ease and feel relaxed. 
  
       Definitely    
       Usually   
       Not often   
       Not at all   
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8 I feel as if I am slowed down. 
  
       Nearly all the time   
       Very often   
       Sometimes   
       Not at all   
 
 
9 I get a sort of frightened feeling like “butterflies” in my stomach. 
  
       Not at all   
       Occasionally   
       Quite often   
       Very often   
 
 
10 I have lost interest in my appearance. 
  
       Definitely    
       I don’t take so much care as I should   
       I may not take quite as much care   
       I take just as much care as ever   
 
 
11 I feel restless as if I have to be on the move. 
  
       Very much indeed   
       Quite a lot   
       Not very much   
       Not at all   
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12 I look forward with enjoyment to things. 
  
       As much as ever I did   
       Rather less than I used to   
       Definitely less than I use to   
       Hardly at all   
 
 
13 I get sudden feelings of panic. 
  
       Very often indeed   
       Quite often   
       Not very often   
       Not at all   
 
 
14 I can enjoy a good book or radio or TV programme. 
  
       Often   
       Sometimes   
       Not often   
       Very seldom   
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
7.9 Section 5:  Pittsburgh Sleep Quality Index (PSQI) 
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Section 5:   Questions about sleep (PSQI) 
 
We would like to ask you questions about sleep. 
 
During the past month, did you: 
(Please tick the appropriate box) 
  Not 
at all 
Yes 
  1-3 
days 
4-7 
days 
8-14 
days 
15-21 
days 
22-31 
days 
1 Have trouble falling asleep?  
 
     
2 Wake up several times at night?  
 
     
3 Having trouble staying asleep 
(including waking far too early)? 
      
4 Wake up after your normal amount 
of sleep feeling tired and worn out? 
      
 
 
5  During the past month, what time have you usually gone to bed? 
  
       BED TIME   
 
 
6 During the past month, how long (in minutes) has it usually taken you to fall 
asleep each night?  
       NUMBER OF MINUTES   
 
 
7 During the past month, what time have you usually gotten up in the morning? 
  
       GETTING UP TIME   
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8 During the past month, how many hours of actual sleep did you get at night?  
(This may be different than the number of hours you spent in bed.)  
  
       HOURS OF SLEEP PER NIGHT   
 
For the following questions, tick the one best response.  During the past 
month, how often have you had trouble sleeping because you…  (Please tick) 
 
  Not 
during 
the past 
month 
Less 
than 
once a 
week 
Once or 
twice a 
week 
Three or 
more 
times a 
week 
9 Could not get to sleep within 30 
minutes. 
    
10 Woke up in the middle of the night or 
early in the morning. 
    
11 Had to get up to use the bathroom. 
 
    
12 Could not breathe comfortably. 
 
    
13 Coughed or snored loudly. 
 
    
14 Felt too cold.  
 
   
15 Felt too hot.  
 
   
16 Had bad dreams.  
 
   
17 Had pain. 
 
    
18 Other reason(s), please describe ……....
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19 During the past month, how would you rate your sleep quality overall?  
(Please tick)  
       
         
  Very good  Fairly good  Fairly bad  Very bad 
 
 
20 During the past month, how often have you taken medicine to help you 
sleep? (prescribed or “over the counter”)?  (Please tick)  
       
         
  Not during 
the last 
month 
 Less than 
once a 
week 
 Once or 
twice a 
week 
 Three or 
more times 
a week 
 
 
21 During the past month, how often have you had trouble staying awake while 
driving, eating meals, or engaging in social activity?  (Please tick)  
       
         
  Not during 
the past 
month 
 Less than 
once a 
week 
 Once or 
twice a 
week 
 Three or 
more times 
a week 
 
 
22 During the past month, how much of a problem has it been for you to keep up 
enough enthusiasm to get things done?  (Please tick)  
       
         
  No problem 
at all 
 Only a very 
slight 
problem 
 Somewhat 
of a 
problem 
 A very big 
problem 
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23 Do you have a bed partner or roommate?  (Please tick) 
       
         
  No bed 
partner or 
roommate 
 Partner / 
roommate 
in the other 
room 
 In same 
room, but 
not same 
bed 
 Partner in 
same bed 
 
 
If you have a roommate or partner, ask him / her how often in the past month 
you have had ……… 
(Please tick) 
  Not during 
the past 
month 
Less than 
once a 
week 
Once or 
twice a 
week 
Three or 
more times 
a week 
24 Loud snoring. 
 
 
    
25 Long pauses between 
breaths when asleep. 
 
    
26 Legs twitching or 
jerking while you 
sleep. 
    
27 Episodes of 
disorientation or 
confusion during sleep. 
    
28 Other restlessness 
while you sleep, 
please describe …… 
    
 
 
 
